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ABSTRACT 
 
 Relapse in acute myeloid leukaemia (AML) is driven by additional cooperating 
somatic mutations that were acquired (or selected for) after chemotherapy, where the 
relapsing clone evolves from a cell carrying leukaemia-initiating genetic lesions, 
including gene fusions such as RUNX1/ETO. Some fusion genes are thought to confer 
a mutator phenotype that predisposes cells to the acquisition of cooperating mutations. 
As such, it is important to understand how chemotherapy and fusion gene expression 
contribute to mutagenesis in relapsing AML. 
 The effect of chemotherapeutic agents on the mutation frequency was 
determined at the thymidine kinase (TK) and hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) loci in a fully controlled cell model system using 
TK6 human lymphoblastoid cell lines. Both daunorubicin and cytarabine were 
mutagenic to DNA at the TK and HPRT loci. Comparison of the daunorubicin-treated 
and vehicle-treated mutational spectra at the HPRT coding region revealed a 
significant increase in large deletions in daunorubicin-treated cells relative to vehicle-
treated cells, demonstrating daunorubicin as a powerful mutagen, inducing almost 
exclusively gene deletions presumably via strand break induction. 
 The effect of RUNX1/ETO fusion gene expression on mutation frequency was 
also determined both spontaneously and after chemotherapy treatment using a cell 
line transduced with the full-length RUNX1/ETO fusion gene. RUNX1/ETO significantly 
increases spontaneous mutation frequency at both TK and HPRT loci; however, there 
is no strong evidence that RUNX1/ETO fusion gene expression sensitises cells to 
chemotherapy-induced mutation. Interrogation of the spontaneous HPRT base 
substitution spectrum revealed that RUNX1/ETO significantly increases T:A > G:C 
transversions in vitro, and particularly at the central base position of 5’ApTpA3’ / 
5’TpApT3’ sequences, although this observation was not evident in primary t(8;21) AML. 
 A flow cytometric method was established to evaluate the effect of RUNX1/ETO 
fusion gene expression on mutation frequency at specific base residues in an AML 
relevant gene. RUNX1/ETO significantly increase the type A exon 12 NPM1 mutation 
frequency over time, suggesting this fusion protein predisposes cells to the acquisition 
of somatic mutation at loci relevant to leukaemogenesis. 
 Relapsed AML is associated with the acquisition of additional somatic mutations 
which are thought to drive phenotypic adaptability driving clonal selection during 
treatment and evolution of leukaemic clones. Analysis of high-throughput exome 
ii 
 
sequencing of a small cohort of matched presentation and relapse AML samples 
revealed clonal evolution patterns in AML, characterised by the continuous acquisition 
of additional somatic mutations during disease progression and provided important 
insight on the clonal origins of relapsed AML. 
 Data generated from these studies demonstrate the in vitro mutagenicity of 
chemotherapeutic agents used in AML remission induction treatment. Furthermore, 
RUNX1/ETO fusion gene expression increases spontaneous mutation rate, including 
mutation at the NPM1 locus. However, there is insufficient evidence from the induced 
mutation spectrum to discern the underlying mechanism of RUNX1/ETO-driven 
mutagenesis. Taken together, these data inform on the aetiology of somatic mutations 
in AML. 
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1.1. Acute Myeloid Leukaemia 
 
 Acute myeloid leukaemia (AML) is a malignant disorder of the blood and bone 
marrow which arises as a result of haematopoietic failure or de-regulation of 
haematopoiesis, the process by which the cellular components of blood are formed 
(Figure 1.1). It is a heterogeneous clonal disorder characterised by the proliferation 
and accumulation of immature myeloid progenitor cells (blasts) in bone marrow and 
blood, which occurs when the blasts lose the ability to differentiate normally and fail to 
respond to normal regulators of proliferation. Patients with AML are usually taken ill 
over a short timeframe and experience infection, bleeding or organ infiltration, and 
succumb to the disease within weeks or months if untreated. 
 
1.1.1. AML incidence and epidemiology 
 
 In the United Kingdom (UK), AML is a relatively rare cancer, with an incidence 
of approximately 2,480 cases annually and median age at presentation of 71.6 years 
(Figure 1.2) (https://www.hmrn.org). Recent incidence data demonstrates a rate of 
diagnosis of 2 – 3 per 100, 000 annually in children, increasing to 15 per 100, 000 in 
older adults (Burnett and Venditti, 2011). As such, AML can be considered a disease 
related with older age, although it can present at any age. AML risk is slightly higher in 
males than females with three men affected for every two women. AML is the most 
common type of acute leukaemia in adults that accounts for about 6.3% of total 
haematological malignancies, and has the lowest survival rate of all the leukaemias 
(Deschler and Lübbert, 2006). The high median age of diagnosis has important 
implications for treatment strategies which are associated with chemoresistance and 
comorbidity that limits treatment options. 
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Figure 1.1. Haematopoiesis in human. 
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Figure 1.2. Incidence of AML in the UK in different age and gender 
(https://www.hmrn.org; 15 September 2018). 
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1.1.2. AML classification 
 
 The French-American-British (FAB) classification system was introduced in 
1976 for classifying AML (Bennett et al., 1976), and noted that many cases of AML are 
associated with recurring genetic abnormalities that affect cellular pathways of myeloid 
maturation and proliferation. The FAB classification provides a well-defined structure, 
based on morphological, immunological and clinical features, by which to classify 
disease into prognostically-relevant groups. Under the FAB classification system, AML 
is classified into 8 subtypes depending on the specific cell lineage(s) affected, defined 
by morphological appearance of the myeloblasts populating the leukaemic bone 
marrow (Table 1.1). 
 However, it was found that the correlation between morphology and genetic 
findings predicts the prognosis and biologic properties of the leukaemia more 
accurately than morphology alone. Thus, although the FAB classification recognises 
the morphologic heterogeneity of AML, it does not always reflect the genetic or clinical 
diversity of the disease. A revised classification devised under the auspices of the 
World Health Organization (WHO) recognizes accumulating knowledge of the 
cytogenetic and molecular characteristics (Table 1.2) (Arber et al., 2016). In addition 
to morphological classification, detection of certain genetic mutations (cytogenetic and 
molecular genetic) can also delineate specific AML subtypes. Furthermore, many 
commonly detected genetic mutations are prognostically relevant (Table 1.3) (Döhner 
et al., 2017) and, in some cases, can direct therapeutic choice. Specific chromosome 
aberrations and their molecular counterparts have been included in the WHO 
classification of haematologic malignancies, and together with morphology, 
immunophenotype and clinical features are used to define distinct disease entities for 
proper classification and prognostication (Vardiman et al., 2002; Betz and Hess, 2010). 
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FAB Subtype Description Morphology 
M0 Acute myeloblastic leukaemia, 
minimally differentiated 
Immature myeloblasts without 
definite myeloid differentiation 
M1 Acute myeloblastic leukaemia 
without maturation 
Immature myeloblasts, Auer rods 
may be present 
M2 Acute myeloblastic leukaemia 
with maturation 
Immature myeloblasts (more 
mature than M1), Auer rods often 
present 
M3 Acute promyelocytic 
leukaemia (APL) 
Hypergranularpromyelocytes, 
bundles of Auer rods 
M4eo Acute myelomonocytic 
leukaemia 
Mixture of abnormal monocytes 
and myeloblasts/promyelocytes 
(eosinophil precursors in M4eo) 
M5a 
M5b 
Acute monocytic leukaemia M5a 80% immature monoblasts 
M5b 20% differentiated 
monocytes 
M6 Acute erythroleukaemia Abnormal multinucleated 
erythroblasts, characterised by 
ringed sideroblasts 
M7 Acute megakaryoblastic 
leukaemia 
Megakaryoblasts, often 
myelofibrils, increased bone 
marrow reticulin 
 
Table 1.1. Overview of the French-American-British (FAB) classification system 
of AML (Bennett et al., 1976). 
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Acute myeloid leukaemia with recurrent genetic abnormalities 
AML with t(8;21)(q22;q22); RUNX1/ETO 
AML with inv(16)(p13q22) or t(16;16)(p13;q22); CBFβ/MYH11 
APML with t(15;17)(q22;q12); PML/RARα 
AML with t(9;11)(p21.3;q23.3); MLLT3/KMT2A (MLL) 
AML with t(6;9)(p23;q34); DEK/NUP214 
AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); GATA2/MECOM 
AML (megakaryoblastic) with t(1;22)(p13.3;q13.3); DEK/NUP214 
AML with mutated NPM1 
AML with biallelic mutations of CEBPA 
Provisional entity: AML with BCR/ABL1 
Provisional entity: AML with mutated RUNX1 
Acute myeloid leukaemia with myelodysplasia changes 
Therapy-related myeloid neoplasms 
Acute myeloid leukaemia, not otherwise categorized 
Classify as: 
AML with minimally differentiated 
AML without maturation 
AML with maturation 
Acute myelomonocytic leukaemia 
Acute monoblastic/acute monocytic leukaemia 
Acute erythroid leukaemia (erythroid/myeloid and pure erythroleukaemia) 
Acute megakaryoblastic leukaemia 
Acute basophilic leukaemia 
Acute panmyelosis with myelofibrosis 
Myeloid sarcoma 
Myeloid proliferations related to Down syndrome 
Transient abnormal myelopoiesis (TAM) 
Myeloid leukaemia associated with Down syndrome 
 
Table 1.2. WHO classification of AML (Arber et al., 2016). 
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Prognosis Genetic abnormality 
Favourable 
t(8;21)(q22;q22); RUNX1/ETO 
t(15;17)(q22;q21); PML/RARα 
inv(16)(p13;q22) or t(16;16)(p13;q22); CBFβ/MYH11 
Mutated NPM1 without FLT3-ITD (normal karyotype) 
Biallelic mutated CEBPA (normal karyotype) 
Intermediate I 
Mutated NPM1 and FLT3-ITD (normal karyotype) 
Wild-type NPM1 and FLT3-ITD (normal karyotype) 
Wild-type NPM1 without FLT3-ITD (normal karyotype) 
Intermediate II 
t(9;11)(p22;q23); MLLT3/KMT2A 
Cytogenetic abnormalities not classified as favourable or adverse 
Adverse 
inv(3)(q21q26) or t(3;3)(q21;q26); GATA2/MECOM (EVI1) 
t(6;9)(p23;q34); DEK/NUP214 
t(v;11)(v;q23); KMT2A rearranged 
-5 or del(5q); -7; -17/abnormality (17p) 
Complex karyotype, monosomal karyotype 
Wild-type NPM1 and FLT3-ITDhigh 
Mutated RUNX1 
Mutated ASXL1 
Mutated TP53 
 
Table 1.3. Prognostic classification of AML based on genetic abnormalities 
(Döhner et al., 2017). 
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1.2. Genetic Mutations in AML Pathogenesis 
 
 The acquisition of somatic mutations underpins cancer development, which can 
either be caused by large-scale mutations (e.g. chromosomal translocations, 
inversions and numerical aberrations) or small-scale mutations (e.g. point mutations 
and microdeletions). Cytogenetic analysis has contributed to the identification of gross 
chromosomal abnormalities that play essential roles in AML pathogenesis, and 
remains the first tier of screening for AML classification. Abnormal karyotype with a 
recurrent chromosomal aberration constitutes approximately 55% of de novo AML 
cases, while the remaining 45% have a cytogenetically normal karyotype (CN-AML) 
(Mrózek et al., 2004; Sanderson et al., 2006a). Clinical management of AML patients 
with a normal karyotype was previously a major challenge, but which is now improving 
with the identification of distinct sub-groups characterised by somatic base 
substitutions.  
 Recent advances in molecular diagnostic techniques have facilitated in the 
discovery of nucleotide-level mutations that undetectable by standard cytogenetics 
(Betz and Hess, 2010).  AML has fewer mutations than many other adult cancer with 
an average of 13 somatic driver mutations. In contrast, some solid tumours such as 
breast, lung or pancreatic cancers can have hundreds of mutations (Cancer Genome 
Atlas Research, 2013). The most frequent mutations found in CN-AML are FLT3 
internal tandem duplications (ITDs), FLT3 tyrosine kinase domain mutations, MLL 
partial tandem duplications, and a range of base-substitution mutations, short insertion 
or deletion mutations within the coding region of the NPM1, CEBPA, NRAS, WT1 and 
other genes. Among these mutations, NPM1, CEBPA, and FLT3-ITD mutations now 
have sufficiently well-established prognostic significance that testing is recommended 
for CN-AML patients in order to stratify patients for appropriate treatment (Renneville 
et al., 2008; Döhner et al., 2009) 
 As well as major cytogenetic abnormalities, sub-cytogenetic somatic mutations 
also constitute key events in AML pathogenesis and the affected genes have 
significant roles in key pathways involves in the regulation of haematopoietic cell 
survival, proliferation or differentiation. The two-hit model of leukaemogenesis has 
served as a basis to understand how genetic mutations drive AML (Kelly and Gilliland, 
2002). According to this model, mutations that frequently detected in AML can be 
grouped into two classes, class I mutation and class II mutation, which cooperate and 
cause leukaemic transformation of a myeloid progenitor. This model is supported by 
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the observation in which a single mutation alone is often insufficient to drive AML 
transformation. AML-associated chromosomal translocations such as core-binding 
factor (CBF) translocations [t(8;21), inv(16)] and translocation involving retinoic acid 
receptor alpha, RARα [t(15;17)] can be found in a proportion of healthy individuals 
(Quina Ana et al., 2000; Basecke et al., 2002; Mori et al., 2002; Song et al., 2011). It 
was demonstrated in murine models that these chromosomal translocations have a 
significant effect on cells by conferring increased self-renewal capacity and reduced 
differentiation; however, none of these mutations are sufficient to induce malignant 
transformation (Downing, 2003). Collectively, these findings demonstrate a 
requirement for both classes of mutation in the same cell for AML transformation. 
 In addition, genomic studies have revealed the presence of mutations in genes 
associated with epigenetic modification (ASXL1, DNMT3A, IDH1/2, TET2, EZH2 and 
MLL) in a significant proportion of AML patients (Shih et al., 2012). Disruption of 
epigenetic processes including DNA methylation and histone modification can lead to 
altered function in genes involve in key cellular pathways such as DNA repair, RAS 
signalling, cell cycle and apoptosis, which contribute to malignant transformation 
(Kanwal and Gupta, 2012). Furthermore, a genome-wide DNA methylation profiling 
study has demonstrated that specific methylation profiles are associated with specific 
AML subtypes (Figueroa et al., 2010b), which identified oncogenic cooperativity 
between somatic alterations in epigenetic regulators and known AML driver mutations. 
Therefore, an additional class of mutation was defined, termed epigenetic modifiers 
(Conway O'Brien et al., 2014). 
 
1.2.1. Class I mutations 
 
 The class I mutations confer a proliferative and survival advantage to cells and 
frequently target key components of kinase signalling pathways. These mutations 
generally occur late and are associated with AML progression (Kelly and Gilliland, 
2002). The genes in this group are: 
 
FLT3 
The FMS-related tyrosine kinase 3 (FLT3) gene, located on chromosome 13q12 
encodes a membrane-bound receptor tyrosine kinase (RTK) involved in the regulation 
of proliferation, differentiation and apoptosis of haematopoietic cell progenitors 
(Stirewalt and Radich, 2003). Mutation in FLT3 is one of the most frequent mutations 
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observed in AML, found in 25 – 45% of all AML patients (Renneville et al., 2008). ITDs, 
which result from the duplication and tandem insertion of a variably sized (3–400 
nucleotides) fragment of the gene, are the most common mutations in FLT3 and occur 
in a wide range of cytogenetic subsets including 20 – 30% of CN-AML cases (Bacher 
et al., 2007). Other mutations detected in FLT3 include missense point mutations and 
small insertion/deletions within the tyrosine kinase domain (FLT3-TKD). These 
mutations result in uncontrolled proliferation and decreasing apoptosis of leukaemic 
blasts (Gilliland and Griffin, 2002). 
 
RAS 
RAS oncogenes encode a family of guanine nucleotide-binding proteins that regulate 
intracellular signal transduction on binding to a variety of membrane receptors, 
including c-KIT and FLT3, and play an important role in proliferation, differentiation and 
apoptosis (Reuter et al., 2000). H-RAS (Harvey sarcoma virus), K-RAS (Kirsten 
sarcoma virus), and N-RAS (neuroblastoma RAS viral oncogene homolog) are the 
most frequently mutated oncogenes in human cancer (Renneville et al., 2008). In AML, 
point mutations in N-RAS and K-RAS are found in approximately 10 – 15% and 5% of 
the cases, respectively, with N-RAS codon 12 mutation being the most frequent (43%), 
followed by N-RAS codon 13 (21%) and K-RAS codon 12 (21%) (Pedersen-Bjergaard 
et al., 2008; Renneville et al., 2008). These mutations confer constitutive activation of 
the RAS protein by abrogating guanosine triphosphatase (GTPase) activity that affect 
cellular proliferation, differentiation and apoptotic processes (Beaupre and Kurzrock, 
1999). 
 
KIT 
The KIT proto-oncogene, located on chromosome 4q12 encodes a transmembrane 
glycoprotein, which is a member of the type III RTK family, and whose ligand is stem 
cell factor (SCF). SCF binding promotes c-KIT dimerization and transphosphorylation 
that leads to activation of downstream signalling pathways involved in proliferation, 
differentiation, migration and survival, particularly of haematopoietic stem cells (Blume-
Jensen and Hunter, 2001). Ligand-independent activation of c-KIT can be caused by 
different types of mutations which lead to deregulation of intracellular signal-
transduction pathways mediating development and multicellular communication. c-KIT 
mutations have been identified with high frequency in CBF AML and are mainly found 
in AML FAB subtype M1, M4, M4eo and particularly in M2, where nearly 70% of 
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patients have mutated c-KIT (Beghini et al., 2000; Goemans et al., 2005). c-KIT 
mutation is a common co-operating event is t(8;21) AML, detected in up to 50% of the 
cases (Beghini et al., 2000; Care Rory et al., 2003; Goemans et al., 2005; Kohl et al., 
2005; Wang et al., 2005; Reikvam et al., 2011). 
 
1.2.2. Class II mutations 
 
 In contrast to class1 mutations, class II mutations primarily lead to impaired 
myeloid differentiation during haematopoiesis by affecting genes involved in 
transcriptional regulation. These mutations occur early during leukaemogenesis and 
are stable throughout the disease course and have been proposed to be founder 
(initiating) mutations (Kelly and Gilliland, 2002). The genes in this group are: 
 
NPM1 
The nucleophosmin 1 (NPM1) gene, located on chromosome 5q35 encodes a 
multifunctional phosphoprotein that shuttles between nuclear compartments and the 
cytoplasm. Among other functions, one role of NPM1 thought to be important for 
leukaemogenesis is its involvement in regulation of ARF and p53 tumour suppressor 
function (Falini et al., 2009). Insertion/deletion in exon 12 of NPM1 is the most common 
mutation in AML, reported in approximately 35% of primary AML cases (Falini et al., 
2005). There are different types of NPM1 exon 12 insertions. Type A mutation 
(c.860_863insTCTG) are the most frequent NPM1 mutation in AML, representing 69% 
of NPM1 mutations. Type B (c.862_863insCATG) and Type D (c.863_864insCCTG) 
mutations are also relatively common, representing 11% and 8% of NPM1 mutations 
respectively, while other mutations are rare, accounting for  <1% of NPM1 mutations 
(Alpermann et al., 2016; Kumar et al., 2018). In addition, chromosomal aberrations 
involving NPM1 are also a common observation in AML and other haematological 
malignancies, such as  non-Hodgkin lymphoma, acute promyelocytic leukaemia (APL) 
and myelodysplastic syndrome (MDS) (Falini et al., 2007). NPM1 mutations are now 
considered the most common genetic lesion in AML, occurring in approximately 30% 
and 60% of adult de novo cases and CN-AML cases, respectively (Betz and Hess, 
2010; Webersinke et al., 2014). Mutation of NPM1 results in aberrant localisation of 
the protein in the cytoplasm (Mariano et al., 2006) which could promote tumour growth 
by inactivation of tumour suppressor p53/ARF pathway, and is thought to be an early 
event in leukaemogenesis (Thiede et al., 2006; Cheng et al., 2010; Vassiliou et al., 
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2011). However, there is recent data suggesting that some NPM1 mutations occur late 
and are the final transforming event in secondary AML (Schnittger et al., 2014). 
Although this mutation is associated with a good response to induction therapy and a 
favourable prognosis, the favourable impact of NPM1 mutation is highly dependent on 
FLT3-ITD status (Betz and Hess, 2010). 
 
C/EBPα 
The CCAAT/enhancer binding protein alpha (C/EBPα) gene, located on chromosome 
19q13.1, encodes a transcription factor that plays a crucial role during differentiation 
of various cell types. In haematopoiesis, C/EBPα plays a key role in early stages of 
granulocyte development and differentiation from haematopoetic precursors (Tenen, 
2003; Nerlov, 2004). Mutations of C/EBPα are reported in 15 – 20% CN-AML 
(Pedersen-Bjergaard et al., 2007), particularly in patients with AML M1 and M2 FAB 
morphologic subtypes (Pabst and Mueller, 2009; Dufour et al., 2010). In general, 
C/EBPα mutations span the whole protein coding region of the gene and 2 types of 
mutation are predominantly observed: N-terminal frameshift mutations which result in 
a truncated form of the CEBPA protein; and C-terminal insertions which result in 
deficient DNA binding (Pabst et al., 2001). The majority of patients have biallelic 
C/EBPα mutation with many having an N-terminal frameshift and a C-terminal insertion 
or deletion on different alleles (Pabst and Mueller, 2007). Mutations resulting in loss of 
C/EBPα function are thought to promote leukaemogenesis by blocking granulocytic 
differentiation (Pabst et al., 2001). In addition, it was demonstrated that mutation of 
C/EBPα is associated with the upregulation of genes involved in erythroid 
differentiation, and downregulation of genes involved in driving myeloid differentiation 
and proliferation (Marcucci et al., 2008). Like mutations in NPM1, mutations of C/EBPα 
are also associated with a good response to induction therapy and a favourable 
prognosis, but the favourable impact is highly dependent on FLT3-ITD status. 
 
RARα 
The retinoic acid receptor alpha (RARα) gene, located on chromosome 17q21 encodes 
a nuclear receptor in humans that regulates transcription in a ligand-dependent 
manner. Translocations between this locus and several other loci have been 
associated with acute promyelocytic leukemia (APL), AML of subtype M3. The most 
frequent translocation is t(15,17)(q21;q22), which fuses the RARα gene with the PML 
gene (Kakizuka et al., 1991). The resulting chimeric protein suppresses transcription 
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of a number of genes containing retinoic acid response elements, leading to blocked 
myeloid differentiation and promoting cellular proliferation and survival (Pandolfi, 
2001). 
 
RUNX1 
The human RUNT-related transcription factor 1 (RUNX1, also called AML1) gene, 
located on chromosome 21q22 encodes for one of the two subunits forming the human 
core binding factor (CBF) (Miyoshi et al., 1991). RUNX1 is one of the genes most 
frequently deregulated in leukaemia mainly through chromosomal translocations, point 
mutations and amplifications. In AML, the RUNX1/ETO fusion oncoprotein arises from 
a balanced translocation between chromosomes 8 and 21 represents the most 
common type of mutation affecting the RUNX1 gene AML and is reported in 10 – 15% 
of adult AML cases (Kantarjian, 2015). t(8;21) is a defining feature of the FAB M2 AML 
subtype (Renneville et al., 2008). This fusion oncoprotein cause deregulation of 
haematopoietic differentiation by targeting a number of haematopoietic transcription 
factors including PU.1, GATA-1 and C/EBPα (Petrie and Zelent, 2007). The 
mechanism by which RUNX1/ETO contribute to the AML leukaemogenesis will be 
further described in Section 1.3. 
 
CBFβ 
The core binding factor beta (CBFβ) gene, located on chromosome 16q22 encodes 
the β subunit of a heterodimeric core-binding transcription factor belonging to the 
PEBP2/CBF transcription factor family which functions as a master regulator of 
numerous genes specific to haematopoiesis (e.g. RUNX1) and osteogenesis (e.g. 
RUNX2) (Liu et al., 1993). Mutations in this gene are commonly associated with an 
inversion on chromosome 16 (inv16), giving rise to a fusion  with the MYH11 gene at 
16p13 (Sinha et al., 2015). The resulting CBFβ/MYH11 fusion oncoprotein, has a 
similar function to the RUNX1/ETO fusion protein in that is can repress transcription 
leading to impaired haematopoietic differentiation (Reilly John, 2004). Given that both 
fusion products have similar pathogenic mechanisms they are grouped together and 
termed CBF leukaemias. 
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1.2.3. Class III mutations 
 
 Class III mutations represent a recently discovered group of mutations that 
affect proteins involved in epigenetic regulation which can lead to malignant cellular 
transformation by disrupting key cellular pathways such as DNA repair, RAS signalling, 
cell cycle and apoptosis (Conway O'Brien et al., 2014). The genes mutated in this 
group are: 
 
ASXL1 
The additional sex-comb like 1 (ASXL1) gene, located on chromosome 20q11.21 
encodes for a chromatin-binding protein that has repressive or activating effects on 
transcription through modification of histone methylation in haematopoietic cells (Chi 
et al., 2010; Abdel-Wahab et al., 2012). Somatic mutations in the ASXL1 gene have 
been reported in several types of myeloid malignancies including MDS, 
myeloproliferative neoplasia (MPN), chronic myelomonocytic leukaemia (CMML) and 
AML (Pratcorona et al., 2012). In AML, ASXL1 mutation occur in approximately 10.8% 
of de novo cases (Chou et al., 2010), with most mutations located in exon 12 of the 
gene resulting in protein truncation and loss of the PHD domain, an important feature 
for physical interaction with chromatin (Boultwood et al., 2010; Chou et al., 2010). 
ASXL1 mutations in leukaemia are associated with loss of ASXL1 function (Abdel-
Wahab et al., 2012) and deregulated expression of several genes involved in 
haematopoiesis (Davies et al., 2013). In addition, loss of ASXL1 function has been 
shown to impair granulocyte differentiation in human CD34+ progenitor cells (Davies et 
al., 2013) and contribute to the development of myelodysplastic syndrome-like disease 
in mice (Wang et al., 2014). 
 
IDH1/2 
The IDH1/2 genes encode for isocitrate dehydrogenase, a metabolic enzyme that 
catalyse the conversion of isocitrate to α-ketoglutarate (α-KG) to produce reduced 
nicotinamide adenine dinucleotide phosphate (NADPH) from NADP+, which is 
essential for many cellular processes including epigenetic regulation (Clark et al., 
2016; Medeiros et al., 2016). Recurring mutations in IDH genes are reported in 
approximately 20% of adult AML and 5% of adult MDS (Figueroa et al., 2010a; Abdel-
Wahab and Levine, 2013), with IDH2 mutations being more common than IDH1 
mutations (Döhner et al., 2015). Both IDH1 and IDH2 mutations are frequently 
16 
 
associated with substitution of arginine residues; R132C or R132H for IDH1 and 
R140Q or R172K for IDH2 (Molenaar et al., 2015). Expression of mutant IDH1/2 is 
associated with DNA and histone hypermethylation, altered gene expression and 
blocked differentiation of hematopoietic progenitor cells (Clark et al., 2016; Medeiros 
et al., 2016). 
 
TET2 
The ten-eleven translocation 2 (TET2) gene, located on chromosome 4q24 encodes 
for tet methylcytosine dioxygenase 2 which plays a key role in DNA demethylation by 
catalysing the conversion of the modified DNA base methylcytosine to 5-
hydroxymethylcytosine (Pastor et al., 2013). Somatic TET2 mutations are frequently 
observed in myeloid malignancies including MDS, MPN, CMML, AML and secondary 
AML (sAML) (Ko et al., 2010). In AML, mutations in TET2 are reported in 7 – 27% of 
cases (Weissmann et al., 2011; Gaidzik et al., 2012), and are predominantly 
associated with CN-AML (Weissmann et al., 2011). In a murine model loss of TET2 
leads to DNA hypermethylation and downregulation of several tumour suppressor 
genes in haematopoietic cells, conferring a proliferative and survival advantage 
contributing to the development of leukaemia (Rasmussen et al., 2015). 
 
1.3. RUNX1/ETO Confers a Mutator Phenotype 
 
 Cancer is driven by somatic mutations acquired during disease progression. 
The high number of mutations observed in many cancers led to the mutator phenotype 
hypothesis, which suggests that an early initiating mutational event in many cancers 
gives rise to an increase in spontaneous mutation rate (Loeb, 1991). This initiating 
mutational event acts as a driver for the acquisition of additional mutations which 
eventually lead to transformation of normal cells to the malignant phenotype. This 
theory is supported by the observation that constitutional  mutations in DNA mismatch 
repair (MMR) genes confer susceptibility to mutations and promote genomic instability, 
causing malignant transformation in hereditary non-polyposis colorectal cancer 
(HNPCC) (Eshleman and Markowitz, 1996). In leukaemia, such a mutator phenotype 
was identified in chronic myeloid leukaemia (CML) where the BCR/ABL fusion protein 
promotes the acquisition of point mutations in cells through inhibition of the mismatch 
repair (MMR) pathway, driving genomic instability and point mutations in tumour 
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suppressor genes including p53 and Rb, eventually leading to malignant progression 
of the disease (Stoklosa et al., 2008). 
 A recent study has demonstrated that expression of the RUNX1/ETO fusion 
protein confers a mutator phenotype by predisposing cells to the acquisition of somatic 
mutations, both spontaneously and after exposure to genotoxic chemotherapy, with 
downregulation of OGG1 expression hypothesised as one possible mechanism 
(Forster et al., 2015). The RUNX1/ETO fusion gene, a product of t(8;21) translocation, 
is one of the most common genetic lesion observed in AML (Klaus et al., 2004; 
Sanderson et al., 2006b; Grimwade et al., 2010). It is observed in approximately 40% 
of FAB M2 AML cases (Peterson et al., 2007) and is defined as a distinct entity 
according to WHO classification (Arber et al., 2016), having specific clinical and 
biological characteristics compared to other AML subtype. The resulting fusion 
oncoprotein was demonstrated to block myeloid differentiation and downregulate 
several DNA repair proteins, leading to genomic instability and elevated DNA damage 
which are crucial in AML pathogenesis (Alcalay et al., 2003). 
 
1.3.1. RUNX1/ETO structure and interactions 
 
 The t(8;21) translocation fuses the RUNX1 gene (also called AML1) on 
chromosome 21 with the ETO gene (also called RUNX1T1) on chromosome 8 to form 
the RUNX1/ETO fusion gene. The expressed RUNX1/ETO fusion protein consists of 
752 amino acids comprising the N-terminal portion of RUNX1, with the intact Runt 
homology domain (RHD) and almost the entire ETO protein, containing four intact 
nervy-homology regions (NHRs) (Figure 1.3). Numerous RUNX1/ETO transcript 
isoforms are reported in t(8;21) AML patients, which encode truncated proteins shorter 
than the full-length RUNX1/ETO protein due to alternative splicing (Tighe and Calabi, 
1994; van de Locht et al., 1994). One transcript variant of particular interest widely 
detected in AML is RUNX1/ETO9a, characterised by an additional 155bp from exon 9 
of ETO (Yan et al., 2006). The RUNX1/ETO9a transcript results in the production of a 
C-terminal truncated RUNX1/ETO protein of 572 amino acids (Yan et al., 2006). Similar 
to other truncated isoforms of RUNX1/ETO, RUNX1/ETO9a lacks the NHR3 and 
NHR4 domains which are important for interaction with transcriptional repressors like 
NCoR and SMRT (Lutterbach et al., 1998; Wang et al., 1998; Zhang et al., 2001). 
Despite that, RUNX1/ETO9a rapidly induces leukaemia compared to full-length 
RUNX1/ETO in a murine model (Yan et al., 2006), which demonstrated that disruption  
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Figure 1.3. Structures of the full-length RUNX1/ETO protein and truncated 
RUNX1/ETO9a protein. 
The RUNX1/ETO full-length fusion protein is comprised of 177 amino acids from the 
N-terminal of RUNX1 (including a RHD) and almost the whole ETO protein containing 
four NHRs, produce a 752 amino acid form of RUNX1/ETO. The RUNX1/ETO9a fusion 
protein comprises the same 177 amino acids of RUNX1 but lacks the NHR3 and NHR4 
domains from ETO, giving rise to a truncated protein of 572 amino acids. 
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of the NHR3 and NHR4 domains via deletion or mutation of full-length RUNX1/ETO 
enhances leukaemia development  (Ahn et al., 2008). However, the exact mechanism 
by which RUNX1/ETO9a drives leukaemogenesis remains unclear and further studies 
are needed to delineate the role of this truncated fusion protein, especially because it 
is frequently co-expressed with full length RUNX1/ETO protein in primary t(8;21) AML 
(Ommen Hans et al., 2010).  
 RUNX1 belong to heterodimeric transcription factors family known as CBFs. 
Each CBF constitutes a non-binding CBFβ subunit and one of three DNA-binding 
CBFα subunit (RUNX1, RUNX2 and RUNX3) (Ogawa et al., 1993; Levanon et al., 
1994). The RHD of RUNX1 mediates DNA binding of RUNX1 with CBFβ subunit to 
interact with other transcription factors (Figure 1.4a). A wide variety of genes including 
IL3, GM-CSF, MPO and P14ARF are bound by the RUNX1/CBFβ complex, where 
transcriptional activity is generally up-regulated. Numerous RUNX1/CBF target genes 
are involved in the regulation of haematopoiesis (Meyers et al., 1993). In addition to 
interacting with CBFβ, RUNX1 can also interact with various other transcription factors 
and transcriptional co-regulators including ETS1, PU.1, C/EBPα, p300, mSin3a, 
GATA1, and FLI1 by coordinating their transcriptional activity via its RHD (Gunther and 
Graves, 1994; Zhang et al., 1996; Petrovick et al., 1998; Gu et al., 2000; Imai et al., 
2004; Xu et al., 2006; Huang et al., 2009). These studies show that the function of 
RUNX1 depends on its interaction partners to regulate target genes in an organised 
manner. 
 The four NHRs of ETO, all of which are retained in the RUNX1/ETO fusion 
protein, mediate interaction with other proteins. Briefly, NHR1 is homologous to several 
TATA binding protein-associated factors (TAFs) and mediates interactions with E 
proteins such as inhibition of transcriptional activation to recruit co-activator molecules 
such as p300/CREB-binding protein (CBP) (Zhang et al., 2004). NHR2 contains a 
hydrophobic amino acid heptad repeat (HHR) and mediates oligomerization of ETO 
and its family members (MTG8, MTG16, and MTGR1), as well as interaction with co-
repressor proteins such as nuclear receptor corepressor (NCoR), thyroid hormone 
receptors (SMRT), mSin3a, and histone deacetylases (HDAC) (Kitabayashi et al., 
1998; Zhang et al., 2001; Liu et al., 2006). NHR3 contains a coiled-coil structure, which 
facilitates binding to the regulatory subunit of type II cyclic AMP-dependent protein 
kinase (PKA RIIα), mediating interaction with PKA anchoring proteins (AKAPs) 
(Fukuyama et al., 2001). NHR4, a myeloid-Nervy-DEAF1 (MYND) homology domain, 
contains a zinc chelating structure and mediates interaction with co-repressor 
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NCoR/SMRT complexes (Lutterbach et al., 1998; Wang et al., 1998; Zhang et al., 
2001). Despite their significant involvement in protein-protein interaction, these 
domains lack DNA-binding ability as compared to RUNX1. In a polymerase chain 
reaction (PCR)-based DNA-binding site screen ETO was not able to bind DNA, unlike 
RUNX1 which preferentially bound to DNA sequences with duplicated RUNX1 
consensus sites (Okumura et al., 2008). 
 Based on  interaction of ETO with co-repressors it was suggested that the N-
terminal portion of RUNX1 in RUNX1/ETO binds to DNA (RUNX1 target gene 
promoter) via RHD to repress the transcription of RUNX1 target genes (Wildonger and 
Mann, 2005). The ETO portion of RUNX1/ETO recruits NCoR/SMRT/SIN3/HDAC 
complexes, leads to decreased histone acetylation and chromatin accessibility at 
RUNX1 targets (Zhang et al., 2001; Liu et al., 2006; Lin et al., 2017). Taken together, 
these data provide evidence that RUNX1/ETO drives repression of RUNX1 target 
genes and inhibits expression of haematopoietic differentiation genes (Figure 1.4b). 
 
1.3.2. RUNX1/ETO cooperating mutations and additional cytogenetic 
abnormalities 
 
 There is a growing body of evidence demonstrating that RUNX1/ETO alone is 
insufficient for leukaemogenesis, as it requires additional co-operating mutations for 
progression to AML. Transgenic mice with expression of full-length RUNX1/ETO did 
not result in the development of leukaemia and remain healthy during their life spans 
(Yuan et al., 2001). However, following treatment with a strong mutagen 
(ethylnitrosourea (ENU)), 55% of RUNX1/ETO-expressing transgenic mice developed 
AML and the remaining transgenic mice and all of the wild-type mice developed acute 
lymphoblastic leukaemia (ALL). These studies demonstrate a requirement for 
additional co-operating mutations to facilitate transformation to AML in transgenic 
mice. In support of this conclusion, t(8;21)(q22;q22) has been reported in non-
leukaemic haematopoietic stem cells (HPSCs) of AML patients, potentially 
representing ancestral cells prior to the acquisition of co-operating mutations 
(Miyamoto et al., 2000).  
 Collaboration between different classes of mutations is necessary for the 
malignant transformation of hematopoietic progenitor cells (Section 1.2). The 
RUNX1/ETO fusion gene is generally recognised as a class II mutation, which affects 
genes involved in transcriptional regulation and leads to impaired myeloid  
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Figure 1.4. Transcriptional repression of RUNX1 target genes by RUNX1/ETO 
(Vassiliou and Green, 2010). 
(a) The normal CBF dimer (composed of RUNX1 and CBFβ) binds specific DNA 
sequences through the RUNX1 subunit and recruits transcriptional activators (TA) that 
upregulate the expression of many genes important for haematopoietic cell 
differentiation. (b) In leukaemic cells carrying the RUNX1/ETO fusion gene, ETO 
recruits a co-repressor complex comprising NcoR, SIN3 and HDAC to repress 
transcription of RUNX1 target genes which may lead to inhibition of the expression of 
haematopoietic differentiation genes. 
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differentiation during haematopoiesis (Kelly and Gilliland, 2002). Although numerous 
co-operating mutations have been reported in t(8;21) AML (Table 1.4) (Reikvam et al., 
2011), only mutations in certain categories of genes such as type III RTK family were 
shown to be ‘co-operating hits’ responsible for driving leukaemic transformation in 
t(8;21)/RUNX1/ETO AML (Yuan et al., 2001; Higuchi et al., 2002). One example is 
FLT3 gene, which encodes a membrane-bound RTK is involved in the regulation of 
proliferation, differentiation and apoptosis of haematopoietic cell progenitors (Stirewalt 
and Radich, 2003). Activating mutations of FLT3 such as FLT3-ITD cooperate with 
RUNX1/ETO to induce leukaemia in a murine bone marrow transplantation model 
(Schessl et al., 2005). 
 Mutations in the KIT gene represent the most common co-operating event 
associated with t(8;21) AML, and are detected in up to 50% of the cases (Beghini et 
al., 2000; Care Rory et al., 2003; Goemans et al., 2005; Kohl et al., 2005; Wang et al., 
2005). This gene encodes a transmembrane glycoprotein, and whose ligand is SCF. 
SCF binding promotes KIT dimerization and transphosphorylation that leads to 
activation of downstream signalling pathways involved in proliferation, differentiation, 
migration and survival, particularly of haematopoietic stem cells (Blume-Jensen and 
Hunter, 2001). Ligand-independent activation of KIT caused by mutations in the gene 
leads to deregulation of intracellular signal-transduction pathways (Blume-Jensen and 
Hunter, 2001). Different KIT mutations have been detected in t(8;21) AML, with most 
mutations predominantly occurring in the TKD2 of the gene (Wang et al., 2005; 
Paschka et al., 2006; Shimada et al., 2006). The most common KIT mutation in TKD2 
is N822K with a frequency of 39% (Reikvam et al., 2011), followed by three variants of 
D816 (D816H, D816V and D816Y) with frequencies between 10 – 35% (Paschka et 
al., 2006; Reikvam et al., 2011). Oncogenic cooperativity between activating KIT 
mutation and RUNX1/ETO has been demonstrated in murine models where the N822K 
mutation was shown to cooperate with the full-length RUNX1/ETO in the induction of 
a transplantable AML in mice (Wang et al., 2011). 
 RAS mutations represent another frequent co-operating event in t(8;21), found 
in approximately 17% of t(8;21) AML cases, with majority of the mutations occurred at 
codon 12 of N-RAS (Krauth et al., 2014). RAS is a family of small GTPase proteins 
that regulate intracellular signal transduction from a variety of membrane receptors, 
including c-KIT and FLT3 (Reuter et al., 2000). Activating RAS mutations abrogate 
GTPase activity which affect cellular proliferation, differentiation and apoptotic 
processes (Beaupre and Kurzrock, 1999). Co-expression of N-RAS G12D mutation 
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Abnormality Frequency in t(8;21) AML (%)a 
Chromosomal abnormalities: 
     -X in female patients 
     -Y in male patients 
     Del(9q) 
     Trisomy 8 
     Complex karyotype 
 
30 – 40 
50 – 60 
13 – 20a,b 
4 – 8a,b 
9 – 23 
Gene mutations: 
     FLT3-ITD 
     FLT3 D853 
     KIT mutations 
          Specifically: 
               KIT N288K 
               KIT D816 (D816H, D816V, D816Y) 
     RAS G12D 
     JAK2 V617F 
 
5 
3 – 7 
25 – 50 
 
39 
10 – 35a,c 
17b 
6 – 8 
 
Table 1.4. Genetic abnormalities commonly detected in combination with t(8;21). 
a Frequency obtained from (Reikvam et al., 2011) unless otherwise stated. 
b Frequency obtained from (Krauth et al., 2014). 
c Frequency obtained from (Paschka et al., 2006). 
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and RUNX1/ETO in human haematopoietic cells increases colony forming and 
replating ability, which reflects the proliferative advantage conferred by N-RAS G12D, 
thus promoting progression towards transformation in RUNX1/ETO-expressing cells 
(Chou et al., 2011). 
 In addition to gene mutations, a variety of chromosomal abnormalities are 
observed concurrently with t(8;21). Loss of a sex chromosome represents the most 
frequent cytogenetic abnormality, with 30 – 40% of de novo t(8;21) AML cases having 
monosomy X in females and 50 – 60% having loss of the Y chromosome in males 
(Reikvam et al., 2011). The loss of sex chromosomes is associated with aging; 
however, a higher incidence observed in younger patients with t(8;21) AML (Mertens 
et al., 1993) indicates possible importance of this abnormality in t(8;21) AML 
leukaemogenesis. One gene of particular interest is CSF2RA, located on the located 
on the pseudo-autosomal region of the sex chromosomes, encodes the granulocyte-
macrophage colony-stimulating factor (GM-CSF) receptor α subunit that functions as 
a cytokine to promote myeloid proliferation, differentiation and cell survival (Burgess 
and Metcalf, 1980). A high penetrance of AML was observed in irradiated mice when 
transplanted with RUNX1/ETO-expressing HSCs that lack GM-CSF (Matsuura et al., 
2012), demonstrating potential oncogenic cooperativity between RUNX1/ETO and 
disrupted GM-CSF signalling via loss of CSF2RA expression in the development of 
t(8;21) AML. 
 Other cytogenetic abnormalities recurrently observed in t(8;21) AML include 
chromosome 9q deletion (del(9q)) and trisomy 8, with incidence of 13 – 20% and 4 – 
8%, respectively (Reikvam et al., 2011; Krauth et al., 2014). Oncogenic cooperation 
between del(9q) and RUNX1/ETO in AML leukaemogenesis is associated with loss of 
transcriptional co-repressors TLE1 and TLE4 on chromosome 9 that cause increased 
cell proliferation in RUNX1/ETO-expressing cells (Dayyani et al., 2008). In contrast, 
the contribution of trisomy 8 to leukaemogenesis in t(8;21) AML is unclear, since it 
commonly presents as a sole cytogenetic abnormality in AML (Paulsson and 
Johansson, 2007).  
 Collectively, these observations indicate that genetic abnormalities affecting 
transcription factors (class I mutations) and mutations affecting genes involved in 
signal transduction (class II mutations) represent two classes of the most frequent 
somatic events in t(8;21) AML, and both are required for malignant transformation. 
However, the fact that other cytogenetic abnormalities found concurrently with t(8;21) 
in AML cannot be disregarded as their role in AML leukaemogenesis is still unknown. 
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1.3.3. Regulation of DNA repair by RUNX1/ETO and susceptibility to mutations 
 
 DNA is subjected to a constant barrage of stress from both normal cellular 
metabolic processes (endogenous stress) and environmental factors (exogenous 
stress) that can ultimately lead to DNA damage. Endogenous sources of DNA damage 
include hydrolysis, oxidation and alkylation while exogenous sources of DNA damage 
include ultraviolet (UV) light, ionising radiation and genotoxic chemicals (Marnett and 
Plastaras, 2001; Norbury and Hickson, 2001; Fry et al., 2005). DNA damage produced 
by reactive oxygen species (ROS), a natural by-product of normal cellular oxidative 
metabolism, is the most frequently occurring damage in cancer cells (Liou and Storz, 
2010). ROS are reactive chemical species containing oxygen that include superoxide, 
hydrogen peroxide, hydroxyl radicals and singlet oxygen. The production of ROS is 
also influenced by exogenous factors such as exposure to UV and ionising radiation 
which can increase the level of intracellular ROS (Liou and Storz, 2010). Uncontrolled 
production of ROS lead to oxidative stress in cells and can cause several types of DNA 
damage, including oxidized bases and single‐ and double‐strand breaks (Wiseman 
and Halliwell, 1996; Maynard et al., 2009). Cells are equipped with a number of 
different DNA repair pathways that attempt to remove damage and restore the 
structure of DNA, by either repairing the damage or inducing cell death if the damage 
is irreparable. The base excision repair (BER) pathway is the primary mechanism for 
the removal of damaged bases caused by oxidation, deamination and alkylation 
(Wilson and Bohr, 2007), whereas the nucleotide excision repair (NER) pathway is 
responsible for the removal of bulky DNA adducts caused by UV radiation, mutagenic 
chemicals or chemotherapeutic drugs (Leibeling et al., 2006). The MMR pathway 
detects and removes mismatched DNA bases, including those arising due to DNA 
replication errors, and inserts the correct complementary base into the daughter DNA 
strand (Jiricny, 2006). Each of these DNA repair pathways excise a damaged region 
and insert new DNA bases to fill the gap. Furthermore, there are two major pathways 
for repairing double strand breaks (DSBs); non-homologous end joining (NHEJ) and 
homologous recombination (HR) (Lieber, 2010). However, in cancer cells, many of the 
components of DNA repair pathways are dysregulated or mutated, and such defect 
can result in low efficiency or low fidelity of repair and predispose to mutations. 
 Evidence suggests that RUNX1/ETO promotes mutagenesis through 
downregulation of genes involved in several DNA repair pathways (Alcalay et al., 2003; 
26 
 
Krejci et al., 2008). The impairment of DNA repair pathways and the accumulation of 
DNA damage in RUNX1/ETO-expressing cells is theorised to promote an elevated 
mutation rate and increase the chances of acquiring subsequent genetic alterations. It 
is suggested that the mechanisms by which RUNX1/ETO downregulate expression is 
through direct binding of RUNX1/ETO to conserved RUNX1 binding sites in regulatory 
regions of DNA repair genes (Krejci et al., 2008). 
 
1.3.3.1. Inactivation of p53 Pathway 
 
 Activation of the p53 pathway is a key cellular response to DNA damage and its 
inactivation plays an important role in the development of many cancers (Kirsch and 
Kastan, 1998; Amundson et al., 1999). It was demonstrated in vitro that p53 is 
upregulated after exposure to ROS-inducing agents such as hydrogen peroxide and 
2-methoxyestradiol, which indicates importance of this pathway in regulating response 
to DNA damage (Kitamura et al., 1999; Siebert et al., 2011). p53 is a nuclear 
transcription factor, encoded by TP53 gene on chromosome 17p13, which modulates 
cellular responses to DNA damage through the transcriptional activation of genes 
involved in cell cycle control, DNA repair and apoptosis (Vousden and Lu, 2002; Harris 
and Levine, 2005). 
 Tight regulation of p53 function is critical for normal cell growth and 
development. In normal cells, the expression of p53 protein is controlled through 
interaction with the Mdm2 protein. Mdm2 forms a complex with p53 that stabilises the 
endogenous levels of p53 through the proteasomal degradation pathway mediated by 
Mdm2 E3 ubiquitin ligase (Haupt et al., 1997; Kubbutat et al., 1997). Upon DNA 
damage, p53 become phosphorylated through post-translational modifications, 
preventing the formation of the p53/Mdm2 complex resulting in increased endogenous 
p53 levels (Harris and Levine, 2005). As a transcription factor, p53 mainly exerts its 
function through transcriptional regulation of its target genes. One of the important 
genes regulated by p53 is WAF1. Activated p53 binds to the promoter region of WAF1 
resulting in increased expression of the encoded protein, p21. p21 then binds to 
CDK4/Cyclin D complex and inhibits transcription of genes essential for cell cycle 
progression from G1 phase to S phase, activating cell cycle arrest at G1/S checkpoint. 
p53-mediated cell cycle arrest allows cells to repair damaged DNA. Once DNA is 
repaired, p53 degrades spontaneously and cells re-enter the normal cell cycle. In 
contrast, if the damage is too serious and irreparable, p53 exerts its function by causing 
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permanent arrest/senescence or activating pro-apoptotic genes to induce apoptosis. 
Therefore, dysfunction of p53 causes improper binding to target genes, and as a 
consequence, p21 protein is not transactivated and is not available to act as the "stop 
signal" for cell division. In this scenario, cell cycle progresses with damaged DNA 
resulting in fixation to mutation, genomic instability and malignant transformation. 
 Loss of p53 function is can be caused by mutation in the TP53 gene itself or by 
defects in the p53 signalling pathway. Mutation in TP53 is one of the most frequent 
genetic alterations in human cancers, found in about 50% of lung, oesophageal, 
colorectal, breast and ovarian cancers (Hollstein et al., 1991; Olivier et al., 2004). 
However, TP53 is rarely mutated in AML, and occurs in only 2 – 3% of all AML cases 
(Fenaux et al., 1992; Haferlach et al., 2008). Banker and colleagues reported no TP53 
mutations in in a group of 28 t(8;21) AML cases (Banker et al., 1998). Given the low 
rate of TP53 mutation in AML, including t(8;21) AML, it is thought that p53 is often 
inactivated by alternative mechanisms. 
 Numerous mechanisms have been proposed to interfere with p53 signalling in 
t(8;21) AML, including up-regulation of the BCL2 gene (Klampfer et al., 1996), silencing 
of the p15 and p16 gene loci (Wong et al., 2000) and direct transcriptional repression 
of p14ARF (Linggi et al., 2002; Hiebert et al., 2003). The BCL2 protein encoded by is a 
founding member of Bcl-2 family and constitutes an important regulator of apoptosis 
by either inducing apoptosis (pro-apoptotic) or inhibiting apoptosis (anti-apoptotic) in a 
context dependent manner (Kelly and Strasser, 2011). A consensus RUNX1 DNA 
binding sequence (TGT/CGGT) was identified in the 5' regulatory region of the BCL2 
gene, which demonstrated binding affinity for RUNX1/ETO leading to direct 
upregulation of BCL2 expression (Klampfer et al., 1996) delayed apoptosis in several 
cell types (Kelly and Strasser, 2011). The p15 and p16 proteins are recognised tumour 
suppressor proteins in both solid tumours and haematological malignancies (Takeuchi 
et al., 1995; Herman et al., 1996; Ng et al., 1997). These proteins function as cyclin-
dependent kinase inhibitor which form complexes with CDK4 or CDK6 and prevent the 
activation of cyclin dependent kinases (CDKs) by cyclin D, which subsequently inhibit 
cell cycle progression from G1 phase to S phase (Takeuchi et al., 1995). Concomitant 
p15 and p16 methylation is reported in M2 and M4 AML subtypes (Wong et al., 2000), 
and is associated with transcriptional loss of gene expression (Herman et al., 1996; 
Wong et al., 1998) leading to activation of the CDK/Cyclin D complex and failure of the 
G1/S checkpoint. Another important component of the p53 pathway is p14ARF, which 
acts as a mediator of p53 by indirectly activating p53 through inhibition of Mdm2 E3 
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ubiquitin ligase activity (Jing et al., 2003). However, evidence demonstrates that 
p14ARF is able to bind p53 directly if MDM2 is absent (Sherr, 1998; Lin and Lowe, 2001). 
The human p14ARF gene contains eight consensus RUNX1 binding sites in its promoter 
region, which makes it a direct transcriptional target of RUNX1/ETO (Linggi et al., 
2002). Experimental evidence has confirmed reduced endogenous levels of p14ARF 
expression in cells expressing RUNX1/ETO (Linggi et al., 2002). Loss of p14ARF leads 
to increased levels of MDM2 and reduced p53 levels, and therefore impairs p53-
mediated cell cycle arrest and/or apoptosis. 
 Collectively, these observations indicate that the mechanisms by which 
RUNX1/ETO impairs p53 signalling is complex and may involve deregulated 
expression of various genes. Regardless of the mechanism, disruption of p53 function 
could lead to inappropriate progression of cell cycle with damaged DNA in the genome, 
which is hypothesised to be one mechanism responsible in driving mutagenesis in 
t(8;21) AML. 
 
1.3.3.2. Downregulation of OGG1 by RUNX1/ETO 
 
 DNA glycosylases are a group of enzymes that play an essential role in the 
initiating step of BER in response to a wide range of DNA damage caused by oxidation, 
deamination and alkylation (Jacobs and Schär, 2012). 8-oxoguanine glycosylase 
(OGG1) encoded by the OGG1 gene, is a primary DNA glycosylase enzyme 
responsible for the excision of 8-oxoguanine (8-oxoG), a common DNA base lesion 
that occurs as a result of exposure to ROS (Ba and Boldogh, 2018). Indeed, previous 
studies have demonstrated increased OGG1 expression in response to increased 
ROS levels (Ishchenko et al., 2003) and oxidative DNA damage (Jankowska et al., 
2007). 8-oxoG is a pro-mutagenic DNA lesion which can cause mispairing of guanine 
with adenine, resulting in G:C to T:A transversion mutations if left unrepaired (Cheng 
et al., 1992; Boiteux and Radicella, 2000; Suzuki et al., 2010). OGG1 has the ability to 
directly remove 8-oxoG from DNA and protect against the mutagenic effects of 8-oxoG. 
Briefly, 8-oxoG lesions are principally detected by OGG1, which activates the BER 
pathway by catalysing the excision of 8-oxoG from the DNA strand, creating an apurinic 
(AP) site. OGG1 is also known as a bifunctional glycosylase, due to its ability to create 
a 3’ incision of the phospodiester backbone of DNA without the need for an 
independent AP endonuclease (Boiteux and Radicella, 2000; Shinmura and Yokota, 
2001). Following the 3’ incision of the phospodiester backbone a 5’ incision is made by 
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AP exonuclease. Re-synthesis of the resultant DNA gap is mediated by polymerase β 
and subsequently sealed by DNA ligase I to complete the repair process. 
 Mutation or deletion of the OGG1 gene is associated with impaired OGG1 DNA 
glycosylase activity that can lead to the accumulation of 8-oxoG and elevated 
spontaneous mutation in cells, which is predicted to contribute to cancer in humans 
(Shinmura and Yokota, 2001). Disruption of Ogg1 by partial deletion of the coding 
sequence in yeast increases spontaneous G:C to T:A transversions in cells (Thomas 
et al., 1997). In Ogg1-deficient mice, accumulation of 8-oxoG was associated with the 
development of lung adenoma/carcinoma (Sakumi et al., 2003). Moreover, Ogg1-
deficient mice were also susceptible to 8-oxoG formation after ultraviolet B (UVB) 
exposure, resulting in skin carcinogenesis (Kunisada et al., 2005). In addition, it was 
shown that substitution of arginine to glutamine at codon 229 (R229Q) caused by point 
mutation in the human OGG1 gene results in functional loss of OGG1 enzymatic 
activity that leads to accumulation of 8-oxoG lesions and activation of apoptosis in the 
myeloid leukaemia cell line KG-1 (Hyun et al., 2000). 
 The OGG1 gene is highly polymorphic in human populations and somatically 
mutated in some cancers (Shinmura and Yokota, 2001), which is thought to contribute 
to the loss of OGG1 function. Single nucleotide polymorphisms (SNPs) and somatic 
mutations in OGG1 have been associated with increased cancer risk (Boiteux and 
Radicella, 2000). One of the most common OGG1 polymorphisms is a C > G 
transversion at nucleotide position 1245 in OGG1 exon 7, resulting in a serine to 
cysteine alteration at codon 326 (S326C; ref SNP ID: rs1052134) (Simonelli et al., 
2013) which has been associated with impaired OGG1 DNA glycosylase activity 
(Kershaw and Hodges, 2012). This polymorphism can be found in 40 – 60% of Asian 
and 13 – 38% of Caucasian individuals (Morreall et al., 2015), and has been associated 
with increased risk of stomach, lung, prostate, nasopharyngeal, cervical and 
oesophageal cancers (Goode et al., 2002; Weiss et al., 2004). In haematological 
malignancies, rs1052134 is reported  with increased risk of childhood ALL (Stanczyk 
et al., 2011). However, there is no strong evidence that rs1052134 is associated with 
AML risk. 
 OGG1 is downregulated in human CD34+ haematopoietic progenitor cells 
expressing RUNX1/ETO when assessed by quantitative real-time PCR (qRT-PCR) 
(Krejci et al., 2008). In addition, gene expression data from a cohort of AML patient 
database showed that OGG1 was significantly downregulated in patient samples with 
t(8;21) as compared to other sub-types of AML (Liddiard et al., 2010). In a more recent 
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study, reduced OGG1 protein levels were observed in TK6 RUNX1/ETO clones and 
OGG1 transcript levels were found to be inversely proportional to the expression of 
RUNX1/ETO (Forster et al., 2015). Moreover, siRNA-mediated depletion of 
RUNX1/ETO resulted in an increase in OGG1 transcript levels and a concomitant 
increase in OGG1 protein (Forster et al., 2015). Taken together, these data suggest 
that OGG1 is downregulated in RUNX1/ETO-expressing cells. Moreover, the 
RUNX1/ETO fusion protein directly binds to the OGG1 gene promoter and negatively 
regulate its transcription (Ptasinska et al., 2012; Forster et al., 2015), providing a 
plausible mechanism by which RUNX1/ETO downregulates OGG1 expression and 
drives mutagenesis in t(8;21) AML patients. 
 
1.4. Treatment Strategies for Acute Myeloid Leukaemia 
 
 The aim of AML treatment is to restore normal haematopoiesis. To achieve this, 
the predominant abnormal cells, which are immature leukaemic blasts, need to be 
eliminated in order to allow normal cells to re-populate the marrow. Significant progress 
has been made in AML treatment including the use of alternative nucleoside analogues 
and targeted therapies in specific contexts. However, standard remission induction 
chemotherapeutic regimens consisting of cytarabine (ara-C) and an anthracycline, 
remain the main treatment for AML in most patients. 
 
1.4.1. Standard remission induction chemotherapeutic regimes in AML 
treatment 
 
 The nucleoside analogue ara-C in combination with and anthracycline has 
formed the backbone of intensive AML remission induction chemotherapy for the past 
40 years (Saultz and Garzon, 2016). AML treatment includes at least one course of 
intensive remission induction chemotherapy, followed by an additional course of 
intensive consolidation therapy (Figure 1.5). The first phase of the treatment aims to 
improve marrow function by inducing complete remission (CR), a condition in which 
the return of normal blood count with blast constituting less than 5% of the marrow 
population, while the second phase of the treatment aims to prolong the CR. The 
possibility of relapse declines to less than 10% if the patient has been in remission for 
3 years (Creutzig and Kaspers, 2004). In AML, the induction period is very intensive 
and patients do have significant treatment related mortality and morbidities. Such  
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Figure 1.5. Treatment options in acute myeloid leukaemia (Burnett and Venditti, 
2011). 
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treatment is necessary because AML could only be brought under control with 
intensive chemotherapy. Ara-C is usually administered in combination with 
daunorubicin (or in some cases idarubicin). Other agents sometimes used in 
combination with ara-C and daunorubicin include the base analogue 6-thioguanine and 
topoisomerase inhibitors such as etoposide (Burnett and Venditti, 2011). 
 Overall, approximately 60 – 80% of adult AML patients will achieve CR following 
standard remission induction chemotherapy (Shipley and Butera, 2009), with a higher 
CR rate reported in younger patients (< 60 years) compared to older patients (Saultz 
and Garzon, 2016). The low CR rate in older patients is partly due to an inability to 
tolerate aggressive therapeutic regimes. In contrast to AML at presentation, the 
treatment of relapsed or refractory AML remains a major problem and more difficult to 
treat, with reported CR rates after the first relapse to be as low as 28% (Larson, 2007), 
where disease is often associated with a chemoresistant phenotype. Relapsed AML 
often warrants the use of high-dose chemotherapy or alternative treatments such as 
targeted therapies. 
 
1.4.2. Alternative nucleoside analogues 
 
 Efforts to improve the CR rate have also included the use of alternative 
nucleoside analogue such as clofarabine and fludarabine, in combination with high-
dose ara-C. Both clofarabine and fludarabine share a similar mechanism of action to 
ara-C, with incorporation of nucleoside analogues into replicating DNA leading to 
termination of chain elongation and inhibition of DNA synthesis (see Section 1.7.1). 
 Clofarabine is a next generation nucleoside analogue used for the treatment of 
ALL in children and young people up to the age of 21 who failed initial treatment. It is 
also being tested in elderly AML patients who are unable to tolerate intensive 
chemotherapy and patients with relapsed or refractory AML. Previous studies have 
evaluated the use of clofarabine in combination with high-dose ara-C in 
relapsed/refractory AML patients (Faderl et al., 2005) and with low-dose ara-C in 
elderly AML patients (Faderl et al., 2008), with some evidence of improved CR rates 
and minimal cytotoxicity. 
 Fludarabine is an adenosine nucleoside analogue commonly used in the 
treatment of chronic lymphocytic leukaemia (CLL). It is currently being tested in 
combination with ara-C in patients with relapsed or refractory AML. The use of 
fludarabine in combination with high-dose ara-C, granulocyte colony-stimulating factor 
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and idarubicin significantly increased CR rate and reduced the risk of relapse, 
particularly in patients with favourable and intermediate risk karyotype (Table 1.3) 
(Burnett et al., 2013). 
 
1.4.3. Targeted therapies 
 
 Increased understanding of the pathogenesis of AML has fostered the 
development of targeted therapies that utilise the molecules present on the leukaemic 
cells as a mediator for the chemotherapy drug. The primary aim of a targeted approach 
is to preserve normal cell function and minimise adverse side effect while maintaining 
anti-leukaemic efficacy and improving the quality of life of AML patients. 
 The immunotoxin gemtuzumab ozogamicin (GO), commercially known as 
Mylotarg®, was the first approved targeted therapy as a single agent for the treatment 
of relapse in adult AML patients over the age of 60 who are unfit for further intensive 
cytotoxic chemotherapy (Stasi et al., 2008). GO consists of a monoclonal antibody 
conjugated to a highly potent anti-tumour antibiotic calicheamicin. This antibody binds 
to CD33, which is highly expressed on the surface of most AML cells, leading to 
internalisation of the  chemotherapy drug and induction of cytotoxic DNA DSBs (Stasi 
et al., 2008). GO has also shown remarkable activity in APL, possibly due to the high 
expression of CD33 on APL blasts (Estey et al., 2002; Lo-Coco et al., 2004), showing 
promising efficacy for the treatment of other AML patient subgroups. Recently, GO has 
also been approved for the treatment of adults with newly diagnosed CD33+ AML and 
for patients aged ≥2 years with CD33+ AML who have experienced a relapse or who 
have not responded to initial treatment (Appelbaum and Bernstein, 2017).  
 The advent of next generation sequencing (NGS) technologies has facilitated 
the discovery of sub-cytogenetic recurrent genetic mutations responsible for the 
development and progression of AML, which has subsequently driven the development 
of targeted therapies against mutant driver proteins. Examples of targeted therapies 
include FLT3 and IDH inhibitors, that are used either as a single agents or in 
combination with standard chemotherapy drugs to treat newly diagnosed AML patients 
with FLT3 and IDH1/2 gene mutations (Stein and Tallman, 2016). In addition to 
targeted therapies, the development of novel therapies that targeting biological 
processes essential to AML cell survival, such as cell cycle inhibitors, have shown 
promising early results in clinical trials either as single agents or in combination with 
standard remission induction agents (Saygin and Carraway, 2017). 
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1.5. Therapy-related Acute Myeloid Leukaemia 
 
 Therapy-related acute myeloid leukaemia (t-AML) is recognised as a specific 
form of AML that occurred as a late complication following cytotoxic therapy 
(chemotherapy and/or radiotherapy) for a primary cancer, such as Hodgkin lymphoma 
(HL), non-Hodgkin lymphoma (NHL), ALL, multiple myeloma, breast cancer, ovarian 
cancer and prostate cancer, or for non-malignant condition in some cases (Bhatia, 
2013). The latency period between diagnosis of the primary cancer and development 
of t-AML varies, which can range between several months to several years and is 
associated with cumulative dose, dose intensity and type of previous cytotoxic therapy 
(Godley and Larson, 2008). Two distinct subtypes of t-AML have been recognised, 
depending on the causative therapeutic exposures: an alkylating agents/radiation-
related type and a topoisomerase II (topo II) inhibitor-related type (Vardiman et al., 
2002). Abnormal cytogenetics are the frequent observation in t-AML patients, 
associated with increased prevalence of adverse-risk karyotype (Pedersen-Bjergaard 
et al., 2008). Patients with alkylating agent-related t-AML have a high incidence of 
abnormalities involving chromosome 5 (-5/del(5q)) and 7 (-7/del(7q)) (Smith et al., 
2003). In contrast, t-AML following chemotherapy with topo II inhibitors is frequently 
associated with balanced translocations involving chromosome bands 11q23 or 21q22 
(Olney et al., 2002). However, the classification of t-AML are no longer subcategorised 
since most patients received treatment with both alkylating agents and topoisomerase 
II inhibitors in recent years (Arber et al., 2016). Currently, t-AML account for 
approximately 10% of all AML cases in the UK (www.hmrn.org). t-AML patients is 
associated with low CR rate, to be as low as 28% (Larson, 2007). 
 
1.6. Clonal Evolution in Acute Myeloid Leukaemia 
 
 Despite the ability of standard regimes to induce remission in 60 – 80% of AML 
patients at diagnosis, the majority of patients develop relapse within 2 years (Shipley 
and Butera, 2009). Relapse remains difficult to treat and most patients with AML die 
from progressive disease after relapse. One reason for this is that relapse often occurs 
because the leukaemia cells have become resistant to drug treatment, which is 
associated with clonal evolution of the leukaemic cells. 
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 AML demonstrates clonal heterogeneity, where clones and cells compete with 
each other for resources and space within the bone marrow microenvironment. 
Competition generates natural selection that favour clones that grow faster, can 
disperse and invade. This model of clonal selection and evolution is thought to operate 
in most human cancers and is similar in principle to Darwin’s theory of natural selection, 
in which heritable traits that help organisms survive and reproduce become more 
common in a population over time. The genetic heterogeneity of cancer cells is shaped 
by clonal evolution, a multistep process by which random mutations are acquired 
during disease progression, resulting in a genetically diverse cell population that is then 
the subject of natural selection (Nowell, 1976; Merlo et al., 2006; Burrell et al., 2013). 
The advent of NGS technologies has allowed for a more comprehensive analysis of 
somatic variants in individual cancers, including the characterisation of very low 
frequency clones, which has facilitated better understanding of clonal evolution in 
cancer (Figure 1.6). AML genomes and HSPCs from normal individuals generally 
contain hundreds of random background mutations which accumulate over the time 
(Ley et al., 2008; Ding et al., 2012; Welch et al., 2012). Most of these mutations, which 
can be termed “passenger mutations”, are thought to be benign and irrelevant for AML 
pathogenesis. In addition to non-functional passenger mutations, initiating leukaemia-
driver mutations have also been reported and are associated with clonal 
haematopoiesis of indeterminate potential (CHIP) (Steensma et al., 2015). Specifically, 
CHIP refers to a common aging-related genetic event in which HSPCs or other early 
blood cell progenitors acquire somatic mutations, primarily in genes associated with 
myeloid neoplasm (e.g. DNMT3A, TET2, ASXL1) that drive clonal expansion and 
results in a genetically distinct subclone, without any apparent sign of haematological 
malignancy (Steensma et al., 2015). It is suggested that the presence of CHIP 
increases the risk of subsequent haematological malignancy when acquire an 
additional advantageous mutation (cooperating mutation) that accelerate the growth of 
cells which eventually transform to a clone that results in a clinically diagnosed AML 
phenotype. This is supported by genetic analysis of normal HSPCs and AML blasts 
from the same AML patients, where normal HSPCs contain pathogenic mutations in 
DNMT3A gene, but without the NPM1 mutations found in association with the same 
DNMT3A mutations in AML blasts (Shlush et al., 2014). In addition to CHIP mutations, 
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Figure 1.6. Clonal evolution of leukaemia. 
Leukaemia, like all cancers, is an evolutionary process that is driven by stepwise, sequential acquisition of somatic mutations and subclonal selection. 
Hematopoietic stem or progenitor cells (HPSCs) commonly acquire mutations throughout the human lifespan, with many of these are passenger 
mutations. However, acquisition of certain mutations can confer a survival advantage to the cells and allow clonal expansion without any apparent 
disease feature, a condition called clonal haematopoiesis of indeterminate potential (CHIP), until they acquire a cooperating mutation for progression 
to AML. Although remission is achievable after chemotherapy (CT), relapse may occur due to re-population of the dominant presentation clone (green), 
or as a result of subsequent clonal evolution from either the presentation clone (yellow) or from an ancestral clone (red). In a small subset of cases, the 
relapse clone is entirely genetically distinct from the presentation clone and may represent a second independent leukaemia or a therapy-related 
leukaemia. This genetic heterogeneity poses a difficult challenge in the management of relapsed AML.
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chromosomal translocations are recurrently found in 6 to 15% of cases (Schoch and 
Haferlach, 2002) and are thought to play an essential role in the early stages of disease 
pathogenesis (Döhner and Döhner, 2008; Chen et al., 2010). Many AML-associated 
chromosomal translocations, including t(15;17) and t(8;21), are found in non-leukaemic 
cells in a small number of healthy individuals (Quina Ana et al., 2000; Mori et al., 2002), 
which represent early genetic events in AML pathogenesis. In addition, expression of 
RUNX1/ETO in Drosophila also causes an expansion of blood cell lineage progenitors 
(Osman et al., 2009). Like CHIP mutations, these chromosomal translocations also 
require additional cooperating mutations to induce AML. Taken together, these 
evidences suggest that cells harbouring these mutations may serve as pre-leukaemic 
stage until one of the cell acquire an additional cooperating mutation for progression 
to AML. 
 Genomic instability is a prominent source of genetic diversity in leukaemic 
clones and is thought to drive phenotypic adaptability which may contribute to clonal 
selection during treatment and ultimately result in the evolution of relapse clones. High 
throughput sequencing of matched presentation and relapse AML samples have 
revealed two major patterns of AML relapse evolution (Ding et al., 2012; Welch et al., 
2012; Garg et al., 2015; Sood et al., 2015). Firstly, a leukaemic clone at disease 
presentation acquires additional mutations and evolves into the relapse clone after the 
chemotherapy, and secondly, the pre-leukaemic ancestral clone from the founding 
clone acquires additional mutations and evolves into a relapse clone via a semi-
independent pathway (Figure 1.6). In the former model, the relapse clone is a direct 
evolutionary descendent of the presentation clone. In the latter model, the relapse 
clone shares ancestry with the presentation clone, but is not a direct descendent. This 
is supported by a finding of RUNX1/ETO fusion gene in HPSCs of AML patients with 
long-term remission (Miyamoto et al., 2000), which suggests that the fusion gene 
persists in a long lived pre-leukaemic ancestral clone that survive chemotherapy. 
Importantly, both patterns of relapse are defined by the acquisition of additional novel 
somatic mutations.   
 The fact that AML relapse is associated with the addition of new mutations and 
clonal evolution, which is shaped, in part by the chemotherapy, warrant further 
investigation on the mutagenicity of chemotherapy agents used in AML remission 
induction treatment. A recent study has showed that ara-C, which is commonly used 
in AML remission induction treatment, preferentially induces mutation at the central 
base position of 5’TpGpA3’/5’TpCpA3’ sequences in the AML genome. These mutations 
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occur at a significantly higher frequency in relapsed AML patients after exposure to 
cytarabine-containing regimens (Fordham et al., 2015) compared to chemotherapy-
naïve AML, suggesting the existence of a “mutational fingerprint” induced by 
chemotherapy that can be identified in relapsed AML. 
 
1.7. Chemotherapy-induced DNA Damage 
 
 The current treatment of many cancers including AML is still largely based on 
the use of DNA-damaging chemotherapy agents. Although direct evidence is limited, 
chemotherapy used to treat AML is predicted to induce mutations detectable in 
relapsed disease. Chemotherapy contributes to relapse in cancer patients by 
damaging DNA and generating new mutations that allow tumour cells to evolve and 
become resistant to treatment. This is supported in a study that genotoxic 
chemotherapy such as FLT3 inhibitors might predispose to the development of new 
mutations in a cellular model (Leung et al., 2013). In addition, the type of DNA damage 
caused by each chemotherapeutic agent can be different, and is determined by the 
specific mechanism of action of each drug. 
 
1.7.1. Mechanism of ara-C in inducing DNA damage and mutation 
 
 Ara-C is a pyrimidine nucleoside analogue which resembles the structure of 
deoxycytidine in DNA, distinguished by a hydroxyl group in the β-D-configuration on 
the 2’-carbon of the deoxyribose ring (Figure 1.7). The cytotoxicity of ara-C is primarily 
mediated by its rapid conversion into ara-C triphosphate (ara-CTP) and incorporation 
into replicating DNA during cell cycle, resulting in chain termination (Graham and 
Whitmore, 1970; Zahn et al., 1972). Briefly, the penetration of ara-C into cells is through 
specific membrane-bound nucleoside transporters (Matsuda and Sasaki, 2005). Once 
inside cells, ara-C is converted into ara-CTP through a series of phosphorylation 
events mediated by deoxycytidine kinase. Ara-CTP then competes with CTP for 
incorporation into replicating DNA during S phase of cell cycle. Following incorporation, 
ara-CTP induces significant conformational perturbations in the DNA backbone, which 
subsequently inhibit DNA polymerase binding, leading to induced stalled replication 
and inhibition of chain elongation (Figure 1.8) (Gao et al., 1991; Schweitzer et al., 
1994). This process triggers the intra-S phase DNA damage checkpoint which results 
in cell cycle arrest (Shi et al., 2001) that allows the removal of ara-C lesion by DNA 
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repair pathways, particularly BER pathway (Wilson and Bohr, 2007). However, 
experimental evidence suggests that the exonuclease activities associated with 
replicative DNA polymerases are inefficient at removing ara-C lesions from the DNA 
strand (Huang et al., 1991; Perrino et al., 1999). 
 Another potential mechanism of ara-C-mediated cytotoxicity is incorporation 
into repair patches during DNA repair. Ara-CTP is an efficient substrate for both 
polymerase λ (pol λ) and polymerase β (pol β), which are responsible for re-synthesis 
of DNA during BER pathway (Garcia-Diaz et al., 2010; Prakasha Gowda et al., 2010). 
Incorporation of fraudulent pyrimidine nucleoside bases of ara-C into DNA by 
polymerases during BER can decrease the ligation rate of DNA ligases, subsequently 
leading to to stalled replication and fork collapse (Ewald et al., 2008; Prakasha Gowda 
et al., 2010). 
 The mechanisms by which ara-C induces cytotoxicity may also be enhanced 
through inhibition of the topoisomerase I (topo I) enzyme. In normal conditions, topo I 
binds to DNA and catalyses the relaxation of supercoiled DNA distal to replication forks 
during DNA replication by inducing transient single strand break (SSB) and subsequent 
rejoining (Roca, 1995). Incorporation of ara-C into replicating DNA increases the 
concentration of topo I-DNA covalent complexes and decrease the re-ligation rate 
giving rise to unstable protein:DNA complexes that result in the generation of DSBs 
(Chrencik et al., 2003). If unrepaired, DNA DSBs can induce apoptosis and cell death. 
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Figure 1.7. Structure of ara-C and deoxycytidine. 
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Figure 1.8. Mechanism of action by which ara-C induces DNA damage and 
mutation. 
Incorporation of ara-CTP into replicating DNA during S phase induces conformational 
perturbations at the site of incorporation, leading to stalled replication and activation of 
the intra-S phase DNA damage checkpoint. If the damaged base cannot be repaired, 
permanent arrest can occur which eventually leads to mutation, apoptosis or cell death. 
Inefficient removal of incorporated ara-C lesions by exonucleases during BER (Huang 
et al., 1991; Perrino et al., 1999) may also increase rates of mutation or induce cell 
death. 
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1.7.2. Mechanism of daunorubicin in inducing DNA damage and mutation 
 
 Daunorubicin belongs to the anthracycline class of drugs,  which are widely 
used in the treatment of numerous cancers, including AML (Minotti et al., 2004). 
Daunorubicin is composed of four tetracyclic ring with an adjacent quinone-
hydroquinone group (aglycone moiety) and a sugar (aminosugar 42oiety) attached by 
a glycosidic linkage (Figure 1.9). 
 Daunorubicin can intercalate between DNA base pairs and inhibit DNA 
replication and transcription (Minotti et al., 2004). However, the primary mechanism by 
which daunorubicin induces cytotoxicity to cancer cells is via the inhibition of the DNA 
topo II enzyme (Gewirtz, 1999). DNA topoisomerases become targets for several 
classes of anti-cancer drugs including daunorubicin due to their key function in 
catalysing the relaxation of supercoiled DNA during DNA replication and transcription, 
mediated through the controlled transient generation and re-ligation of DSBs (Fortune 
and Osheroff, 2000). During DNA replication and transcription DNA becomes 
overwound distal to replication forks (Figure 1.10). Topo II binds to DNA and excises 
the phosphodiester backbone of both DNA strands to allow the DNA to be unwound 
temporarily in order to release the torsional strain before being re-ligated (Champoux, 
2001; Wang, 2002). However, intercalation of daunorubicin into DNA stabilises topo II- 
DNA complexes, preventing re-ligation of the break and inhibiting the progression of 
replication forks (Hande, 2008). Failure to repair DNA DSBs at sites of topo II-DNA 
complex formation can lead to chromosomal breakage, which can ultimately induce 
mutation, apoptosis and cell death. 
 There are two major pathways for repairing DSBs; NHEJ and HR (Lieber, 2010). 
HR is generally considered to be a high-fidelity repair pathway whereas evidence 
demonstrates that NHEJ has lower fidelity. Specifically, NHEJ frequently induces 
insertions or deletions (indels) at the site of breakpoint repair. Although HR-mediated 
repair is considered to be an error-free repair process, it can also lead to mutations 
such as base pair substitutions, indels, and complex chromosome rearrangements 
(Rodgers and McVey, 2016). Gene translocations represent one form of DSBs 
misrepair that arise from inhibition of DNA topo II enzyme (Richardson and Jasin, 
2000). Several partner genes involved in leukaemis-specific translocations are 
proposed to occur as a result of misrepair of DSBs induced by daunorubicin-mediated 
inhibition of topo II. For example, fusion of AF4 and AF9 in the t(9;11) translocation, 
PML and RARA in the t(15;17) translocation and RUNX1 and ETO in the t(8;21) 
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translocation are all thought to be induced by exposure to topo II poisons such as 
daunorubicin. Furthermore, translocations involving MLL at chromosome 11q23 
(Lovett et al., 2001; Zhang et al., 2002; Whitmarsh et al., 2003; Mistry et al., 2005) are 
also common in cancers that arise following exposure to topo II posions. 
 In addition to inhibiting ligation of topo II-cleaved DNA complexes, daunorubicin 
can also redox cycle resulting in the formation of free radicals, such as reactive oxygen 
species (ROS), that damage DNA, proteins and cell membranes (Powis, 1989). 
Specifically, the quinone moiety of daunorubicin can undergo enzymatic reduction 
forming semiquinone and oxygen radicals (Bachur et al., 1978; Bates and Winterbourn, 
1982; Muindi et al., 1984). However, the contribution of free radical generation to the 
cytotoxicity of the anthracyclines remains unclear, as there is no strong evidence 
demonstrating free radical generation at clinically relevant concentrations of 
anthracyclines and at the oxygen tension in cancer cells (Gewirtz, 1999). 
 
 
 
 
Figure 1.9. Structure of daunorubicin. 
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Figure 1.10. Mechanism of daunorubicin-induced DNA damage and mutation. 
DNA topoisomerase II (topo II) is responsible for relaxing the torsional strain in 
overwound DNA through controlled transient generation of double strand breaks 
(DSBs) and re-ligation of the breaks. Intercalation of daunorubicin between DNA base 
pairs stabilises topo II-cleaved DNA covalent complexes, preventing re-ligation of the 
break, thus inhibiting the progression of replication forks. If the damage cannot be 
repaired, the induced DSBs can ultimately lead to mutation, apoptosis or cell death. 
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1.8. Aims of Project 
 
 Although remission is achievable in AML patients, relapse remains a major 
clinical problem and most patients with AML die from progressive disease after relapse. 
It is thought that relapse is driven by additional cooperating somatic mutations that 
were acquired (or selected) after chemotherapy, which drive phenotypic adaptability 
and clonal selection during treatment. The mechanisms by which novel mutations are 
acquired at relapse remain unclear, although there is strong evidence that some are 
chemotherapy-induced. Despite considerable efficacy in the treatment of cancer, many 
chemotherapeutic agents are also mutagenic and could contribute to the aetiology of 
relapse-driver mutations.  
 Deep sequencing has identified two patterns of AML relapse evolution, where 
in both patterns, the relapsing clone evolves from a cell carrying leukaemia-initiating 
genetic lesions, including gene fusions such as RUNX1/ETO. Moreover, evidence 
suggests that the RUNX1/ETO fusion gene confers a mutator phenotype which 
predisposes cells to the acquisition of additional cooperating mutations through 
downregulation of DNA repair. Therefore, understanding how chemotherapy and 
fusion gene expression cause mutations in cells that survive remission induction is 
fundamental in preventing the acquisition of relapse-driver mutations and developing 
approaches to reduce AML relapse risk. 
 The primary objective of this project was to investigate the contribution of 
remission induction chemotherapy and fusion gene expression to the aetiology of 
pathogenic mutations in AML. The strategies for achieving this were: 
 
• To determine the effect of chemotherapeutic agents, particularly ara-C and 
daunorubicin on mutation frequency in vitro using a cell model system. 
• To determine whether RUNX1/ETO fusion gene expression affects 
mutagenesis in vitro, both spontaneously and after exposure to ara-C and 
daunorubicin. 
• To investigate whether RUNX1/ETO fusion gene expression predisposes to 
mutation at specific sequence of the genome. 
• To determine whether RUNX1/ETO fusion gene expression predisposes cells 
to mutations in leukaemia relevant genes, particularly NPM1 gene. 
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• To perform high-throughput exome sequencing of a cohort of matched 
presentation and relapse AML samples, in order to investigate the clonal 
architecture of AML and clonal evolution during AML treatment. 
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Chapter 2. Materials and Methods 
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2.1. Chemicals and Reagents 
 
 All chemicals and reagents used were of Analar grade and purchased from 
Sigma Aldrich Co. Ltd. (Dorset, UK) unless otherwise stated. Phosphate buffered 
saline (PBS) was prepared from PBS tablets (Life Technologies, Paisley, UK) 
dissolved in deionised distilled water (ddH2O) and autoclaved prior to use for sterility. 
Preparation of all additional reagents for use in specific experiments are detailed in 
relevant sections. 
 
2.2. Cell Lines 
 
TK6 B lymphoblastoid cells were a kind gift from Professor William Thilly (MIT, 
MA, USA). TK6 RE1 and TK6 RE8 cell lines were engineered to express RUNX1/ETO 
by Dr Vicky Forster (Northern Institute for Cancer Research (NICR), Newcastle, UK). 
These cell lines were used throughout the project to determine the effect of 
chemotherapy and the RUNX1/ETO fusion gene expression on the acquisition of 
somatic mutations. However, TK6 and its derivative cell lines are B lymphoblastoid 
cells; therefore, consideration needs to be given to expression of recombination-
activating genes (RAGs) and activation-induced cytidine deaminase (AID) in relation 
to the types of mutations seen. RAG expression is important for V(D)J genes 
recombination during early B-cell development and AID drives somatic hypermutation 
via deamination of cytosine to uracil in order to produce antibody diversity during late 
stage B cell development. Both of these pro-mutagenic processes are known to 
inappropriately target non-immunoglobulin genes and induce somatic mutation in other 
parts of the genome (Jones and Gellert, 2004; Larson and Maizels, 2004; Teng and 
Papavasiliou, 2007). 
Specific features of TK6 and other cell lines used in this project are described 
in Table 2.1. All cell lines were defrosted from liquid nitrogen stocks held in the 
Northern Institute for Cancer Research (NICR). 
 
 
 
 
 
49 
 
2.3. General Cell Culture Methods 
 
2.3.1. Routine cell culture 
 
Cell culture RPMI-1640 medium (Roswell Park Memorial Institute 1640) and 
reagents were purchased from Sigma Aldrich Co. Ltd. (Dorset, UK). Fetal bovine 
serum (FBS) was purchased from Gibco (ThermoFisher Scientific) and cell culture 
plasticware was from Corning-Costar (VWR International Ltd., Leicesterchire, UK). All 
cell culture work was performed in a class II microbiological safety cabinet ((BIOMAT-
2), Medical Air Technology., Oldham, UK)) using aseptic technique. All cell lines were 
maintained as suspension cultures in sterile 25cm2 cell culture flasks and passaged as 
required (Table 2.1) using 10 ml RF10 medium [RPMI-1640 medium supplemented 
with 10% (v/v) FBS and 50 µg/ml penicillin/streptomycin]. Cultures were incubated at 
37°C in a humidified 5% CO2 incubator (Hareus Equipment Ltd., Essex, UK). 
Experiments were performed on exponentially growing cells with fewer than 25 
passages. Testing for mycoplasma was performed by E. C. Matheson (Northern 
Institute for Cancer Research (NICR), Newcastle, UK) at 3 month intervals using a 
MycoAlert kit (Lonza Biologics, Slough, UK). 
 
2.3.2. Cell counting and determination of dell density 
 
A 10µl aliquot of cells in suspension was mixed with 10µl 0.4% solution of trypan 
blue (Life Technologies, Paisley, UK) in a 1:1 ratio and 10μl of the mixture was loaded 
onto a Neubauer haemocytometer (VWR International Ltd.) and counted using 
established techniques. An average from at least two separate counting for each cell 
sample were taken to determine the cell concentration. 
 
2.3.3. Cryopreservation of cell stocks 
 
 Cell stocks from all cell lines were prepared and stored long term in liquid 
nitrogen. An appropriate volume of cell suspension containing 5 x 106 cells was 
dispensed into a sterile 15ml BD Falcon™ centrifuge tube (BD Biosciences, Oxford, 
UK) and centrifuged at 300 x g for 5 minutes (min). Supernatant was discarded and 
the cell pellet was resuspended 1ml freezing medium [FBS supplemented with 10% 
(v/v) dimethyl sulphoxide (DMSO)]. The cell suspension was then transferred to a 
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sterile 1.8ml polypropylene cryovial (Invitrogen Life Technologies) and frozen slowly 
inside a Mr. Frosty™ Freezing Container (Thermo Fisher Scientific) by incubation at -
80°C overnight before being transferred to liquid nitrogen. 
 
2.3.4. Resuscitation of frozen cell stocks 
 
 Frozen cell aliquots were quickly thawed at 37°C and immediately transferred 
to 5ml of pre-warmed RF10 medium in a sterile 15ml BD Falcon™ centrifuge tube 
followed by centrifugation at 300 x g for 5 min. Supernatant was discarded and the cell 
pellet was resuspended in 5ml RF10 medium. Cell suspensions were then transferred 
to sterile 25cm2 cell culture flasks and monitored daily for growth. Once cell populations 
had recovered, suspensions were maintained as in Table 2.1 in preparation for use in 
experiments. 
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Cell Line Morphology 
Optimum 
Density 
(x106 cells/ml) 
No. of Days 
between 
Passage 
Split 
TK6 Lymphoblastoid, non-leukaemic 0.2 – 1.0 2 1:10 
TK6 RE1 
Lymphoblastoid, RUNX1/ETO-
transduced, clone 1 
0.2 – 1.0 2 1:10 
TK6 RE8 
Lymphoblastoid, RUNX1/ETO-
transduced, clone 8 
0.2 – 1.0 2 1:10 
Kasumi-1 Myeloid leukaemia with t(8;21) 0.3 – 3.0 3 1:10 
AML-3 
Myeloid leukaemia with NPM1 
mutation (type A) and the 
DNMT3A R882C mutation 
0.5 – 2.0 3 1:8 
THP-1 
Monocytic leukaemia with RAS 
G12D mutation 
0.2 – 0.8 3 1:8 
 
Table 2.1. Cell lines used in this project and their routine passage schedule. 
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2.3.5. Preparation of cell pellets 
 
 Aliquot of cell suspension containing 5 x 106 cells were dispensed into 15ml BD 
Falcon™ centrifuge tubes and centrifuged at 300 x g for 5 min. Supernatant was 
discarded and cell pellets were washed using 3ml cold sterile PBS. Suspension was 
centrifuged again and cell pellets were resuspended 1ml cold sterile PBS. Suspension 
was transferred to a sterile 1.5ml Eppendorf tube and centrifuged at 300 x g for 5 min. 
Supernatant was discarded and cell pellets were stored at -80°C until required. 
 
2.4. Western Immunoblotting 
 
Western blotting was used to quantify RUNX1/ETO fusion protein expression in 
RUNX1/ETO-transduced cell lines relative to their respective parental cells (Chapters 
3 and 5), and also to determine the specificity of mutant NPM1-specific antibodies 
(Chapter 5). Western immunoblotting comprises extraction of proteins, electrophoretic 
separation of proteins according to size on a polyacrylamide gel followed by 
immobilisation onto a membrane, and subsequent detection of target proteins of 
interest using labelled antibodies. The number of antibody molecules that bind to the 
target protein is proportional to the amount of protein present, therefore protein 
expression levels can be semi-quantitatively compared between different cell lines. 
 
2.4.1. Preparation of protein extract 
 
 A frozen cell pellet containing 5 x 106 cells (described in Section 2.3.5) was 
thawed and resuspended in 150μl sodium dodecyl sulphate (SDS) sample buffer 
[62.5M Tris-HCl pH 6.8, 2% (w/v) SDS, 20% (v/v) glycerol].  The cells were then 
disrupted by passing through a 21-gauge needle (attached to a 1ml syringe) several 
times. The cell lysate was heated at 100°C for 5 min in a heat block followed by 
centrifugation at 14,000 x g for 10 min to pellet cell debris. The supernatant was 
transferred to a fresh sterile Eppendorf for quantification of protein concentration using 
the Pierce BCA assay as described in Section 2.4.2. 
 After determination of protein concentration, 250µg of protein was transferred 
to a fresh 1.5ml Eppendorf tube and made up to 200µl using SDS sample buffer 
followed by the addition of 25µl 0.2% bromophenol blue aqueous solution (final 
concentration 0.01% v/v) and 25µl β-mercaptoethanol (final concentration 20% v/v), 
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resulting in a protein concentration of 1mg/ml. Aliquots of 50µl were stored at -20°C 
until required. 
 
2.4.2. Quantification of protein concentration by Pierce BCA assay 
 
 Pierce® BCA Protein Assay Kit (Fisher Scientific UK Ltd., Leicestershire, UK) 
was used for the quantification of protein concentration in the extract. The principle of 
this assay is based on colorimetric detection following reduction of copper cations 
(Cu+2 to Cu+1) by protein with bicinchoninic acid (BCA) in an alkaline medium, results 
in the generation of a purple coloured complex. The absorbance of this coloured 
complex can be measured at 562nm and increases linearly with increasing protein 
concentration, thus allowed for an estimation of protein concentration to be made. The 
assay was performed according to manufacturer’s protocols which are described as 
follows: 
 A fifty microliter aliquot of diluted extract was made by adding 5µl of neat extract 
to 45µl dH2O (1:10 dilution) to give an approximate protein concentration within the 
detection range of the kit (0.2 – 1.2 mg/ml). A set of standard dilutions of bovine serum 
albumin (BSA) was prepared according to Table 2.2. For each standard and diluted 
extract, 10µl was transferred into four wells of a 96-well flat-bottomed plate (VWR 
International Ltd.) starting from the second column of the plate and 10µl of dH2O was 
added to each eight wells in the first column of the plate as blanks. An appropriate 
volume of BCA working reagent was prepared (Reagent A + Regent B in a 50:1 ratio) 
and 190µl was added into each well and the contents of the plate were gently mixed 
on a plate shaker, followed by incubation at 37°C for 30 min. 
 Following incubation, the plate was placed in a Spectromax® 250 Microplate 
Spectrophotometer System (Molecular Devices Corporation, Crawley, UK) for 
absorbance reading at 562nm. Protein concentrations were calculated via comparison 
of a corrected mean absorbance value of the diluted extract to a standard curve 
generated by the set of BSA standards (0.2 – 1.2 mg/ml). The concentration of the 
neat protein extract was determined by multiplying the measured value by 10 (to 
account for dilution factor). 
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Volume of BSA 
stock solution (µl) 
Volume of dH2O 
(µl) 
Final concentration 
of standard (mg/ml) 
240 160 1.2 
200 200 1.0 
160 240 0.8 
120 280 0.6 
80 320 0.4 
40 360 0.2 
 
Table 2.2. Preparation of BSA standard solution. 
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2.4.3. SDS PAGE and electrophoretic transfer 
 
 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed for separation of proteins in the extract according to size. Mini-PROTEAN® 
TGX™ 4-20% Tris-Glycine precast gels (Bio-Rad) were placed in a mini PROTEAN 
Tetra system filled with SS electrode buffer [41.2mM Tris-HCl pH 6.8, 192 mM glycerol, 
0.1% (w/v) SDS]. In the first lane of each gel, 10µl of PageRuler™ Prestained Protein 
Ladder (ThermoFisher Scientific) was loaded. For each sample, 20µl of cytosolic 
extract (20µg of protein) was loaded per well. Electrophoresis was performed using a 
constant voltage of 150V for approximately 1 hour. 
 Following separation by electrophoresis, proteins were transferred from the gels 
onto a polyvinylidenefluoride (PVDF) membrane (Bio-Rad Laboratories Ltd., 
Hertfordshire, UK) via another round of electrophoresis. Briefly, gels were removed 
from their casing and assembled on the cassette accordingly to Figure 2. PVDF 
membranes were soaked in 100% methanol for 20 seconds (sec) and placed in 
transfer buffer [10mM CAPS-NaOH pH 11, 10% (v/v) methanol] before use. Gels were 
removed from their casing transferred onto the membrane before being sandwiched 
between two 3mm Whatman® chromatography papers (VWR International Ltd.) and 
two transfer sponges, all of which had been pre-soaked in transfer buffer. Cassettes 
were placed in a Mini Trans Blot Electrophoretic Transfer Cell (Bio-Rad Laboratories 
Ltd.) filled with transfer buffer and electrophoresis was performed overnight at a 
constant voltage of 100V using a magnetic stirrer to maintain ion distribution within the 
buffer and with an ice block to prevent extreme increases in temperature. 
 
2.4.4. Antibody detection and visualisation of bound proteins 
 
 PVDF membranes with bound proteins were removed from transferred 
cassettes and placed in 50ml BD Falcon™ tubes containing 20ml of 5% blocking 
solution [TBS/Tween [0.01M Tris-HCl pH 7.5, 0.1M NaCl, 0.05% (v/v) Tween-20] and 
5% (w/v) dried non-fat skimmed milk powder]. The membranes were constantly 
agitated on a roller mixer at room temperature for one hour to block non-specific 
antibody binding sites. After the blocking, membranes were divided into appropriate 
sections depending on the size of protein of interest (as estimated using the protein 
ladder). Each section of the membrane was transferred to a separate 50ml BD 
Falcon™ tube containing 5ml of primary antibody solution (prepared according to 
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dilutions specified in Table 2.3). All membranes were incubated overnight at 4°C on a 
roller mixer (with constant gentle agitation). 
 Following exposure to appropriate primary antibodies, membranes were 
transferred to a fresh 50ml BD Falcon™ tube and washed three times using 5ml 
TBS/Tween [0.01M Tris-HCl pH 7.5, 0.1M NaCl, 0.05% (v/v) Tween-20] on a roller 
mixer at room temperature for 10 min each wash. Wash steps were performed to 
ensure removal of any unbound primary antibody. Membranes were then transferred 
to fresh 50ml BD Falcon™ tubes containing appropriate secondary antibody 
conjugated to horseradish peroxidase (prepared according to dilution specified in 
Table 2.3) and incubated at room temperature for 1 hour on a roller mixer (with 
constant gentle agitation). After exposure to secondary antibodies, membranes were 
washed four times in the same way as above to remove any unbound antibody. 
 Bound antibodies were detected using Amersham™ ECL™ Prime Western 
Blotting Detection Reagent (GE Healthcare Ltd., Buckinghamshire, UK) according to 
the manufacturer’s protocol. Chemiluminescence from bound antibodies was 
visualised by exposing the membrane to Carestream Kodak BioMax light film (Sigma 
Aldrich Co. Ltd., Dorset, UK) for between 5 sec and 10 min, depending on the strength 
of the signal. Films were developed using a Mediphot 937 X-Ray Filmprocessor 
(Colenta Lobortechnik, Austria). 
 
2.4.5. Quantification of protein bands 
 
 The developed film was placed in a LAS-3000 Luminescent Image Reader V2.2 
(Fujifilm) to capture the image of the protein bands by using white light transilluminator. 
The captured protein bands were then quantified in relative to control sample using 
AIDA Image Analyser V3.28 software (Elysia-Ratest, Germany). 
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Antibody Host / Type Supplier Dilution 
P
ri
m
a
ry
 
AML1 (RUNX1) 
Rabbit, 
Polyclonal 
Merck Millipore 
#PC285 
1 : 40 
NPM1 
Rabbit, 
Polyclonal 
Invitrogen 
#PA5-12446 
1 : 1000 
NPM1 (mutant) 
Rabbit, 
Polyclonal 
Invitrogen 
#PA1-46356 
1 : 1000 
RAS 
Rabbit 
Monoclonal 
Cell Signalling Tech. 
#8955s 
1 : 1000 
RAS  
(G12D mutant) 
Rabbit 
monoclonal 
Cell Signalling Tech. 
#14429 
1 : 1000 
GAPDH 
Rabbit, 
Polyclonal 
Santa Cruz Biotech. 
#SC25778 
1 : 400 
S
e
c
o
n
d
a
ry
 
 
Anti-rabbit 
 
Goat, 
Polyclonal 
Dako 
#P0448 
1 : 2000 
 
Table 2.3. Antibodies used in western immunoblotting. 
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2.5. Cytotoxicity Assay 
 
 Cytotoxicity assays were performed to assess drug response in TK6 and its 
derivative subclones, in order to determine the efficacy of chemotherapeutic agents on 
the survival and proliferation of cells and to identify appropriate doses for evaluating 
the effect of chemotherapeutic agents on mutation frequency (MF) (Chapter 3). 
 
2.5.1. Preparation of chemotherapeutic agents 
 
 All chemotherapeutic agents used for in in vitro cytotoxicity and mutation assays 
were purchased from Sigma-Aldrich Co. Ltd. (Dorset, UK). Stock solutions were 
prepared according to Table 2.4 using sterile ddH2O and appropriate working solutions 
were prepared by dilution of stock solutions in sterile ddH2O before use in experiments. 
 
2.5.2. 96-well clonogenic assay 
 
 Clonogenic assays were performed to assess the ability of TK6 cells to grow 
and survive at a very low density (i.e. 101 cells/ml) following exposure to appropriate 
doses of daunorubicin. 
 An accurate cell count was performed to and a cell suspension at a density of 1 
x 105 cells/ml in 10ml RF10 medium was generated for each cell line. Following this, a 
10-fold serial dilution was carried out using RF10 medium to derive cell suspensions 
at 1 x 103 cells/ml, 1 x 102 cells/ml and 1 x 101 cells/ml (each in a volume of 30ml). An 
appropriate volume of daunorubicin working solution (depending on the final 
concentration of daunorubicin) was added to each cell suspension in a 50ml BD 
Falcon™ tube. Drug exposed cells (200 μls) were then transferred to each well of a 
96-well culture plate (VWR International Ltd.). The lowest doses were applied to cell 
suspensions at a density of 1x101 cells/ml (2 cells/well), mid-range doses were applied 
to cell suspensions at a density of 1x102 cells/ml (20 cells/well) and the highest doses 
were applied to cell suspensions at a density of 1x103 cells/ml (200 cells/well). A 
vehicle-only control was also prepared by adding an appropriate volume of solvent to 
30ml of 1x101 cells/ml cell suspension and 200μl was transferred to each well of a 
plate. The design of the plating for each cell line is illustrated in Figure 2.1. All plates 
were incubated at 37°C/5% CO2 for approximately 20 days.  
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 Following 20 days growth period, the number of negative wells (wells in which 
no viable colony had grown) was scored per plate at each dose including vehicle-only 
control. Calculation of cloning efficiency (CE) was performed using the following 
formula (Furth et al., 1981) : 
 
𝐶𝑙𝑜𝑛𝑖𝑛𝑔 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (𝐶𝐸) =
− ln(𝑁𝑜. 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑤𝑒𝑙𝑙𝑠 ÷ 𝑡𝑜𝑡𝑎𝑙 𝑛𝑜. 𝑜𝑓 𝑤𝑒𝑙𝑙𝑠)
𝑁𝑜. 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑤𝑒𝑙𝑙
 
 
All calculations were performed using Microsoft Excel. The survival fraction at each 
dose was determined by calculating the mean CE of the dosed cells as a percentage 
of the mean CE of the vehicle-treated cells and each experiment was repeated three 
times. The dose-response curve was generated using mean survival fractions and 
standard error of the mean (SEM) of the data from three independent experiments 
using GraphPad Prism 6 software (San Diego, USA). 
 
2.5.3. Dose finding assay 
 
 A dose-finding assay was carried out to identify appropriate doses inducing 
relevant cytotoxicity following 16 hours exposure to escalating doses of 
chemotherapeutic agents prior to use in mutation assays. 
 An accurate cell count was performed to generate a cell suspension at a density 
of 1 x 105 cells/ml in 10ml RF10 medium. An appropriate volume of working 
concentration drug solution was added to each flask and incubated at 37°C/5% CO2 
for 16 hours. Following incubation, the cell suspension was transferred to 15ml BD 
Falcon™ centrifuge tube and centrifuged at 300 x g for 5 min. Supernatant was 
discarded and cells were washed twice using 3 ml sterile PBS and resuspended in 
fresh RF10 medium for cytotoxicity assessment. 
 An accurate cell count was performed to determine the volume of cell 
suspension required to give 5 x 105 cells/ml. An appropriate volume of cell suspension 
was dispensed into a sterile BD Falcon™ centrifuge tube and centrifuged at 300 x g 
for 5 min. Supernatant was discarded and the cell pellet was resuspended in 5ml RF10 
medium to give a cell suspension at 1 x 105 cells/ml. A 10-fold serial dilution was 
performed using RF10 medium to derive cell suspensions at 1 x 102 cells/ml and 1 x 
101 cells/ml (in a volume of 30ml). For each cell density a 96-well culture plate was 
prepared and incubated at 37°C/5% CO2 for approximately 20 days. 
60 
 
 
 
 
 
 
Chemotherapeutic Agent Molecular Weight Solvent 
Stock Solution 
(mM) 
Daunorubicin hydrochloride 563.98 
Sterile 
ddH2O 
5 
Cytarabine hydrochloride 
(1-β-D-ararbinofuranosylcytosine) 
279.68 
Sterile 
ddH2O 
1 
 
Table 2.4. Preparation of stock solutions of chemotherapeutic agents. 
 
 
 
 
 
Figure 2.1. The design of the 96-well plating for clonogenic assay. 
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Following a 20 days growth period, the survival fraction at each dose was 
determined according to Section 2.5.2. Each experiment was performed on three 
independent occasions. A dose-response curve was generated using mean survival 
fractions and SEM of the data from three independent experiments (using GraphPad 
Prism 6 software). 
 
2.6. In Vitro Mutation Assay 
 
In vitro mutation assays were used to evaluate the effect of chemotherapeutic 
agents and RUNX1/ETO status on MF in TK6 cells using thymidine kinase (TK) and 
hypoxanthine-guanine phosphoribosyltransferase (HPRT) as reporter genes (Chapter 
3). The workflow for setup of the assays is summarised in Figure 2.2 and specific 
details of each step are described in Sections 2.6.1, 2.6.2, 2.6.3 and 2.6.4. 
 
2.6.1. Removal of spontaneous mutants using CHAT medium 
 
Prior to performing mutation assays, pre-existing spontaneous TK mutants 
(TK+/+/TK+/-) and HPRT mutants (HPRT+/-) in a cell population were purged by culture 
in CHAT (cytidine, hypoxanthine, aminopterin, thymidine) medium. Inhibition of purine 
nucleotide synthesis by aminopterin requires cells to rely on exogenous DNA 
precursors in the medium (hypoxanthine and thymidine) to evade DNA synthesis 
blockage (salvage pathways). TK and HPRT mutants unable to survive due to an 
inability to incorporate DNA precursors from the culture medium. 
For each cell line, 5 x 105 cells were centrifuged at 300 x g for 5 min, 
resuspended in 25ml CHAT medium [RF10 medium supplemented with 10μM 2-
deoxycytidine, 17.5μM thymidine, 200μM hypoxanthine and 0.2μM aminopterin] and 
transferred to a 75cm2 cell culture flask. Cultures were incubated at 37°C/5% CO2 for 
48 hours. 
 Following 48 hours incubation, cells were centrifuged at 300 x g for 5 min and 
the supernatant discarded. The cells were washed twice with 3ml sterile PBS and 
resuspended in 25ml THC medium [the same as CHAT medium but without 
aminopterin] and transferred to a fresh 75cm2 culture flask. Cultures in THC medium 
were incubated at 37°C/5% CO2 until cell populations recovered as indicated by 
exponential growth. The cultures were maintained daily by gradually replacing THC  
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Figure 2.2. General workflow of in vitro mutation assay (TK and HPRT). 
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medium with normal RF10 medium. Mutation assays were commenced immediately 
once normal exponential cell growth had been achieved. 
 
2.6.2. Drug exposure 
 
 A 50ml aliquot of cell suspension at a density of 1 x 105 cells/ml for each cell 
line (TK6 and TK6 RE8) was prepared using RF10 medium. The cell suspension was 
transferred to a sterile 50ml BD Falcon™ centrifuge tube and centrifuged at 300 x g for 
5 min. Supernatant was discarded and the cell pellet resuspended in 50ml RF10 
medium supplemented with an appropriate volume of drug or solvent and transferred 
to 175cm2 cell culture flasks. Each cell line was divided into four 50ml cultures in 175 
cm2 flasks for drug dosing. Three flasks from each cell line were designated as drug-
dosed flasks and one flask as a solvent control flask (vehicle-treated control). Cultures 
were incubated at 37°C/5% CO2 for 16 hours and each experiment was performed on 
three independent occasions. 
Following a 16 hour incubation, the dosed cell suspension was transferred to a 
sterile 50ml BD Falcon™ centrifuge tube and centrifuged at 300 x g for 5 min. 
Supernatant was discarded and cells were washed twice using sterile PBS. An aliquot 
of 5 x 105 cells from each dosed cell suspension was transferred to a sterile 50ml BD 
Falcon™ tube for cytotoxicity assessment as described in Section 2.5.3. The remaining 
cell suspensions were transferred to fresh 175cm2 culture flasks and incubated at 
37°C/5% CO2. Cell suspensions were maintained daily at a density between 2 x 105 
and 1 x 106 cells/ml (in a volume of 50ml) using RF10 medium. 
 
2.6.3. Selection of TK mutants 
 
 TK mutants were selected based on resistance to trifluorothymidine (TFT) after 
3 days in culture; the time required for expression of the TK mutant phenotype (Liber 
and Thilly, 1982). A 96-well non-treated plate was prepared to enable calculation of 
CE in the absence of selection and six 96-well TFT-treated plates were prepared for 
TK mutant selection. 
For each drug dosed and vehicle control cell suspension, an accurate cell count 
was performed and used to establish a cell suspension at a density of 1 x 105 cells/ml 
(in a volume of 155ml) using RF10 medium. The remaining cell suspension was 
returned to the incubator for subsequent HPRT mutant selection. In order to determine 
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cloning efficiency in the absence of TFT selection, a 5ml aliquot from this suspension 
was removed and a 10-fold serial dilution was performed using RF10 medium to derive 
a cell suspension at 1 x 101 cells/ml (in a volume of 30ml). The cell suspension was 
then transferred to a 96-well culture plate (200μl/well with average 2 cells/well). For the 
TFT-treated plates, the remainder of the cell suspension (150ml) was supplemented 
with 37.5µl of a 4mg/ml TFT solution (final concentration 1µg/ml) and transferred to six 
96-well culture plates (200µl/well with average 20,000 cells/well). All plates were 
incubated at 37°C/5% CO2 for approximately 20 days. 
 
2.6.4. Selection of HPRT mutants 
 
 HPRT mutants were selected based on resistance to 6-thioguanine (6-TG) after 
7 days in culture; the time required for expression of the HPRT mutant phenotype 
(Liber and Thilly, 1982). Similar to the TK mutant selection protocol, a 96-well plate 
was prepared to enable calculation of CE in the absence of 6-TG selection and six 96-
well 6-TG treated plates were prepared for HPRT mutants selection. 
For each drug dosed and vehicle control cell suspension, an accurate cell count 
was performed and used to establish a cell suspension at density of 1 x 105 cells/ml 
(in a volume of 155ml) using RF10 medium. In order to determine cloning efficiency in 
the absence of 6-TG selection, a 5ml aliquot from this suspension was removed and a 
10-fold serial dilution was performed using RF10 medium to derive a cell suspension 
at 1 x 101 cells/ml (in a volume of 30ml). The cell suspension was then transferred to 
a 96-well culture plate (200μl/well with average 2 cells/well). For the 6-TG-treated 
plates, the remainder of the cell suspension (150ml) was supplemented with 120µl of 
a 2.5mg/ml 6-TG solution (final concentration 2µg/ml) and transferred to six 96-well 
culture plates (200µl/well with average 20,000 cells/well). All plates were incubated at 
37°C/5% CO2 for approximately 20 days. 
 
2.6.5. Calculation of mutation frequency 
 
 Following a 20 day growth period for mutant colonies, the number of positive 
wells (wells in which mutant colonies had grown) was scored per plate from the six 
TFT- and 6-TG-treated plates for each dose. For calculation of CE in the absence of 
selection, the number of negative wells (wells in which no cell growth had occurred) 
was scored and the CE was determined according to the formula in Section 2.5.2. 
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 MF at each dose was calculated according to Liber and Thilly (Liber and Thilly, 
1982) using the following formula: 
 
𝑀𝑢𝑡𝑎𝑡𝑖𝑜𝑛 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 (𝑀𝐹) =
𝑇𝑜𝑡𝑎𝑙 𝑛𝑜. 𝑜𝑓 𝑚𝑢𝑡𝑎𝑛𝑡 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠
𝐶𝐸 𝑥 𝑇𝑜𝑡𝑎𝑙 𝑛𝑜. 𝑜𝑓 𝑐𝑒𝑙𝑙𝑙𝑠 𝑝𝑙𝑎𝑡𝑒𝑑
 
 
All calculations were performed using Microsoft Excel. The survival fraction at each 
dose was determined as described in Section 2.5.2 and each experiment was repeated 
three times. The cytotoxicity-MF exponential curve was generated using mean and 
SEM values from three independent experiments (using GraphPad Prism 6 software). 
 
2.6.6. Statistical analysis 
 
One-way and two-way analysis of variance (ANOVA) was used to assess the 
effects of drug dose and RUNX1/ETO status on MF. A p-value of < 0.05 was 
considered statistically significant in all cases. All statistical analyses were performed 
using GraphPad Prism 6 software (San Diego, USA). 
 
2.7. Molecular Analysis of HPRT Mutants 
 
 To further investigate the mutagenicity of RUNX1/ETO, both spontaneously and 
after chemotherapy treatment (Chapter 3), a number of spontaneous and 
daunorubicin-induced HPRT mutants were subject to molecular analysis in order to 
generate a daunorubicin-induced and RUNX1/ETO-induced mutational spectrum. 
HPRT cDNA was used for the mutation screening as it can specifically reveal mutations 
in the HPRT coding region which might give rise to dysfunctional protein (missense 
and nonsense mutations). In addition, mutation screening using cDNA can be achieved 
via a single amplicon. In contrast, mutation screening using genomic DNA would 
require amplification of each exon independently or the use of multiplex PCR. Both of 
these approaches would require optimisation and would be time consuming and 
laborious compared to the PCR of the HPRT cDNA. 
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2.7.1. Generation of spontaneous and daunorubicin-induced mutant cell 
populations 
 
 A small batch of CHAT-treated cell population was performed every time to 
minimise the number of duplicate mutations derived from the same parental flask which 
likely represent clonal expansions. The CHAT-treated parental population was divided 
into twenty independent populations in 25cm2 cell culture flasks (5ml/flask). A summary 
of the workflow used to generate spontaneous and daunorubicin-induced HPRT 
mutants is shown in Figure 2.3. 
 For the assessment of spontaneous mutants, the cell suspension were 
passaged every 2 days for 21 days to allow for the acquisition of spontaneous 
mutations. Following this acquisition period, the cell suspension from each flask was 
transferred to a 96-well culture plate under 6-TG selection to select for spontaneous 
HPRT mutant colonies. On the other hand, the cells were exposed to the highest 
dose of daunorubicin for 16 hours and transferred to a 96-well plate under selection of 
6-TG to generate daunorubicin-induced HPRT mutant colonies. 
 Following 20 days of growth, one mutant colony from each plate was randomly 
selected and transferred to a well of a sterile 24-well cell culture plate containing 1ml 
RF10 medium supplemented with 2μg/ml 6-TG. Plates were incubated at 37°C/5% 
CO2 and assessed daily for cell growth (indicated by a change in colour of culture 
medium and confirmed microscopically). Once sufficient cell numbers were generated 
(after approximately 7 days in culture), as estimated microscopically, each population 
was washed and cell pellets were prepared according to Section 2.3.5 (without 
performing cell counts). The cell pellets were stored at -80°C until required for 
DNA/RNA extraction (Section 2.7.2). 
 
2.7.2. DNA/RNA extraction and quantitation 
 
 Frozen cell pellets of HPRT mutants were thawed and resuspended in 350µl 
RLT Plus buffer. DNA and RNA extraction was performed using the AllPrep DNA/RNA 
Mini Kit (Qiagen) according to the manufacturer’s protocol. Briefly, DNA and RNA 
extraction was achieved through binding of DNA/RNA to a QIAamp® silica gel 
membrane (in spin-column format) after which contaminants were removed by 
washing using provided buffers. The DNA and RNA was eluted in respective elution 
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buffer (DNA: 50μl Buffer EB; RNA: 30μl RNase-free water). The eluted DNA and RNA 
was stored at -20°C and -80°C respectively until required. 
 Quantitation of RNA was performed using a NanoDrop® ND-1000 
spectrophotometer (Thermo Scientific, DE, USA) which measures the absorbance of 
UV light at 260nm passing through a 1.5μl aliquot of extracted RNA, and performs the 
necessary calculations according to the Beer Lambert Law to provide an estimate of 
RNA concentration (in ng/μl). Following quantitation, an appropriate dilution was 
performed using nuclease-free water to obtain 15µl of RNA at a concentration of 
200ng/µl for HPRT cDNA preparation. 
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Figure 2.3. Summarised workflow for the generation of spontaneous and daunorubicin-induced HPRT mutants. 
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2.7.3. PCR of HPRT cDNA 
 
2.7.3.1. Reverse transcription of RNA into cDNA 
 
 HPRT cDNA was prepared using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Warrington, UK), which uses the random primer 
method for initiating reverse transcriptase (RT)-mediated cDNA synthesis. 
  An appropriate volume of RT mastermix was prepared according to the 
manufacturer’s protocol as shown in Table 2.5 and 10μl of the mastermix was 
dispensed into an appropriate number of sterile 0.2ml PCR tubes (Eppendorf). For 
each sample, 10μl of 200ng/μl total RNA was added. A blank reaction (negative 
control) was also prepared using nuclease-free dH2O in place of RNA, to ensure no 
contamination of reagents. The following single cycle was performed using a 
GeneAmp® PCR System 9700 (Applied Biosystems): 
 
  Step 1 : 25°C 10 min 
  Step 2 : 37°C 120 min 
  Step 3 : 85°C 5 sec 
  Step 4 : 4°C Hold 
 
  1 cycle. 
 
Hypothetically, this protocol will yield 20µl of cDNA at a concentration of 100ng/µl by 
assuming 100% efficiency of RT reaction. 
 
2.7.3.2. Amplification of HPRT cDNA 
 
 PCR of HPRT cDNA was performed using a set of primer that amplify the exonic 
sequence of HPRT (Meng et al., 2002), as follows: 
 
   Forward: 5’CCTGAGCAGTCAGCCCGCGC3’ 
   Reverse: 5’CAATAGGACTCCAGATGTTT3’ 
  
 Primers were manufactured by Sigma-Aldrich, reconstituted to 100pmol/μl 
using TE buffer upon receipt and stored at -20°C. Working stocks of primers at a 
concentration of 10pmol/μl were prepared using nuclease-free dH20 and stored at 4°C. 
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 2X ReddyMix PCR Master Mix containing 0.625 u Taq DNA Polymerase, 75mM 
Tris-HCL, 20mM (NH4)2SO4, 1.5mM MgCl2 and 0.2mM each dNTP was obtained from 
ThermoFisher Scientific. This pre-mix of PCR components enables quick PCR 
preparation and reduces risk of contamination due to a reduced number of pipetting 
steps required for PCR set-up. 
 An appropriate volume of PCR master mix with primers was prepared according 
to Table 2.6 for each PCR reaction and 15µl of the master mix was dispensed into an 
appropriate number of sterile 0.2ml PCR tubes (Eppendorf). For each sample, 2μl of 
cDNA (200ng) was added and made up to a total volume of 25µl using nuclease-free 
dH2O. A blank reaction (negative control) was also prepared using nuclease-free dH2O 
in place of cDNA to ensure no contamination of reagents. Thermal cycle conditions 
were as follows: 
 
Initial denaturation 95°C 2 min  
Denaturation 95°C 25 sec 
36 cycles Annealing 55°C 3 sec 
Extension 72°C 65 sec 
Final extension 72°C 5 min  
 
2.7.4. Agarose gel electrophoresis 
 
A 1% agarose solution was prepared by melting 1g of Ultrapure™ agarose in 
100ml 1X TBE buffer using a 650W microwave on medium power. Following cooling 
to ‘hand heat’, 10μl of GelGreen Nucleic Acid Stain (10,000X in water) was added. Gel 
solutions were mixed thoroughly, poured into assembled large gel cassettes with 
combs and allowed to set at room temperature. 
 Gel cassettes were placed in Sub-Cell® GT Agarose Gel Electrophoresis 
Systems filled with 1X TBE buffer. To allow estimation of the size of PCR products, 
10μl of Quick-Load® 100bp DNA Ladder was loaded into the first well of each gel. For 
each reaction, 5μl of PCR product was loaded into each well of the gel. A negative and 
positive control was loaded into the second and third well, respectively. Amplicons 
derived from HPRT mutant colonies were loaded into the remaining wells and 
electrophoresis was performed at 100V for approximately 1 hour. 
 Following electrophoresis, the gel was removed from the cassette and placed 
in a Gel Doc™ XR (Bio-Rad Laboratories Ltd.) system and the Quantity One® V4.5.0 
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Component 
Volume per reaction 
(µl) 
Final concentration 
2X ReddyMix PCR Master 
Mix 
12.5 1X 
Forward primer (10µM) 1.25 0.5µM 
Reverse primer (10µM) 1.25 0.5µM 
Template cDNA* 2.0 200ng 
Nuclease-free dH2O* 8.0  
Total volume 25.0  
 
Table 2.6. Preparation of PCR master mix. 
*Separately added into each PCR tube containing 15µl of PCR master mix with 
primers. 
 
 
 
 
Reagent 
Volume per reaction 
(µl) 
Final concentration 
RT Buffer (10X) 2.0 2X 
dNTP mix (100mM) 0.8 8mM 
RT Random Primers (10X) 2.0 2X 
Multiscribe Reverse 
Transcriptase (50U/µl) 
1.0 5U/µl 
RNase inhibitor (20U/µl) 1.0 2U/µl 
Nuclease-free dH2O 3.2  
Total volume 10.0  
Table 2.5. Preparation of reverse-transcription master mix. 
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software was used to capture an image of the gel by using UV light for visualisation of 
PCR products. The presence of a DNA band in the positive control and absence of a 
DNA band in the negative control indicated successful PCR. Amplicons derived from 
HPRT mutants were assessed by size comparison with the positive control sample (as 
estimated using the DNA ladder) and PCR reactions where there was an absence of 
a DNA band were not further investigated for Sanger sequencing. 
 
2.7.5. Clean-up of PCR products for Sanger sequencing 
 
 Prior to Sanger sequencing, clean-up of PCR products (mutants with DNA 
band) was performed using the QIAquick® PCR Purification kit (Qiagen) according to 
the manufacturer’s protocol. Briefly, buffer PBI was mixed with PCR products in a 5:1 
ratio, followed by the addition of 10µl 3M sodium acetate (pH 5) to ensure correct pH 
of the mixture (indicated by the yellow colour of the mixture). The mixture was then 
transferred to a spin column, centrifuged at 15,000 x g for 1 min and the flow-through 
was discarded. A wash step was performed by adding 750µl of Buffer PE to the spin 
column and centrifuged at 15,000 x g for 1 min. The flow-through was discarded and 
the spin column was again centrifuged for an additional 1 min to dry the spin column 
membrane. The spin column was then transferred to a sterile 1.5ml Eppendorf tube 
and 30µl of Buffer EB was added directly to the centre of the spin column membrane 
to elute the DNA. The spin column was incubated at room temperature for 5 min, 
followed by centrifugation at 15,000 x g for 1 min for the collection of purified PCR 
products. 
 Quantitation of purified PCR products was performed as described in Section 
2.7.2 and the concentration was adjusted to 10ng/µl using nuclease-free dH2O. The 
purified PCR products were Sanger sequenced by Source BioScience LifeSciences 
(Nottingham, UK) using appropriate primers (section 2.7.3.2). 
 
2.7.6. Sequence analysis 
 
 Sanger sequence data was received in FASTA format, viewed using EditSeq 
(DNASTAR Inc., WI, USA) and compared to human HPRT exon sequences (NCBI 
Reference Sequence: NM_000194) using Multiple Sequence Alignment tools 
(https://www.ebi.ac.uk/Tools/msa/muscle).  Both forward and reverse sequences were 
analysed to ensure accurate coverage of entire exons. In addition, sequence traces 
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(chromatogram format) were viewed using FinchTV (Geospiza Inc., WA, USA) in order 
to assess quality of sequence reads.  
 
2.7.7. Classification of spontaneous and daunorubicin-induced mutation 
 
 HPRT mutants were grouped into five classes; partial gene duplications, base 
substitutions, small deletion/insertions, internal exon deletions and terminal deletions 
(5’ or 3’ terminal deletions). The number of mutants from each class was used to 
estimate the proportion of each class as a fraction of the total HPRT mutants analysed 
and mutation spectra were generated using Microsoft Excel. 
 
2.7.8. Statistical analysis 
 
 A Chi-squared test was performed to determine if there were any significant 
difference between the spontaneous and daunorubicin-induced HPRT mutational 
spectra, and also to determine whether RUNX1/ETO status significant affected 
mutation induction. The Fisher’s exact test was used to determine whether the 
frequency of specific classes of mutants differed significantly between spontaneous 
and daunorubicin-induced and also between RUNX1/ETO-negative and RUNX1/ETO-
positive cells, both spontaneously and after exposure to daunorubicin. A p-value of < 
0.05 was considered statistically significant in all cases. All statistical analyses were 
performed using GraphPad Prism 6 software. 
 
2.7.9. Interrogation of base substitution spectrum 
 
 Base substitution spectrum was further investigated as a function of local 
sequence context to identify a mutational signature of base substitutions induced by 
RUNX1/ETO (Chapter 4). Mutations at the central base in each possible trinucleotide 
sequence (32 combinations) were examined to identify sequences over-represented 
in RUNX1/ETO transduced cells compared to cells negative for RUNX1/ETO 
expression. In addition, gene specific sequencing data from 56 diagnostic AML t(8;21) 
cases (Hartmann et al., 2016) were also interrogated to provide an in vivo dataset for 
the base substitution pattern in RUNX1/ETO-positive AML. Collectively, these data 
were used to determine whether RUNX1/ETO preferentially induces mutation at 
specific sequences in the genome. For this analysis genes interrogated include 
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ZBTB7A, ASXL2, NRAS, KIT, FLT3, ASXL1, RAD21, TET2, SMC3, DNMT3A, JAK2, 
CBL, FAT1, SMC1A, WT1, KRAS, PTPTN11, IDH2, GATA2 and JAK3. 
 Heatmaps displaying the number of base substitution mutations at the central 
position in each trinucleotide sequence were generated using Microsoft Excel. The 
Fisher’s exact test was used to determine whether the frequency of specific classes of 
mutation differed significantly between RUNX1/ETO-negative and RUNX1/ETO-
positive cells. A p-value of < 0.05 was considered statistically significant in all cases. 
All statistical analyses were performed using GraphPad Prism 6 software. 
 
2.8. Flow Cytometry 
 
 Flow cytometry was used to evaluate the effect of RUNX1/ETO expression on 
MF in AML relevant genes using mutant-specific antibody (Chapter 5). Parental TK6 
and its derivative RUNX1/ETO-positive cell clones (TK6 RE1 and TK6 RE8) were used 
as a model to determine whether the RUNX1/ETO fusion oncoprotein predisposes 
cells to mutation in genes relevant to leukaemogenesis. All antibodies used in flow 
cytometry experiments and their details are shown in Table 2.7. Preparation of all 
additional reagents for use in specific experiments are detailed in sections 2.8.2 and 
2.8.3. 
 
2.8.1. Generation of single clonal population of TK6 and TK6 RUNX1/ETO 
 
TK6 have a high single cell cloning efficiency in liquid culture of approximately 
70% when plated in a 96-well culture plate. This allows for the generation of single 
subclones with a range of RUNX1/ETO expression. 
 For each clone, an accurate cell count using was performed to establish a cell 
suspension at a concentration of 1 x 105 cells/ml using RF10 medium. A 10-fold serial 
dilution was carried out using RF10 medium to give a cell concentration of 10 cells/ml, 
followed by a1 in 2 dilution to give a final cell concentration of 5 cells/ml. 200µl of 
suspension was transferred to each well of sterile 96-well culture plate (average 1 
cell/well) using a multichannel pipette. Ten plates were prepared for each clone and 
incubated at 37°C/5% CO2. Following 20 days growth period, plates were checked 
under microscope for colony formation and any which had visible colonies were 
transferred to 800µl fresh RF-10 media in a 48 well plate for expansion, and finally 
transferred to a 25cm3 sterile cell culture flasks prior to flow cytometry. 
75 
 
2.8.2. Cell preparation, fixing and permeabilisation 
 
For each cell clone, an accurate cell count was performed to get 3 x 106 cells. 
The appropriate volume of cell suspension was dispensed into a sterile 15ml BD 
Falcon™ centrifuge tube, centrifuged at 400 x g for 5 min and supernatant was 
discarded. Cells were washed twice with 1ml of 1% BSA/PBS by centrifugation at 400 
x g for 5 min and the supernatant was discarded each time. A hundred microliter of ice 
cold absolute ethanol was added to the cells, gently mixed and incubated for 15 min 
on ice. Cells were then washed twice with 1ml of 1% BSA/PBS. A hundred microliter 
of 1X FACS permeabilising solution II (0.5 mL; Becton Dickinson, USA) was added to 
the cell suspension, vortexed and incubated for 10 min on ice. Cells were subsequently 
washed twice with 1ml of 1% BSA/PBS and cell pellets were collected by centrifugation 
at 400 x g for 5 min. 
 
2.8.3. Primary and secondary antibodies staining 
 
Primary and secondary antibodies were prepared from stocks by dilution with 
3% BSA/PBS (Table 2.7). A hundred microliters of NPM1 mutant-specific antibody 
(final concentration 1µg/ml) and rabbit IgG isotype control (final concentration 
2.5µg/ml) was added to the appropriate cells, vortexed and incubated at room 
temperature for 1 hour. Cells were then washed twice with 1ml of 1% BSA/PBS by 
centrifugation at 400 x g for 5 min and the supernatant were discarded each time. A 
hundred microliters of conjugated secondary goat anti-rabbit antibody (final 
concentration 2µg/ml) was added to the cells, vortexed and incubated at room 
temperature for 30 min in dark. Samples were then washed twice with 1ml of 1% 
BSA/PBS and the cell pellets were resuspended in 500µl of ice cold 3% BSA/PBS.
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Antibody Type Supplier Host / Isotype Concentration Conjugate Dilution 
NPM1 (mutant) 
Polyclonal 
Primary Invitrogen 
#PA1-46356 
Rabbit / IgG 1 mg/ml Unconjugated 1 : 100 
Rabbit IgG Isotype 
Control 
Primary Invitrogen 
#02-6102 
Rabbit / IgG 5 mg/ml Unconjugated 1 : 200 
Goat anti-Rabbit IgG 
(H+L) Cross-
Adsorbed Polyclonal 
Secondary Invitrogen 
#31212 
Goat / IgG 2 mg/ml Alexa Fluor 488 
conjugated 
1 : 100 
Table 2.7. Antibodies used in flow cytometry. 
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2.8.4. Detection of mutant cells 
 
 The labelled samples were analysed on a FACSCalibur flow cytometer (Becton 
Dickinson, USA) using Cell Quest™ Pro (Becton Dickinson, USA) and FCS Express 6 
Flow cytometry softwares (De Novo, California, USA). The target cell populations were 
gated based on the forward and side scatter signal intensity to exclude the non-target 
populations including dead cells and cell debris. Positive control (AML-3) and isotype 
control (Rabbit IgG Isotype) samples were simultaneously analysed alongside parental 
TK6 and RUNX1/ETO-transduced cells (TK6 RE1 and TK6 RE8) to optimise 
instrument settings (adjust voltages of fluorescence detectors to remove background 
fluorescence and adjust compensation settings for overlap of fluorescent spectra). 
Following optimisation, NPM1 mutant positivity was determined by analysing the Alexa 
Fluor 488 fluorescence of the gated population in a histogram format with a minimum 
of 10,000 events being acquired in this gate. A fluorescence intensity value between 
101 and 102 was defined as “positive” by overlapping the fluorescence spectra of the 
samples simultaneously to exclude the negative events and non-specific binding of the 
secondary antibody (Chapter 5, Section 5.2.2). Based on the acquired criteria for 
positivity, the validity of the assay was determined using flow sorting and Sanger 
sequence analysis of positive events (Section 2.8.5, 2.8.6 and 2.8.7). 
 
2.8.5. Cell sorting of NPM1 mutant population 
 
 The flow cytometry assay was investigated to confirm that positive events were 
cells mutated for NPM1 exon 12. The target population was sorted using an ASTRIOS 
EQ Cell Sorter (Beckman Coulter, London, UK) in the Flow Cytometry Core Facility 
(FCCF) (School of Medical Sciences, Newcastle University). Fifty million of labelled 
TK6 RE8 clone (clone with high expression of RUNX1/ETO) and mixed population of 
5% OCI-AML3/95% TK6 RE8 cells were prepared according to the sample preparation 
protocol (Sections 2.8.2 and 2.8.3) and diluted in 3% BSA/PBS to give a final cell 
concentration of 2 x 107 cells/ml as recommended by the FCCF. Sorted cells were 
collected into 100 µl of 3% BSA/PBS in a 1.5 ml Eppendorf tube and stored at -20°C 
until required. 
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2.8.6. Whole genome amplification of the sorted cells 
 
 Genomic DNA of sorted cells was extracted using a REPLI-g® Single Cell kit 
(Qiagen) according to the manufacturer’s protocol. This kit utilises a long-range DNA 
polymerase capable of amplifying up to 100 kilobases (kb) from small number of cells 
(1 to <1000 bacterial or tumour cells) at a constant temperature (30°C) without 
dissociating from the genomic template. 
 Quantification of DNA was performed as described in Section 2.7.2 and the 
concentration was adjusted to 100ng/µl using nuclease-free dH2O for use in PCR 
reactions. Remaining DNA was stored at -20°C until required. 
 
2.8.7. Amplification of NPM1 exon 12 for sequencing of NPM1 mutation 
 
 PCR of NPM1 DNA was performed using primers that target exon 12 of NPM1 
gene (NCBI Reference Sequence: NG_016018.1) as follows: 
 
   Forward: 5’AACTCTCTGGTGGTAGAATGAAA3’ 
   Reverse: 5’TGAGAACTTTCCCTACCGTGT3’ 
 
 Primers were manufactured by Sigma-Aldrich, reconstituted to 100 pmol/μl 
using TE buffer upon receipt and stored at -20°C. Working stocks of primers at a 
concentration of 10 pmol/μl were prepared using nuclease-free dH20 and stored at 
4°C. 
 Reaction conditions and setup for PCR amplification was prepared according to 
Section 2.7.3.2. A control was also prepared using nuclease-free dH2O in place of 
DNA, to ensure no contamination of reagents. Thermal cycling conditions were as 
follows:   
   
Initial denaturation 95°C 2 min  
Denaturation 95°C 25 sec 
36 cycles Annealing 55°C 3 sec 
Extension 72°C 65 sec 
Final extension 72°C 5 min  
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 To confirm successful amplification of NPM1 exon 12 DNA, an aliquot of each 
reaction (5μl) was assessed using agarose gel electrophoresis according to Section 
2.7.4. Remaining PCR product was prepared and Sanger sequenced by Source 
BioScience LifeSciences (Nottingham, UK) (Section 2.7.5). Sequence analysis was 
performed as described in Section 2.7.6. 
 
2.8.8. Calculation of mutation frequency 
 
 Following confirmation of NPM1 mutant positivity, subsequent experiments 
were performed every 2 weeks to measure the NPM1 MF in RUNX1/ETO-positive 
subclones (TK6 RE1 and TK6 RE8) relative to parental control TK6 subclones. The 
frequency of NPM1 exon 12 positive cells in each cell population was calculated 
according to the following formula: 
 
𝑀𝑢𝑡𝑎𝑡𝑖𝑜𝑛 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 (𝑀𝐹) =
𝑁𝑜. 𝑜𝑓 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑒𝑣𝑒𝑛𝑡
𝑁𝑜. 𝑜𝑓 𝑔𝑎𝑡𝑒𝑑 𝑒𝑣𝑒𝑛𝑡
 
 
All calculations were performed using Microsoft Excel. The individual value, 
mean and SEM of ten replicates were plotted on X-Y scatter graph (using GraphPad 
Prism 6 software). One-way ANOVA and paired t-test were used to assess the effects 
of RUNX1/ETO status on MF. A p-value of < 0.05 was considered statistically 
significant in all cases. All statistical analyses were performed using GraphPad Prism 
6 software (San Diego, USA). 
 
2.9. Whole Exome Sequencing 
 
 Whole exome sequencing (WES) was performed on matched presentation and 
relapsed AML samples in order to investigate clonal evolution of relapsed AML 
(Chapter 6). Exome sequencing provides high throughput sequencing of the protein-
coding genes in a genome (~23 000 genes) which constitute about 2% of the human 
genome, by using biotinylated oligonucleotide probes to selectively hybridize to target 
regions. This allow identification of genetic variants across the region that contains 
~85% of known disease-related variants (van Dijk et al., 2014) and can be used to 
compare genetic variants in presentation and relapse samples for the identification of 
relapse-specific mutations responsible for AML disease progression. 
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2.9.1. Recruitment of patients 
 
 AML samples were collected within the National Referral Centre for Bone 
Marrow Cytogenetics and Molecular Genetics, Institute for Medical Research (IMR, 
Kuala Lumpur, Malaysia) who are collaborating on this study. Ethical approval had 
been acquired form Medical Research and Ethics Committee (MREC), Ministry of 
Health, Malaysia. Written informed consent was obtained from each patient for the use 
of their DNA samples in this study as well as for any scientific publication derived from 
this study. A cohort of 11 matched presentation and relapsed AML cases were 
identified. Patients achieved clinical remission after treatment with combination 
chemotherapy that included ara-C and an anthracycline (daunorubicin or idarubicin), 
followed by consolidation chemotherapy that included high-dose of ara-C. The median 
age was 33 years (range: 10 – 51 years). Detailed information of the recruited patients 
will be further described in Chapter 6. 
 
2.9.2. Preparation of DNA from primary AML samples 
 
 All DNA extraction and preparation were performed by IMR. RNA from all 
primary patient samples was extracted using QIAamp DNA Blood Mini Kit (Qiagen) 
according to manufacturer’s protocol. Quantitation of the extracted DNA was carried 
out using a Nanodrop ND-1000 spectrophotometer and the required concentration and 
volume of RNA for exome sequencing was prepared according to sequencing service 
provider instruction. 
 
2.9.3. Exome sequencing 
 
 Sample preparation, library construction, sequencing and bioinformatics 
analysis were performed offsite by the Beijing Genome Institute (BGI) (Hong Kong, 
China). SureSelect Human All Exon V5 + UTR kit (Agilent Technologies, Santa Clara, 
USA) was used for enrichment of exon sequence including untranslated regions 
(UTR). Samples were sequenced to give an average read depth (reads per base) of 
100X, supporting the identification of minor leukaemic cell clones. Paired-end 
sequencing was performed using Illumina HiSeq 4000 platform and analysis of raw 
data was processed according to BGI analysis pipeline to map reads against the hg19 
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build of the human genome and identify single nucleotide variants (SNVs) and 
insertion/deletions (indels). 
 
2.9.4. Data analysis 
 
 Variant calling files (.VCF) were received from the BGI. Analysis of genetic 
variants was performed using Ingenuity Variant Analysis™ software (Qiagen 
Bioinformatics) to compare the somatic mutation profile of matched AML samples at 
presentation and relapse in order to identify somatic mutations that drive disease 
progression. 
 A series of filters were applied to select variants most likely to impact on gene 
function or biological processes known to be implicated in disease progression. 
Variants with a read depth < 10 were excluded from the analysis as were variants with 
an allele frequency (VAF) ≥ 5% in the healthy population [databases used include the 
1000 Genomes Project, ExAC, gnomAD, NHLBI ESP exomes; minor allele frequency 
(MAF) < 1%)] . 
 Identification of putative AML driver mutations were determined by identification 
of variants in established AML genes. Specifically, the Catalogue of Somatic Mutations 
in Cancer (COSMIC) database was interrogated to identify the most frequently 
recurrently mutated genes in AML (Table 2.8). 
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No. Gene Mutated samples Samples tested Frequency (%) 
1 NPM1 6209 19236 32.28 
2 FLT3 16141 68481 23.57 
3 DNMT3A 2525 13085 19.3 
4 NRAS 1157 8594 13.46 
5 TET2 928 7274 12.76 
6 RET 104 1042 9.98 
7 CEBPA 1351 13823 9.77 
8 IDH2 1489 15414 9.66 
9 TLE4 98 1041 9.41 
10 ATM 102 1116 9.14 
11 WT1 563 6347 8.87 
12 TP53 382 4454 8.58 
13 MAP2K2 88 1042 8.45 
14 ASXL1 671 7965 8.42 
15 KIT 789 9601 8.22 
16 PBRM1 82 1042 7.87 
17 RUNX1 685 8806 7.78 
18 TEK 77 1041 7.4 
19 IDH1 1139 17340 6.57 
20 SRSF2 337 5149 6.54 
21 DNM2 65 1041 6.24 
22 PTPN11 379 6248 6.07 
23 NF1 149 2583 5.77 
24 GATA2 284 5150 5.51 
25 BCOR 243 4464 5.44 
26 KRAS 343 6319 5.43 
27 MUC12 51 947 5.39 
28 GATA1 176 3614 4.87 
29 KMT2D 120 2534 4.74 
30 RAD21 188 4142 4.54 
 
Table 2.8. Top 30 genes frequently mutated in AML 
 (https://cancer.sanger.ac.uk/cosmic). 
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Chapter 3. Evaluating the Mutagenicity of Chemotherapy Agents 
and RUNX1/ETO Expression in a Cell Model System 
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3.1. Introduction 
 
 Cancer is the ultimate genetic disease characterised by the accumulation of 
somatic mutations within the genome of a somatic cell acquired during disease 
progression. Although somatic mutations are known to cause cancer, the biological 
processes generating these mutations are poorly understood. In normal circumstances 
somatic mutations can be acquired spontaneously due to replication errors and 
defective DNA repair. However, the acquisition of somatic mutations can be influenced 
by additional sources of DNA damage including exposure to exogenous agents such 
as UV radiation (Brash et al., 1991; Pierceall William et al., 1991; Weihrauch et al., 
2002; Brash, 2015) and endogenous cellular processes such as energy metabolism 
and lipid peroxidation, which generate reactive genotoxic chemicals (e.g. ROS) 
(Pluskota-Karwatka, 2008). These DNA damaging agents have the potential to be 
mutagenic to DNA and cause genomic instability if the damage is not detected and 
repaired, or if apoptosis is not initiated when repair cannot successfully occur. 
 Despite considerable efficacy in the treatment of cancer, many chemotherapy 
agents are also mutagenic and some have already been shown to induce mutations 
detectable after therapy (Hunter et al., 2006). Ara-C in combination with an 
anthracycline such as daunorubicin are the two most widely used chemotherapeutic 
agents in AML remission induction treatment. Ara-C is a nucleoside analogue 
incorporated into replicating DNA at internucleotide positions leading to inhibition of 
chain extension (Chapter 1, Section 1.7.1). The mutagenicity of ara-C was previously 
described although the effect was relatively weak compared to the mutagenic potency 
of N-methyl-N-nitrosourea (MNU) (Fordham et al., 2015). The cytotoxicity of 
daunorubicin is primarily mediated by the inhibition of topo II, preventing the DNA 
double helix from being re-ligated, thereby stopping the process of replication (see 
Chapter 1, Section 1.7.2), which may eventually lead to elevated DNA strand breaks. 
As well as inducing strand breaks via the inhibition of DNA topo II, daunorubicin is a 
redox cycling agent which can form a complex with iron to generate ROS (Davies and 
Doroshow, 1986; Juchau et al., 1986). This process leads to oxidative stress and 
causes DNA base damage such as 8-oxoG lesions, which can result in base mispairing 
with adenine and generation of G:C to T:A substitution mutations in the genome 
(Cheng et al., 1992). Indeed, evidence has showed that daunorubicin and related 
anthracyclines can induce loss of heterozygosity (LOH) or genetic rearrangements 
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such as deletion and chromosomal translocation, demonstrating the mutagenicity of 
this group of chemotherapeutic agent (Anderson et al., 1991; Lehmann et al., 2004). 
 In addition, genomic instability caused by fusion genes may also contribute to 
increase somatic mutations in AML. Evidence suggests that initiating lesions such as 
RUNX1/ETO may promote mutagenesis (Krejci et al., 2008; Araten et al., 2013) and 
ectopic expression of RUNX1/ETO has been observed to cause downregulation of 
several DNA repair proteins (BRCA2, OGG1 and ATM) and failure to repair DNA 
damage (Alcalay et al., 2003). A recent study has shown that RUNX1/ETO increases 
genomic instability and mutagenesis by predisposing cells to the acquisition of 
mutations, both spontaneously and particularly after treatment with genotoxic agents 
(Forster et al., 2015). RUNX1/ETO is the most frequent fusion gene found in AML and 
is the product of the t(8;21) chromosomal translocation (Klaus et al., 2004; Sanderson 
et al., 2006b; Grimwade et al., 2010). t(8;21) AML is prominent in adolescence but with 
intensive chemotherapy a 60% survival rate can be achieved (Shipley and Butera, 
2009). Despite this success, relapse of t(8;21) AML remains a major clinical problem. 
In both models of relapsed AML (see Chapter 1, Section 1.6), the relapsing clone 
evolves from a cell carrying leukaemia-initiating genetic lesions, including gene 
fusions, suggesting the persistence of pre-leukaemic fusion-positive clones 
susceptible to chemotherapy-induced mutation and which could drive relapse. As 
such, it is important to determine whether the expression of gene fusions affects the 
frequency and pattern of chemotherapy-induced mutation. 
 The mutagenic potential of DNA damaging agents can be evaluated by a 
number of in vitro and in vivo assays using a variety of reporter genes (e.g. HPRT, 
APRT, XPRT, TK, PIGA) to detect mutations induced by these agents (Aaron et al., 
1994). In mammalian cells, TK and HPRT are the most commonly used reporter genes 
for in vitro mutation studies. The in vitro TK and HPRT mutation assays work by treating 
cells with the agent of interest followed by exposure to a selective agent that results in 
death of non-mutant cells. The HPRT enzyme, encoded by the HPRT gene, is an 
important component of the purine salvage pathway. This enzyme is also required for 
conversion of 6-TG to its active DNA precursor, 6-thioguanosine monophosphate (6-
TGMP) which inhibits DNA synthesis and is cytotoxic to cells. Due to loss of HPRT 
enzymatic function, mutant cells are resistant to the cytotoxic effect of 6-TG while cells 
with functional HPRT mutation are selectively killed by 6-TG. The TK assay works on 
the same principle in which TFT is used to select cells with TK mutation. The cells that 
survive and form colonies after the selection are TK mutant resulting from either a 
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spontaneous mutation or from an induced mutation caused by an exogenous DNA 
damaging agent. The frequency of induced mutants, relative to control untreated cells, 
can be used as a measure of the mutagenicity of the agent under investigation. In 
addition, the TK and HPRT assays detect different spectra of genetic events. The 
autosomal location of TK gene (chromosome 17) allows for detection of larger 
mutations, such as large deletions, which is unlikely to be detected at the HPRT locus 
on X chromosome (Liber and Thilly, 1982). 
 A previous study has successfully demonstrated the capability of this assay in 
determining the mutagenicity of cytarabine in mismatch repair proficient and deficient 
cell lines (Fordham et al., 2015). Using a similar approach, in this study, the effect of 
RUNX1/ETO fusion gene on mutation frequency (MF) was determined at the TK and 
HPRT loci, both spontaneously and after treatment with chemotherapy agents in a cell 
model system using immortalised TK6 human lymphoblastoid cells. Importantly, these 
assays allow mutation in surviving cells to be measured simultaneously with 
cytotoxicity, such that the mutagenicity/cytotoxicity ratio can be calculated. In addition, 
HPRT mutant clones were generated (following selection of 6-TG resistant cell clones) 
and subjected to molecular analysis, allowed for a comparison of HPRT mutation 
spectra between chemotherapy-treated and vehicle-treated cells in order to determine 
the spectra of gene deletion mutants and base substitution mutants. 
 
3.1.1. Aims of Chapter 3 
 
 The objective of this investigation is to identify the contribution of remission 
induction chemotherapy and expression of the RUNX1/ETO fusion gene to the 
aetiology of pathogenic mutations in AML using in vitro reporter gene assays. 
 Specifically, the experimental aims were as follows: 
• Determine chemotherapy dose-dependent mutagenicity in a cell model 
system. 
• Determine the effect of RUNX1/ETO fusion gene expression on 
spontaneous mutation frequency. 
• Determine the effect of RUNX1/ETO fusion gene expression on 
chemotherapy-induced mutation frequency. 
• Determine the spectrum of mutations at the HPRT locus, both 
spontaneously and after exposure to daunorubicin. 
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3.2. Results 
 
3.2.1. Expression levels of the RUNX1/ETO fusion protein determined by western 
blotting 
 
 A TK6 cell clone with stable expression of full-length RUNX1/ETO (TK6 RE8) 
was previously generated via lentiviral transduction (see Chapter 2, Section 2.2). The 
clone was re-assessed for RUNX1/ETO expression, in order to confirm the expected 
phenotype. RUNX1/ETO expression was observed in TK6 RE8 cells line which has 
approximately 94% of RUNX1/ETO expression relative to Kasumi-1 but was absent in 
parental TK6 (Figure 3.1). These data confirm that the TK6 RE8 cells have the 
expected phenotype based on genotype and are suitable for use in subsequent 
experiments investigating the influence of RUNX1/ETO fusion gene on the acquisition 
of mutations, both spontaneously and after chemotherapy treatments. 
 
3.2.2. Cytotoxicity in TK6 and TK6 RUNX1/ETO cells following treatment with 
daunorubicin (chronic drug exposure) 
 
 Cytotoxicity in response to treatment with daunorubicin was assessed in TK6 
RUNX1/ETO cells relative to parental TK6 cells using the 96-well clonogenic assay. 
There was a progressive drop in cloning efficiency up to 6nM daunorubicin (Figure 
3.2), demonstrating a significant dose response suggesting that daunorubicin is 
cytotoxic to TK6 cells. TK6 RUNX1/ETO cells were significantly resistant to cell killing 
mediated by daunorubicin compared to parental TK6 cells (P = 0.01; two-way ANOVA). 
This daunorubicin resistant phenotype might be partly caused by a slower growth rate 
of TK6 RUNX1/ETO cells compared to parental TK6 cells (Figure 3.3). These data also 
confirmed that TK6 and its derivative subclones have a high cloning efficiency (50 – 
74%) as demonstrated by their ability to survive and proliferate at low density (2 cells 
per well) in liquid media (data not shown). Collectively, these data were used to identify 
a suitable starting dose of daunorubicin to be used in mutation assays investigating 
the effect of daunorubicin exposure on MF. 
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Figure 3.1. RUNX1/ETO protein expression in TK6 cell lines. 
Western immunoblotting was performed to determine protein expression of 
RUNX1/ETO in parental TK6 and TK6 RE8 cells relative to Kasumi-1 cells. GAPDH 
was used as a loading control for all blots. Each blot is representative of three 
independent experiments. 
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Figure 3.2. Cytotoxicity in response to daunorubicin in TK6 and TK6 RUNX1/ETO 
cells. 
Cell survival in response to daunorubicin in parental TK6 cells (black circles) and TK6 
RUNX1/ETO cells (throughout circles) determined via clonogenic assay in 96- well 
plates using limiting dilution. Data is presented as the number of viable colonies 
(positive wells) from dosed cell suspensions as a percentage of the number of viable 
colonies from vehicle-only treated cell suspensions. Data represents the mean and 
standard deviation (error bars) of three independent experiments. 
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Figure 3.3. Cell proliferation in TK6 and TK6 RUNX1/ETO cell lines. 
Cell proliferation was compared in parental TK6 cells (black circles) and TK6 
RUNX1/ETO cells (throughout circles). Data is presented as the number of cells 
counted every 24 hours. Data represents the mean and standard deviation (error bars) 
of three independent experiments. 
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3.2.3. Cytotoxicity in TK6 and TK6 RUNX1/ETO cells following treatment with 
daunorubicin and ara-C (acute drug exposure) 
 
 In order to identify a suitable starting dose for daunorubicin and ara-C in each 
cell line, dose finding assays were performed by treating cell lines with escalating 
doses of daunorubicin and ara-C for 16 hours. This assay was adapted from the 96-
well clonogenic assay with the aim of identifying doses which result in approximately 
60 – 95% cytotoxicity to be used in in vitro mutation assays. 
 A progressive drop in colony forming efficiency in response to escalating doses 
of daunorubicin and ara-C demonstrated a significant dose response (Figure 3.4). A 
concentration of 15nM, which induces 70 – 80% cytotoxicity, was selected as a starting 
dose for daunorubicin mutagenicity assays. Likewise, a concentration of 1µM, which 
induces 70 – 80% cytotoxicity, was selected as a starting dose for ara-C mutagenicity 
assays.  
 
3.2.4. Effect of daunorubicin exposure on mutation frequency at TK and HPRT 
loci in TK6 and TK6 RUNX1/ETO 
 
 To assess the mutagenicity of daunorubicin, cultures of parental TK6 and its 
RUNX1/ETO-positive subclone TK6 RE8, were first purged of any pre-existing 
spontaneous TK and HPRT mutants (see Chapter 2, Section 2.6.1), then exposed to 
increasingly doses of daunorubicin for 16 hours. MF was subsequently determined at 
the TK and HPRT loci in the surviving cells. 
 Exposure of TK6 and TK6 RUNX1/ETO cells to daunorubicin induced a 
significant dose-dependent increase in MF at both TK and HPRT loci, with the effect 
more prominent at the TK locus (Table 3.1 and Figure 3.5). Moreover, RUNX1/ETO 
significantly increase MF relative to RUNX1/ETO-negative cells in response to 
escalating doses of daunorubicin, although it was statistically not significant at the 
HPRT locus (Table 3.1). The mutagenicity of daunorubicin was further evaluated 
based on cytotoxicity induced by each individual dose of daunorubicin (Figure 3.6). An 
exponential increase in MF demonstrated that exposure to doses that induced higher 
levels of cytotoxicity increase the MF at both loci in both cell lines. A comparison of the 
daunorubicin-induced MF at doses giving near equivalent cytotoxicity was also 
performed to further determine whether RUNX1/ETO influences the mutagenic 
potency of daunorubicin relative to RUNX1/ETO-negative cells. At doses inducing 
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Figure 3.4. Cytotoxicity in response to daunorubicin and ara-C in TK6 and TK6 
RUNX1/ETO cells. 
Cell survival following 16 hours exposure to daunorubicin and ara-C in parental TK6 
cells (black circles) and TK6 RUNX1/ETO cells (throughout circles) via clonogenic 
assay in 96 well plates using limiting dilution. Data is presented as the number of viable 
colonies (positive wells) from dosed cell suspensions as a percentage of the number 
of viable colonies from vehicle-only treated cell suspensions. Data represents the 
mean and standard deviation (error bars) of three independent experiments. 
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Daunorubicin 
(nM) 
TK MF (x10-6) HPRT MF (x10-6) 
TK6 
TK6 
RUNX1/ETO 
TK6 
TK6 
RUNX1/ETO 
0 8.2 (0.0) 13.0 (0.0) 2.9 (0.0) 4.0 (0.0) 
15 57.8 (49.6) 55.5 (42.5) 26.3 (23.4) 18.7 (14.7) 
25 59.2 (51.0) 68.3 (55.3) 38.5 (35.6) 33.2 (29.2) 
30 60.9 (52.7) 74.3 (61.3) 39.6 (36.7) 40.7 (36.7) 
One-way ANOVAa < 0.0001 < 0.0001 < 0.0001 < 0.0001 
Two-way ANOVAb 0.0090 0.1696 
 
Table 3.1. Effect of daunorubicin exposure on mutation frequency at TK and 
HPRT loci. 
Figures represent the observed MF at each drug concentration. Data represent the 
mean of three independent experiments. Numbers in parentheses represent the 
induced MF (x 10-6) at each dose, calculated by subtraction of the spontaneous MF 
(0nM daunorubicin; vehicle-treated). These figures are displayed graphically in Figure 
3.5. 
a Figures represent the P value determined using a one-way analysis of variance 
(ANOVA) test for effect of daunorubicin dose on MF. 
b Figures represent the P value determined using a two-way ANOVA test for effect of 
RUNX1/ETO status on MF. 
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Figure 3.5. Effect of daunorubicin exposure on mutation frequency at the TK and 
HPRT loci. 
MF at the TK and HPRT loci was assessed in parental TK6 cells (black bars) and TK6 
RUNX1/ETO cells (throughout bars) following a 16 hour exposure to daunorubicin. 
Data represents the mean and standard deviation (error bars) of three independent 
experiments. Numbers above bars represent the induced MF (x 10-6) at each dose, 
calculated by subtraction of the spontaneous MF (0nM daunorubicin; vehicle-treated).
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Figure 3.6. Effect of daunorubicin exposure on mutation frequency at the TK and HPRT loci as a function of cytotoxicity. 
MF at the TK and HPRT loci was assessed in parental TK6 cells and TK6 RUNX1/ETO cells following 16 hours exposure to daunorubicin. 
Data represents the mean and standard deviation (error bars) of three independent experiments and is presented as MF observed in 
control vehicle-treated cells (0% cytotoxicity) and at drug doses causing up to 95% cytotoxicity. Exponential curves are displayed for each 
dataset. The associated R2 values represent the square of the Pearson product moment correlation coefficient, indicating the ‘goodness of 
fit’ of the data.
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approximately 95% cytotoxicity, there was no significant difference in induced MF 
between parental TK6 and TK6 RUNX1/ETO-positive cells despite a slight increase in 
MF at both loci (TK: P = 0.0857, HPRT: P = 0.8840; paired t-test) (Figure 3.7). 
 
3.2.5. Effect of ara-C exposure on mutation frequency at the TK and HPRT loci in 
TK6 and TK6 RUNX1/ETO cells 
 
 The mutagenicity of ara-C was evaluated in the same way as daunorubicin, with 
higher doses of ara-C were used to induce the required cytotoxicity. Similar to the 
response observed for daunorubicin, exposure of TK6 and TK6 RUNX1/ETO cells to 
ara-C caused a significant dose-dependent increase in MF at both TK and HPRT loci, 
with the effect being more prominent at the TK locus (Table 3.2 and Figure 3.8). 
However, there was no significant increase in MF at both loci in RUNX1/ETO-positive 
cells relative to RUNX1/ETO-negative cells in response to escalating doses of ara-C 
(Table 3.2), which might be caused by unequal cytotoxicity induced by each individual 
ara-C dose. Despite that, an exponential increase in MF demonstrated that exposure 
to doses that induced higher levels of cytotoxicity increased the MF at both loci in both 
cell lines (Figure 3.9). In addition, comparison of ara-C induced MF at equitoxic doses 
(80% cytotoxicity) showed significant increase in TK6 RUNX1/ETO cells relative to 
parental TK6 cells at the HPRT locus, although it was not statistically significant at the 
TK locus (TK: P = 0.5970, HPRT: P = 0.0424; paired t-test) (Figure 3.10). 
 
3.2.6. Effect of RUNX1/ETO expression on spontaneous mutation frequency at 
the TK and HPRT Loci 
 
 The effect of RUNX1/ETO fusion gene expression on the acquisition of 
mutations were further evaluated by comparison of MF in vehicle-treated control 
populations (Figure 3.11). In daunorubicin vehicle-treated cell populations, a significant 
increase in MF was observed at the TK locus in TK6 RUNX1/ETO cells relative to 
parental TK6 cells (P = 0.0109; paired t-test). Consistently, in ara-C vehicle-treated 
cells, a significant increase in MF was also observed at the TK locus in TK6 
RUNX1/ETO cells relative to parental TK6 cells (P = 0.0469; paired t-test). Similar 
statistical testing performed at the HPRT locus however, showed no significant 
differences in spontaneous MF comparing RUNX1/ETO-positive and parental cell 
populations, although a modest increase in MF was observed in TK6 RUNX1/ETO  
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Figure 3.7. Daunorubicin-induced mutation frequency at the TK and HPRT loci 
at 95% cytotoxicity. 
Induced MF at the TK and HPRT loci was assessed in parental TK6 cells (black bars) 
and TK6 RUNX1/ETO cells (throughout bars) at daunorubicin doses cytotoxic to 
approximately 95% of cells. Data represents the mean and standard deviation (error 
bars) of three independent experiments. Induced MF (numbers shown above bars) 
were calculated by subtraction of the spontaneous MF (0nM daunorubicin). P-value 
was calculated by paired t-test comparing the induced MF between cell lines at each 
locus.
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Ara-C 
(µM) 
TK MF HPRT MF 
TK6 
TK6 
RUNX1/ETO 
TK6 
TK6 
RUNX1/ETO 
0 9.5 (0.0) 14.5 (0.0) 2.6 (0.0) 3.8 (0.0) 
1 38.4 (28.9) 36.7 (22.2) 11.5 (8.9) 5.8 (2.0) 
3 46.6 (37.1) 43.7 (29.2) 15.1 (12.5) 13.7 (9.9) 
5 52.9 (43.4) 53.5 (39.0) 22.0 (19.4) 18.6 (14.8) 
One-way ANOVAa < 0.0001 < 0.0001 0.0014 0.0014 
Two-way ANOVAb 0.9171 0.2608 
 
Table 3.2. Effect of ara-C exposure on mutation frequency at the TK and HPRT 
loci. 
Figures represent the observed MF at each drug concentration. Data represents the 
mean of three independent experiments. Numbers in parentheses represent the 
induced MF (x 10-6) at each dose, calculated by subtraction of the spontaneous MF 
(0µM ara-C; vehicle-treated). These figures are displayed graphically in Figure 6.1. 
a Figures represent the P value determined using a one-way analysis of variance 
(ANOVA) test for effect of ara-C dose on MF. 
b Figures represent the P value determined using a two-way ANOVA test for effect of 
RUNX1/ETO status on induced MF. 
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Figure 3.8. Effect of ara-C exposure on mutation frequency at the TK and HPRT 
loci. 
MF at the TK and HPRT loci was assessed in parental TK6 cells (black bars) and TK6 
RUNX1/ETO cells (throughout bars) following 16 hour exposure to ara-C. Data 
represents the mean and standard deviation (error bars) of three independent 
experiments. Numbers above bars represent the induced MF (x 10-6) at each dose, 
calculated by subtraction of the spontaneous MF (0µM ara-C; vehicle-treated). 
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Figure 3.9. Effect of ara-C exposure on mutation frequency at the TK and HPRT loci as a function of cytotoxicity. 
MF at the TK and HPRT loci was assessed in parental TK6 and TK6 RUNX1/ETO cells following 16 hours exposure to ara-C. Data 
represents the mean and standard deviation (error bars) of three independent experiments and is presented as MF observed in control 
vehicle-treated cells (0% cytotoxicity) and at drug doses causing up to 90% cytotoxicity. Exponential curves are displayed for each dataset. 
The associated R2 values represent the square of the Pearson product moment correlation coefficient, indicating the ‘goodness of fit’ of 
the data. 
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Figure 3.10. Ara-C-induced mutation frequency at the TK and HPRT loci at 80% 
cytotoxicity. 
Induced MF at the TK and HPRT loci was assessed in parental TK6 cells (black bars) 
and TK6 RUNX1/ETO cells (throughout bars) at ara-C doses inducing approximately 
80% cytotoxicity. Data represents the mean and standard deviation (error bars) of 
three independent experiments. Induced MF (numbers shown above bars) were 
calculated by subtraction of the spontaneous MF (0µM ara-C; vehicle-treated). P-value 
was calculated by paired t-test comparing the induced MF between cell lines at each 
locus.
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Figure 3.11. Spontaneous mutation frequency at the TK and HPRT loci. 
MF at the TK and HPRT loci was assessed in parental TK6 cells (black bars) and TK6 RUNX1/ETO cells (throughout bars) following 16 
hour exposure to vehicle control of daunorubicin and ara-C. Numbers above bars represent the MF value (x 10-6) and data represents the 
mean and standard deviation (error bars) of three independent experiments. P-value was calculated by paired t-test comparing the MF 
between cell lines at each locus.
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cells compared to parental TK6. Taken together, these data demonstrate that 
RUNX1/ETO expression increases spontaneous MF at the TK locus, with some 
evidence of higher mutation at the HPRT locus. 
 
3.2.7. Molecular analysis of mutations at the HPRT locus in TK6 and TK6 
RUNX1/ETO cells 
 
To further investigate the mutagenicity of daunorubicin and the influence of the 
RUNX1/ETO fusion gene on the acquisition of mutations, in terms of the structural 
types and their frequency, a number of individual HPRT mutants generated from TK6 
and TK6 RUNX1/ETO cells were subject to molecular analysis in order to generate 
both spontaneously-occurring and daunorubicin-treated mutational spectra. 
 A total of 154 and 292 independent HPRT mutants were generated from TK6 
and TK6 RUNX1/ETO cells. Likewise, a total of 56 and 50 independent HPRT mutants 
were generated from parental TK6 cells and TK6 RUNX1/ETO cells, respectively, 
following a dose of daunorubicin that induced 95% cytotoxicity. RNA was extracted 
from each individual HPRT mutant for reverse-transcription PCR (RT-PCR), PCR and 
cDNA sequencing for characterisation of mutations. 
 
3.2.7.1. Analysis of mutations in the HPRT coding region 
 
HPRT mutants characterised by the absence of a cDNA PCR product (Figure 
3.12) were defined as having terminal deletions (either 5’ or 3’) and were grouped by 
the structure of large deletion (Table 3.3). For parental TK6 cells, a total of 41 (73%) 
daunorubicin-treated mutants, as well as 56 (36%) spontaneously-occurring mutants 
were found to harbour terminal deletions at the HPRT locus. Likewise, 28 (53%) 
daunorubicin-treated HPRT mutants and 105 (36%) spontaneously-occurring mutants 
carry a terminal deletion at this locus for TK6 RUNX1/ETO HPRT mutant population. 
However, no further investigation was performed to distinguish terminal deletions from 
complete gene deletions. 
 Internal exon deletions were defined as the absence of one or more consecutive 
exons in a gene, as evidenced by the presence of a cDNA PCR product, but which is 
shorter than full-length HPRT cDNA (737 bp) (Figure 3.12). For parental TK6 HPRT 
mutant population, a total of 14 (25%) daunorubicin-treated mutants, as well as 54 
(35%) spontaneously-occurring mutants were found to harbour internal exon deletions 
104 
 
 
 
 
 
 
 
 
Figure 3.12. Large deletion in HPRT coding region. 
The gel shows examples of PCR profiles from mutant with terminal deletions (lane 1, 
3, 5), as evidenced by the absence of a cDNA product, and from mutants with internal 
exon deletion (lane 2, 10), as evidenced by shorter than full-length HPRT cDNA wild-
type sequence (737 bp). ‘No cDNA template’ was used as negative control and HPRT 
cDNA wild-type (untreated parental TK6 cells) was used as positive control for PCR 
amplification. 
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Deleted Region 
Spontaneous Daunorubicin-treated 
TK6 
TK6 
RUNX1/ETO 
TK6 
TK6 
RUNX1/ETO 
5’ / 3’ terminal deletions     
Total 56 105 41 28 
Internal exon deletions     
1 6    
1 – 3  1   
2 4 7 2 2 
2 – 3 5 28 3 9 
2 – 4 1 1   
2 – 6  4  1 
2 – 8 1    
3 2  2  
4 16 14  1 
4 – 5 1 5  2 
4 – 6  4   
3 – 8   1  
5 3 20 1 3 
5 – 6 1 1 1  
6 4 15 1 2 
6 – 8   1  
7 5 5   
7 – 8 4 4 2 1 
8 1 3   
Total 54 112 14 21 
Total Large Deletion 110 217 55 49 
 
Table 3.3. Large deletions observed in spontaneous and daunorubicin-treated 
HPRT mutants. 
Figures represent the number of deletions observed in both spontaneously-occurring 
and daunorubicin-treated HPRT mutant populations. Internal exon deletions were 
further classified according to the extent of the deleted region and affected exons. 
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at the HPRT locus. Likewise, 21 (42%) daunorubicin-treated HPRT mutants and 112 
(38%) spontaneously-occurring mutants carried an internal HPRT exon deletion 
derived from TK6 RUNX1/ETO HPRT cells. cDNA sequencing was employed to 
determine the extent of the deleted region. However, no notable differences in the 
structural type of internal exon deletions were observed between daunorubicin-treated 
and spontaneously-occurring HPRT mutants, with both HPRT mutant populations have 
a high proportion of deletions encompassing exons 2 – 3. 
For HPRT mutants with full length HPRT cDNA (737 bp), cDNA sequencing was 
used to identify small deletions/insertions and base substitutions (Figure 3.13). Of 
these, a single mutant clone carrying a base substitution was observed in parental TK6 
and TK6 RUNX1/ETO HPRT populations treated with daunorubicin, which included a 
transition mutation (A > G) in parental TK6 and a transversion mutation (T > A) in TK6 
RUNX1/ETO (Table 3.4). In contrast, a total of 21 (14%) and 49 (17%) base 
substitutions were observed in spontaneously-occurring parental TK6 and TK6 
RUNX1/ETO HPRT mutant populations, respectively. Moreover, there was more T > 
G / A > C, T > C / A > G and C > A / G > T base substitutions derived from TK6 
RUNX1/ETO cells compared to parental TK6. The comprehensive analysis of base 
substitution mutation will be described in the next chapter (Chapter 4). In addition, 23 
(15%) and 26 (9%) spontaneous HPRT mutants derived from parental TK6 and TK6 
RUNX1/ETO HPRT were small deletions/insertions (Table 3.5). This class of mutation 
was not observed in either parental TK6 or TK6 RUNX1/ETO daunorubicin-treated cell 
populations. 
 
 
 
 
 
 
 
 
 
 
107 
 
 
 
 
 
Figure 3.13. Small aberration in HPRT coding region. 
A. The gel shows example of PCR profiles from mutant with base substitutions or small 
deletions/insertions (lane 3, 5, 7, 8, 9, 10), as evidenced by similar size with full length 
of HPRT cDNA wild-type sequence (737 bp). ‘No cDNA template’ was used as 
negative control and HPRT cDNA wild-type (untreated parental TK6 cells) was used 
as positive control for PCR amplification. 
B. Sanger sequencing of cDNA from one HPRT mutant clone (lane 3) revealed a T > 
G base substitution at position E7:522 of the HPRT cDNA.
108 
 
Position 
Sequence 
change 
Target 
sequence 
Spontaneous Dauno-treated 
TK6 TK6 RE TK6 TK6 RE 
Transitions       
E2:48 T > C AGGTTAT  1   
E2:118 G > A CATGGAC 1    
E2:121 C > T GGACTAA  1   
E2:122 T > C GACTAAT  1   
E3:145 C > T CGTCTTG  1   
E3:151 C > T GCTCGAG  1   
E3:281 C > T TTCCTAT  1   
E4:325 C > T GACCAGT 1 2   
E4:355 G > A GGTGGAG  2   
E5:395 T > C TGATTGT 1    
E5:401 A > G TGGAAGT  4   
E6:409 A > G ATAATTG  2   
E6:416 C > T ACACTGG  1   
E6:419 G > A CTGGCAA 1 1   
E6:425 C > T AAACAAT 1    
E6:440 T > C TGCTTTC  1   
E6:454 C > T AGGCAGT 1    
E7:508 C > T CCACGAA 2    
E7:530 A > G CAGACTG 1    
E8:533 T > C TAGTTGT 1    
E8:539 G > A TTGGATT  1   
E8:569 G > A TAGGATA 1    
E8:598 A > G TTCAGGG   1  
E9:610 C > T TAGCATG 1 2   
 
Table 3.4. Base substitutions observed in spontaneous and daunorubicin-
treated HPRT mutants (continued on next page). 
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Position 
Sequence 
change 
Target 
sequence 
Spontaneous Dauno-treated 
TK6 TK6 RE TK6 TK6 RE 
Transversions       
E1:1 A > T GTTATGG 1 1   
E1:2 T > A TTATGGC 1    
E2:82 T > G CATTATG  1   
E2:107 T > G TATTCCT 1    
E2:109 A > T TTTATTC  1   
E2:110 T > A TTATTCC    1 
E2:122 T > G GACTAAT  1   
E2:124 A > T CTAATTA  1   
E2:130 G > T ATGGACA 1    
E3:136 A > C GACTGAA  3   
E3:148 G > C CTTGCTC  1   
E3:194 T > G CCCTCTG  1   
E3:197 G > C TCTGTGT  1   
E3:211 G > C GGGGGCT  1   
E3:216 T > G AATAGT  1   
E3:229 G > T GCTGACC  1   
E3:233 T > A ACCTGCT 1    
E3:238 G > T CTGGATT  1   
E3:292 G > T GTAGATT  1   
E4:354 T > G TGGTGGA  1   
E5:388 G > T AATGTCT  2   
E5:397 G > T ATTGTGG  1   
E6:407 T > G ATATAAT  1   
E6:409 A > T ATAATTG 1    
 
Table 3.4. Base substitutions observed in spontaneous and daunorubicin-
treated HPRT mutants (continued from previous page). 
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Position 
Sequence 
change 
Target 
sequence 
Spontaneous Dauno-treated 
TK6 TK6 RE TK6 TK6 RE 
E6:410 T > A TAATTGA  1   
E6:481 G > C GTCGCAA 1    
E6:482 C > A TCGCAAG 1    
E7:522 T > G ATATAAG  1   
E8:533 T > G TAGTTGT  1   
E8:585 T > G ATTATAG  2   
E8:606 G > C TTTGAAT 1    
E9:610 C > A TAGCATG  1   
Total   21 49 1 1 
 
Table 3.4. Base substitutions observed in spontaneous and daunorubicin-
treated HPRT mutants. 
Figures represent the number of mutations observed in both spontaneously-occurring 
and daunorubicin-treated HPRT mutant populations. Each mutation is identified by the 
exon in which it occurred and is numbered according to the cDNA position. Within the 
target sequence the affected base is underlined. 
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Affected Region 
Spontaneous Daunorubicin-treated 
TK6 
TK6 
RUNX1/ETO 
TK6 
TK6 
RUNX1/ETO 
Small deletion / insertion     
E1:18 1    
E1:27  1   
E2:34 1    
E2:36 2    
E2:37 1    
E2:40 1 1   
E2:70-86 1    
E2:93  1   
E2:114-124  1   
E2:115  1   
E3:140 4    
E3:144  1   
E3:148 1    
E3:158-171 1    
E3:179 1    
E3:204-231  1   
E3:208-225  1   
E3:215-228 1    
E3:231 1    
E3:239  1   
E3:275-294 1    
E3:289-290 1    
E4:352  1   
 
Table 3.5. Small deletion/insertion observed in spontaneous and daunorubicin-
treated HPRT mutants (continued to next page). 
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Affected Region 
Spontaneous Daunorubicin-treated 
TK6 
TK6 
RUNX1/ETO 
TK6 
TK6 
RUNX1/ETO 
Small deletion / insertion     
E5:392  1   
E5:399 2    
E5:402  1   
E6:425  1   
E6:436-444  1   
E6:440  1   
E6:441-443 1    
E6:445  1   
E6:471-476  1   
E7:513-525 1    
E8:536-540  1   
E8:583-606  1   
E8:569-578  1   
E8:607  1   
E9:610-626  2   
E9:615  1   
E9:615-634  1   
E9:633-634  1   
E9:645 1    
Total 23 26 0 0 
 
Table 3.5. Small deletion/insertion observed in spontaneous and daunorubicin-
treated HPRT mutants (continued from previous page). 
Figures represent the number of mutations observed in both spontaneously-occurring 
and daunorubicin-treated HPRT mutant populations. Small deletions/insertions were 
further classified according to the extent of the affected region and exons. 
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3.2.7.2. Comparison of spontaneous and daunorubicin-treated HPRT mutational 
spectra 
 
 The spectrum of mutations at the HPRT locus derived from daunorubicin-
treated cells was compared to that derived from vehicle-treated cells (spontaneously-
occurring mutation) (Figure 3.14). Specifically, the proportion of large deletions, 
comprising terminal and internal exon deletions was significantly higher in 
daunorubicin-treated cells (55/56; 98%) relative to vehicle-treated cells (110/154; 71%) 
in parental TK6 mutant population (P < 0.0001; two-tailed Fisher’s exact test). Similarly, 
in TK6 RUNX1/ETO-expressing cells, the proportion of large deletions was also 
significantly higher following daunorubicin treatment (49/50; 98%) relative to vehicle 
treatment (217/292; 74%) (P < 0.0001; two-tailed Fisher’s exact test). Strikingly, only 
1 base substitution event (TK6: 1/56; 2%, TK6 RUNX1/ETO: 1/50; 2%) was observed 
in each daunorubicin-treated mutant population compared to 21 (14%) and 49 (17%) 
base substitution events observed in vehicle-treated parental TK6 and TK6 
RUNX1/ETO cells, respectively. Taken together, this demonstrates that the spectrum 
of daunorubicin-treated HPRT mutant is clearly distinct from the spontaneously-
occurring mutational spectrum. 
 Daunorubicin-treated mutant populations were compared to investigate the 
influence of the RUNX1/ETO fusion gene on the daunorubicin-induced mutational 
spectrum. A two-tailed Fisher’s exact test demonstrated no significant difference in 
frequency for each class of mutation between both HPRT mutant populations (data not 
shown), although a higher proportion of internal exon deletion was observed in TK6 
RUNX1/ETO-positive cells (42%) compared to parental TK6 cells (25%). In addition, 
similar statistical testing performed for each class of mutation between both vehicle-
treated HPRT mutant populations also did not reach statistical significance (data not 
shown). Collectively, these data demonstrated that the RUNX1/ETO fusion gene does 
not significantly affect the frequency of each class of HPRT mutation, either 
spontaneously or after daunorubicin treatment. 
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Figure 3.14. Mutational spectra of spontaneously-occurring and daunorubicin-treated mutants derived from parental TK6 and 
TK6 RUNX1/ETO-positive cells. 
Spectra of mutations observed at the HPRT locus following 16 hour exposure to 30nM daunorubicin (inducing ~95% cytotoxicity) or 
vehicle control in TK6 and TK6 RUNX1/ETO cells. Coloured sections represent different structural classes of mutation. Numbers in 
parentheses indicate the percentage of mutants in each class. Total number of mutant analysed (n) is shown above the bars. 
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3.3. Discussion 
 
 The mechanisms by which novel mutations are acquired at relapse remain 
unclear, although there is strong evidence that some are chemotherapy-induced 
(Fordham et al., 2015). The carcinogenicity of many chemotherapy agents is partly 
dependent on their ability to induce pro-mutagenic DNA damage. However, there is 
lack of data investigating the mutagenic potential of chemotherapy agents despite 
widespread use in the treatment of AML. In addition, emerging evidence has 
demonstrated the influence of the RUNX1/ETO fusion gene on the acquisition of 
mutations, both spontaneously and after exposure to genotoxic agents (Forster et al., 
2015), suggesting a major contribution of this fusion oncogene to the induction of 
genomic instability and mutagenesis. The main purpose in this study therefore, is to 
determine whether RUNX1/ETO expression sensitises cells to mutations at the TK and 
HPRT loci, both spontaneously and after exposure to chemotherapeutic agents. 
 The TK and HPRT mutation assays used in this study are clonogenic assays, a 
type of in vitro cell survival assay based on the ability of a single cell to grow into a 
colony. For this reason, TK6 human lymphoblastoid cells were selected as a cell model 
to investigate the mutagenicity of chemotherapy agents due to a high cloning efficiency 
as demonstrated by their ability to survive and proliferate at low density (2 cells per 
well) in liquid media. TK6 is a B lymphoblastoid line that is easy to maintain and has a 
low somatic mutation rate (~ 0.3%) (Sie et al., 2009), which make it the preferred choice 
for in vitro mutation studies. Moreover, prior to initiation of the assay, pre-existing TK 
and HPRT mutant cells can be purged from the cell population to minimise the intrinsic 
mutation frequency at these loci, allowing for an accurate measurement of the induced 
mutation frequency as a function of time and exposure, such as oncoprotein 
expression or chemotherapy. 
TK6 cells are heterozygous at the TK locus and hemizygous at the HPRT locus 
(refs). Therefore, mutagenic mechanisms that involve homologous interaction such as 
gene conversion cannot occur at the X-linked HPRT locus. Similarly, large multi-locus 
deletions are unlikely to occur at the HPRT locus since large deletions may span 
adjacent genes essential for cell survival. Therefore, the mutagenic effect of 
chemotherapy agents might be underestimated by the HPRT mutation assay if those 
agents induce homologous interaction or large deletion. However, performing both TK 
and HPRT mutation assays simultaneously using the same cell population may 
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compensate to some extent for the limitations of each individual locus as a reporter 
gene, thus providing accurate information on the mutagenicity of that agents. 
 As expected, a statistically significant dose-dependent increase in MF was 
observed at both TK and HPRT loci in both TK6 and TK6 RUNX1/ETO cells following 
16 hour exposure to escalating doses of daunorubicin and ara-C, suggesting that these 
chemotherapy agents are mutagenic at the doses investigated. As a nucleoside 
analogue which is similar to human cytosine deoxyribose (deoxycytidine), ara-C can 
be incorporated into replicating DNA at internucleotide positions leading to inhibition of 
chain extension (Graham and Whitmore, 1970; Zahn et al., 1972). The induced chain 
termination gives rise to stalled replication forks, which can in turn be converted to 
DSBs (Arnaudeau et al., 2000; Arnaudeau et al., 2001). This could result in large 
deletions if two DSBS are in close proximity due to major loss of DNA sequence. There 
are two repair mechanisms for DSBs; however, HR is thought to be the dominant 
mechanism for DSBs at stalled replication forks (Arnaudeau et al., 2001; Lundin et al., 
2002; Rothkamm et al., 2003), which raises the possibility that ara-C could also induce 
gene conversion type mutations. Collectively, large deletions and gene conversion 
mutations could give rise to LOH which may partly explain the higher ara-C-induced 
MF observed at the TK locus relative to the HPRT locus. This finding is consistent with 
data demonstrating a greater increase in MF at the TK locus than at the HPRT locus 
after exposure to ara-C (Fordham et al., 2015). In addition, studies investigating 
Zidovudine (3’-Azido-2’,3’-dideoxythymidine), a nucleoside analogue which also 
causes DNA chain termination also demonstrated a higher MF at the TK locus than at 
the HPRT locus (Sussman et al., 1999; Meng et al., 2000). 
 The cytotoxicity of daunorubicin is primarily mediated by the inhibition of topo II 
enzyme (Nielsen et al., 1996; Arcamone et al., 1997). In normal condition, topo II binds 
to DNA to catalyse the relaxation of supercoiled DNA distal to replication fork during 
DNA replication by inducing transient double strand break and rejoining both strands 
of the double helix (see Section 1.7.2, Chapter 1). Intercalation of daunorubicin 
between DNA base pairs stabilises the topo II-cleaved DNA covalent complex, 
preventing the DNA double helix from being resealed and thereby inhibiting replication 
(see Chapter 1, Section 1.7.2). Many anti-cancer drugs including anthracyclines that 
target topo II are reported to increase the concentration of topo II-DNA covalent 
complexes and decrease the re-ligation rate which eventually collapse to generate a 
DNA DSB (Fortune and Osheroff, 2000) and which can then induce chromosomal 
breakage and cell death. Indeed, evidence has shown that daunorubicin and related 
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anthracyclines are direct inducers of DNA strand breaks (Blasiak et al., 2002; Yang et 
al., 2015). As such, induced DNA damage,  responsible for daunorubicin cytotoxicity, 
may cause genomic rearrangements (translocations, inversions or deletions) as a 
consequence of attempts to repair the strand break (Felix Carolyn, 2001). NHEJ is a a 
major mechanism for the repair of double strand breaks in DNA; however, data from 
wing Somatic Mutation and Recombination Test (SMART) in Drosophila melanogaster 
demonstrated a high frequency of HR after exposure to daunorubicin, indicating 
daunorubicin as a direct inducer of HR (Lehmann et al., 2004). Although HR-mediated 
repair is considered to be a relatively error-free repair process, it can also lead to LOH 
or genomic rearrangements (Bishop and Schiestl, 2001; Rodgers and McVey, 2016). 
In addition, a study has demonstrated that other anthracycline drug, doxorubicin, also 
induces a substantial increase in the frequency of large deletions in vitro (Anderson et 
al., 1991). Therefore, it is suggested that DNA topo II-mediated chromosomal 
breakage caused by daunorubicin may partly explains the acquisition of large-scale 
mutations, as demonstrated by higher induced MF at the TK locus compared to 
induced MF at HPRT locus at equivalent doses of daunorubicin. 
 TK6 cells transduced with full length RUNX1/ETO (TK6 RUNX1/ETO) were 
used to investigate the influence of RUNX1/ETO expression on the acquisition of 
mutations, both spontaneously and after chemotherapy treatment. Evidences suggest 
that RUNX1/ETO suppresses cellular DNA repair activity to promote mutagenesis and 
facilitate the acquisition of secondary mutations (Alcalay et al., 2003; Krejci et al., 2008; 
Araten et al., 2013). One important DNA repair protein implicated in t(8;21) AML 
pathogenesis is OGG1, which is a key component in BER pathway that initiates repair 
of oxidised lesions, including 8-oxoG (Alcalay et al., 2003; Liddiard et al., 2010). OGG1 
protein expression is downregulated in RUNX1/ETO expressing cells and the depletion 
of RUNX1/ETO via RNA interference increased OGG1 transcript, indicating OGG1 as 
a likely RUNX1/ETO target gene (Forster et al., 2015). Subsequent studies confirmed 
that the RUNX1/ETO fusion protein binds theOGG1 promoter and negatively regulates 
transcription (Forster et al, 2015), which provides a plausible mechanism of 
mutagenesis driven by the RUNX1/ETO fusion protein. In addition, a study in 
Drosophila showed that RUNX1/ETO expression increased the levels of intracellular 
ROS (Sinenko et al., 2010), which may induce elevated DNA damage, making cells 
that express RUNX1/ETO more susceptible to additional genetic mutations. This is 
consistent with evidence in this study which showed that RUNX1/ETO sensitises cells 
to the acquisition of mutations in the absence of an exogenous exposure, as 
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demonstrated by an increased spontaneous mutation frequency at both the TK and 
HPRT loci relative to RUNX1/ETO-negative cells. However, there was no strong 
evidence that RUNX1/ETO expression renders cells more susceptible to mutagenesis 
after exposure to equitoxic doses of daunorubicin; a result that is inconsistent with 
previously reported findings (Forster et al., 2015). This inconsistent finding might be 
due to the very high mutation burden in cells after exposure to highly cytotoxic doses, 
thus mitigating any increase on mutation due to RUNX1/ETO expression.  
 The influence of RUNX1/ETO expression on daunorubicin mutagenicity was 
further investigated to determine the frequency of each class of mutation (i.e. large 
deletion, small deletion/insertion, base substitution) induced by this agent at the HPRT 
locus. Two HPRT mutant spectrums were generated, for RUNX1/ETO-negative and 
RUNX1/ETO-positive cells, to determine the effect of fusion oncoprotein expression 
on spontaneous mutation and chemotherapy-induced mutation. The daunorubicin-
induced mutational spectrum for both RUNX1/ETO-negative and RUNX1/ETO-positive 
HPRT mutant populations are dominated by mutants originating from DNA strand 
breakage events (large deletions), consistent with the inhibitory effect of topo II enzyme 
as a major mechanism of this agent. In fact, an almost complete lack of base 
substitution mutants (base substitution; 2%) suggests that daunorubicin is efficient at 
inducing mutations derived from DNA strand breaks but that mutations arising from 
base mispairing are rare. Although a slightly higher proportion of HPRT internal exon 
deletions was observed in daunorubicin-treated TK6 RUNX1/ETO cells compared to 
daunorubicin-treated parental TK6 cells, further characterisation of these deletion 
revealed no notable differences in the structural type of internal exon deletions. Taken 
together, these data provide strong evidence that daunorubicin almost exclusively 
induces mutations derived from DNA strand breaks, likely resulting from the inhibition 
of topo II. 
The influence of RUNX1/ETO on the acquisition of mutations was further 
evaluated by interrogating the spontaneous mutational spectrum to determine whether 
fusion protein expression is association with acquisition of a particular mutation type. 
In contrast to the daunorubicin-induced mutational spectrum, which is dominated by 
deletions, the frequency for each class of mutation observed in TK6 cells is similar with 
the reported frequency for spontaneous TK6 HPRT-mutations in other studies, 
comprising 45% large deletions, 30% base substitutions, 15% small deletions and 10% 
compound alterations (Giver Cynthia et al., 1993), although the proportion of large 
deletion identified in the current study was slightly higher. The base substitution 
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mutation spectrum analysis is the most anticipated in this study since many mutations 
in AML relevant genes carry this type of mutation in primary AML. All base substitutions 
observed in both HPRT mutant populations were single base substitutions. In the 
absence of an exogenous exposure, such as daunorubicin, base substitutions 
occurred spontaneously at a moderate frequency, although the frequency was slightly 
lower than the 30% frequency reported previously (Giver Cynthia et al., 1993). One of 
the assumptions prior to analysis of spontaneously-occurring mutants was that 
RUNX1/ETO expression would increase the frequency of base substitutions, given the 
fact that downregulation of OGG1 is predicted to lead to an increase of 8-oxoG and 
cause elevated G:C to T:A mutation. However, there was no strong evidence that 
RUNX1/ETO expression resulted in a significant increase in base substitution 
mutations specifically, despite an overall increase in mutation frequency associated 
with expression of the fusion oncoprotein. However, RUNX1/ETO expression was 
associated with an increase in T > G / A > C, T > C / A > G and C > A / G > T HPRT 
mutations, which might suggest the preference DNA base/basepair for RUNX1/ETO 
mutagenicity. Given the heterogeneity in base substitution identified in this study, a 
thorough analysis of the base substitution spectrum will be described in Chapter 4, in 
order to identify the mutational pattern associated with RUNX1/ETO expression. 
 In conclusion, in vitro evidence suggests that daunorubicin and ara-C are 
mutagenic. However, there was no strong evidence that RUNX1/ETO significantly 
affect the chemotherapy-induced mutation frequency after exposure to daunorubicin 
and ara-C. This observation is on contrast to published data showing that RUNX1/ETO 
increases mutagenicity at the the PIGA locus in TK6 cells (Forster et al., 2015). One 
possible explanation for this is that the PIGA locus is more sensitive than either TK or 
HPRT to those types mutations induced by either daunorubicin or ara-C. Indeed, this 
is almost certainly the case for the TK locus, which is recognised as a poor reporter 
gene for large deletions. Furthermore, the PIGA locus is generally more mutable than 
either the TK or HPRT loci and could be generally a more sensitive reporter gene for 
mutation. Despite a low number of characterised HPRT mutants, daunorubicin 
exclusively induces deletions derived from DNA strand break. However, a more 
extensive molecular analysis of spontaneous HPRT mutants is required to expand the 
current dataset so that the types of mutation induced by RUNX1/ETO can be fully 
delineated. Moreover, the data from this study may form the basis for future studies to 
investigate the mutagenic potential of other chemotherapy agents used in AML, as well 
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as the influence of RUNX1/ETO fusion gene on the acquisition of mutations, both 
spontaneously and after chemotherapy treatment. 
 
3.3.1. Summary of chapter 
 
 In summary, these investigations have demonstrated that: 
• Exposure to daunorubicin and ara-C results in a significant dose-
dependent increase in mutation frequency at both TK and HPRT loci in 
both TK6 and TK6 RUNX1/ETO cells, suggesting both chemotherapy 
agents are mutagenic to DNA in vitro. 
• RUNX1/ETO increases spontaneous mutation frequency at both TK and 
HPRT loci relative to RUNX1/ETO-negative cells, although it was not 
statistically significant at the HPRT locus. 
• There was no strong evidence that RUNX1/ETO significantly affect the 
chemotherapy-induced mutation frequency following exposure to 
daunorubicin and ara-C. 
• Large deletions account for most of daunorubicin-treated mutations, 
consistent with the inhibitory effect of topo II enzyme which resulted in 
DNA strand breaks. 
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Chapter 4. Identifying RUNX1/ETO Mutational Signature in Acute 
Myeloid Leukaemia 
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4.1. Introduction 
 
 Cancer is a genetic disease characterised by the accumulation of mutations in 
the somatic genome acquired during disease progression. Although somatic mutations 
are known to cause cancer, the biological processes generating these mutations is 
poorly understood. It is thought that the collective somatic mutations observed in a 
cancer genome are the consequence of several mutational/mutagenic processes that 
have been operative throughout the lifetime of a patient (Helleday et al., 2014). Each 
mutational process comprises both a DNA damage component (endogenous or 
exogenous DNA damage) and a DNA repair or replicative component (defective DNA 
repair pathways) which leave a characteristic imprint on the cancer genome that reflect 
those processes. This characteristic imprint, also known as ‘mutational signature’ is 
represented by specific mutations in the genome that can include base substitutions, 
insertions and deletions or structural variations (genomic rearrangements). Previous 
studies have shown that a certain type of DNA damage has its own preference for 
specific nucleotides. The high frequency of G:C > T:A transversion found in smoking-
associated lung cancer has been attributed to the mutagenic action of polycyclic 
aromatic hydrocarbons (PAH) compounds in cigarette smoke (Pfeifer and Hainaut, 
2003) and single C:G > T:A transition and tandem double CC:GG > TT:AA transition 
are associated with UV DNA damage in skin cancer (Brash et al., 1991; Pierceall 
William et al., 1991; Weihrauch et al., 2002; Brash, 2015). 
 However, it would be naïve to define the cause of cancer by just a single 
mutational process since cancer aetiology is often multifactorial. The numerous 
processes operating during cancer development suggests that cancers genomes 
contain two or more mutational signatures. Mutational signatures in human cancers 
are based on six classes of base substitutions: C > A, C > G, C > T, T > A, T > C and 
T > G (all substitutions are referred to by the pyrimidine of the mutated Watson–Crick 
base pair) which can be further classified by the triplet sequence in which they are 
positioned with the mutated base residing at the central base position of 96 possible 
trinucleotide sequences (Figure 4.1)  (Nik-Zainal et al., 2012; Alexandrov et al., 2013a; 
Alexandrov et al., 2013b; Alexandrov et al., 2015). This 96 substitution classification is 
particularly useful for distinguishing mutational signatures that cause the same 
substitutions but in different sequence contexts. To date, 30 mutational signatures 
have been identified across 40 cancer types with at least two mutational signatures 
found in each cancer type and some cancer types with more than 10 mutational 
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signatures (Figure 4.2) (https://cancer.sanger.ac.uk/cosmic/signatures). Moreover, 
some of the mutational signatures are found in multiple cancer types, while others are 
confined to a single cancer type. The identification of these mutational signatures has 
provided essential information on the aetiology of mutagenesis although the causes of 
many of these remain unknown. Examples of mutational signatures that have been 
attributed to possible aetiology are shown in Figure 4.1.  
 AML is a complex disease comprises of different subtypes, but contains 
relatively few somatic mutations compared to other cancers (Cancer Genome Atlas 
Research, 2013). Two mutational signatures have been found in AML (Figure 4.2). The 
first signature (signature 1) is characterised by an increase of C > T mutations and is 
associated with endogenous mutational process initiated by spontaneous deamination 
of 5-methylcytosine, while the second signature (signature 5) is dominated by C > T 
and T>C mutations, but yet has unknown aetiology 
(https://cancer.sanger.ac.uk/cosmic/signatures). However, it is thought that other 
biological processes may also influence the mutational pattern in AML. A recent study 
has showed that ara-C which is mainly used in AML remission induction treatment 
preferentially induces mutation at central base position of 5’TpGpA3’/5’TpCpA3’ 
sequences in the genome which are significantly higher in relapsed AML patients after 
exposure to ara-C-containing regimens (Fordham et al., 2015). The finding from this 
study demonstrated that specific sequences in the genome were susceptible to 
additional exogenous mutagenic exposures by chemotherapy agents which might 
contribute to the aetiology of relapse disease.  It is important to explore patterns of 
mutations induced by specific mutagens since various endogenous and exogenous 
sources of DNA damage are involved in AML pathogenesis. RUNX1/ETO is one of the 
important initiating genetic lesions in AML and was demonstrated to increase mutation 
frequency both spontaneously and after exposure to genotoxic chemotherapeutic 
agents (Forster et al., 2015).  This finding is further supported by the data presented 
in Chapter 3 of this thesis demonstrating elevated mutagenicity in RUNX1/ETO-
expressing cells. Using the same approaches as Fordham and colleagues (Fordham 
et al., 2015), the base substitution data described in previous chapter (see Table 3.4, 
Chapter 3) was further investigated in order to identify a spontaneous mutational 
signature associated with RUNX1/ETO expression in order to better understand the 
mutational processes contributing to disease progression. 
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4.1.1. Aims of Chapter 4 
 
 The objective of this investigation is to identify a somatic mutational signature 
associated with RUNX1/ETO expression and to determine whether this oncoprotein 
predisposes to mutation at specific sequences in the genome. 
 Specifically, the experimental aims were as follows: 
• Compare the mutational pattern between RUNX1/ETO-positive and 
RUNX1/ETO-negative clones at the HPRT locus. 
• Compare the RUNX1/ETO-induced mutational pattern observed in vitro 
using the cell model system and that seen in primary AML. 
• Identify nucleotide sequences susceptible to RUNX1/ETO-induced 
mutation. 
• Identify “leukaemia genes” susceptible to RUNX1/ETO-induced mutation 
in AML. 
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Figure 4.1. Example of mutational signatures found in human cancers that have 
been attributed to proposed aetiology 
(https://cancer.sanger.ac.uk/cosmic/signatures). 
The signature is displayed according to the 96 substitution classification defined by the 
substitution class and sequence context immediately 5’ and 3’ to the mutated base. 
Signature 1: spontaneous deamination of 5-methylcytosine. 
Signature 2: activity of the AID/APOBEC family of cytidine deaminases. 
Signature 3: failure of DNA double-strand break repair by homologous 
recombination. 
Signature 4: exposed to tobacco carcinogens (e.g., benzo[a]pyrene). 
Signature 6: defective DNA mismatch repair.
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Figure 4.2. The presence of mutational signatures identified across 40 human cancer types 
(https://cancer.sanger.ac.uk/cosmic/signatures). 
Two mutational signatures have been associated with AML (signature 1 and signature 5).
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4.2. Results 
 
4.2.1. Base substitution in TK6 and TK6 RUNX1/ETO at the HPRT locus 
 
 The single base substitutions identified in TK6 and TK6 RUNX1/ETO cells (see 
Table 3.4, Chapter 3) were classified into six classes of mutation: C > A / G > T, C > G 
/ G > C, C > T / G > A, T > A / A > T, T > C / A > G and T > G / A > C. In total, 21 and 
49 independent single base substitutions were derived from HPRT mutant clones of 
TK6 and TK6 RUNX1/ETO cells, respectively. In proportion, the frequency of T > G / 
A > C, T > C / A > G and C > A / G > T base substitutions was higher in TK6 
RUNX1/ETO compared to parental TK6; however, none of these were statistically 
significant (Figure 4.3). Regarding type of mutation, in proportion, transversion 
mutations occurred at a slightly higher frequency in TK6 RUNX1/ETO compared to 
parental TK6 [55% (27/49) vs 43% (9/21)], but this was also not statistically significant 
(P = 0.44; two-tailed Fisher’s exact test) (Figure 4.4). 
 
4.2.2. Mutational pattern between TK6 and TK6 RUNX1/ETO at HPRT locus 
 
 The base substitution mutation data were further analysed in sequence context 
to identify any mutational pattern associated with RUNX1/ETO expression. The six 
classes of base substitution were grouped according to mutation at the central base 
position of 16 different possible trinucleotide sequences, result in 96 possible 
trinucleotide sequences for all 6 classes of mutation (Figure 4.5). Regarding T > G / A 
> C base substitutions, 5 of 13 (39%) occurred at 5′ApTpA3′/5′TpApT3′ sequences in 
RUNX1/ETO clones, compared to 0 of 1 (0%) in parental TK6 cells (P = 1.00; two-
tailed Fisher’s exact test). 
 The 96 possible trinucleotide sequences were then combined and used to 
generate a heatmap in order to identify the affected trinucleotide sequences regardless 
of type of base substitution (Figure 4.6). Strikingly, 7 of 49 (14.3%) base substitutions 
from RUNX1/ETO-positive clones affected the central T:A base-pair in 
5′ApTpA3′/5′TpApT3′ sequences compared to 1 of 21 (4.8%) in RUNX1/ETO-negative 
cells; however, this was not statistically significant (P = 0.42; two-tailed Fisher’s exact 
test). In addition, mutation frequency at the other 31 possible trinucleotide sequences 
in RUNX1/ETO-positive mutational spectrum were also not substantially different 
compared to fusion-negative controls. 
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Figure 4.3. Number of single base substitution identified in TK6 and TK6 
RUNX1/ETO at HPRT locus. 
Single base substitutions were classified into six classes of mutation. The number of 
events (and proportion) from the total number of mutations observed in TK6 and TK6 
RUNX1/ETO clones is shown. Figure shown in parenthesis is the number of mutations 
identified in each class of mutation for TK6 and TK6 RUNX1/ETO cells. P-value was 
calculated by two-tailed Fisher’s exact test comparing the number of mutation between 
TK6 and TK6 RUNX1/ETO cells. 
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Figure 4.4. Type of base substitution mutation. 
Single base substitutions were classified according to type of mutation (transition or 
transversion). The number of events (and proportion) from the total number of 
mutations observed in TK6 and TK6 RUNX1/ETO clones is shown. Figure shown in 
parenthesis is the number of mutations identified in each class of mutation for TK6 and 
TK6 RUNX1/ETO cells. P-value was calculated by two-tailed Fisher’s exact test 
comparing the number of mutation between TK6 and TK6 RUNX1/ETO cells.
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Figure 4.5. Comparison of HPRT base substitution mutational pattern between TK6 and TK6 RUNX1/ETO. 
The mutation at central base position is displayed according to the 96 substitution classification defined by the substitution class and 
sequence context immediately 5’ and 3’ to the mutated base (trinucleotide sequence). Number of event represents number of mutation at 
the central base position of each trinucleotide sequence.
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Figure 4.6. Mutation at central base in each possible trinucleotide. 
The sequence context of HPRT base substitution mutations in TK6 and TK6 
RUNX1/ETO clones. Heatmaps display the number of base substitution mutations at 
the central base position of each trinucleotide sequence. 
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4.2.3. Mutational pattern identified in next generation sequencing data of primary 
RUNX1/ETO AML patients 
 
 To identify the base substitution mutational associated with RUNX1/ETO in 
primary AML cells, interrogation of available targeted amplicon sequencing data from 
56 diagnostic AML t(8;21) samples (Hartmann et al., 2016) was performed. A total of 
86 single base substitutions in 19 leukaemia relevant genes were analysed (Table 4.1). 
Of these, 56% (48/86) were transitions and 44% (38/86) were transversions. In term of 
type of base substitution, C > T / G > A transitions occurred at a higher frequency (38/ 
86, 44.2%) than the other five classes of base substitution (Figure 4.7). Regarding 
gene context, there were 16 of 19 genes affected by C > T / G > A transitions, with 
ZBTB7A (7/38) and NRAS (6/38) were the genes mostly frequently affected by this 
mutation type (Table 4.1). 
 Using the same approach as used to analyse RUNX1/ETO-induced mutations 
at the HPRT locus in vitro (Section 4.2.2), base substitutions were grouped according 
to mutation at the central base position of 16 possible trinucleotide sequences for each 
class of single base substitution (Figure 4.8). Of the most frequent class of mutations 
were C > T / G > A transitions, which commonly occurred at the central base position 
of 5’CpCpG3’ / 5’CpGpG3’ (10/38, 26.3%) and 5’GpCpG3’ / 5’CpGpC3’ (8/38, 21.1%) 
sequences. Other notable trinucleotide sequences affected by C > T / G > A transitions 
at central base position were 5′ApCpC3′/5′GpGpT3′ (5/38, 13.2%) and 
5′TpCpG3′/5′CpGpA3′ (4/38, 10.5%). Genes that were found affected specifically by C > 
T / G > A transitions at C:G basepairs in 5’CpCpG3’ / 5’CpGpG3’ sequences were 
ZBTB7A, DNMT3A, SMC1A, PTPN11 and IDH2 whereas ZBTB7A, ASXL1, TET2, 
DNMT3A, FAT1 and WT1 were affected by C > T / G > A transitions at C:G base pair 
in 5’GpCpG3’ / 5’CpGpC3’ sequences (Figure 4.8). In contrast, only the NRAS gene was 
affected by C > T / G > A transitions at C:G basepairs in 5’ApCpC3’ / 5’GpGpT3’. 
 Regardless of the type of base substitution, 5’CpCpG3’ / 5’CpGpG3’ sequences 
were the most commonly mutated (11/86, 12.8%), followed by 5’GpCpG3’ / 5’CpGpC3’ 
sequences as the second most affected (8/86, 9.3%) (Figure 4.9). Other notable 
affected sequences were 5′ApCpC3′/5′GpGpT3′ (7/86, 8.1%), 5′ApCpA3′/5′TpGpT3′ (6/86, 
7.0%), 5′GpTpC3′ / 5′GpApC3′ (6/86, 7.0%) and 5’TpCpT3’ / 5’ApGpA3’ (6/86, 7.0%). 
Interestingly, it was observed that most of C > T / G > A transitions occurred at the 
cytosine (C) bases of 5′CpG3′ dinucleotide sequences (23/38, 60.5%), with the most 
affected gene was ZBTB7A (7/23, 30.4%) (Figure 4.8) (Table 4.2).
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Gene 
Transition Total no. of 
transition 
Transversion Total no. of 
transversion 
Total no. 
of mutation C > T / G > A T > C / A > G C > A / G > T C > G / G > C T > A / A > T T > G / A > C 
ZBTB7A 7  7 2   3 5 12 
NRAS 6 2 8 3    3 11 
KIT  1 1  2 4 3 9 10 
FLT3  1 1 1 3 2 2 8 9 
TET2 4 1 5 1 1  1 3 8 
DNMT3A 3  3  1 1  2 5 
JAK2 1 2 3 2    2 5 
FAT1 3  3  1   1 4 
ASXL2 1  1 1   1 2 3 
SMC3 1  1 1   1 2 3 
IDH2 2  2     0 2 
JAK3 1 1 2     0 2 
KRAS 2  2     0 2 
PTPN11 2  2     0 2 
RAD21 1  1 1    1 2 
SMC1A 2  2     0 2 
WT1 1 1 2     0 2 
ASXL1 1  1     0 1 
CBL  1 1     0 1 
Total no. of 
mutation 
38 10 48 12 8 7 11 38 86 
 
Table 4.1. Single base substitution mutations identified in t(8;21) AML at 19 leukaemia relevant genes. 
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Figure 4.7. Number of single base substitution mutations identified in t(8;21) 
AML at 19 leukaemia relevant genes. 
Single base substitutions were classified into six types of mutation. Number of event 
represents the number of mutations identified in t(8;21) AML samples. Figure shown 
in parenthesis is the percentage of mutations from the total number of mutations 
identified in t(8;21) AML patients. 
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Figure 4.8. Base substitution mutation pattern identified in t(8;21) AML patients at 19 leukaemia relevant genes. 
The mutation at central base position is displayed according to the 96 substitution classification defined by the substitution class and 
sequence context immediately 5’ and 3’ to the mutated base (trinucleotide sequence). Number of event represents number of mutation at 
the central base position of each trinucleotide sequence.
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Figure 4.9. Mutation at the central base in each possible trinucleotide based on 
data derived from t(8;21) AML leukaemias and mutation from 18 leukaemia 
relevant genes. 
The sequence context of base substitution mutations in t(8;21) AML patients. Heatmap 
displays the number of base substitution mutations at the central position. 
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Trinucleotide Sequence No. of event Genes 
5'ApCpA3' / 5'TpGpT3' 1 SMC3 (1) 
5'ApCpC3' / 5'GpGpT3' 5 NRAS (5) 
5'ApCpG3' / 5'CpGpT3' 1 FAT1 (1) 
5'ApCpT3' / 5'ApGpT3' 0 - 
5'CpCpA3' / 5'TpGpG3' 1 TET2 (1) 
5'CpCpC3' / 5'GpGpG3' 0 - 
5'CpCpG3' / 5'CpGpG3' 10 ZBTB7A (4), DNMT3A (1), SMC1A (2), PTPN11 (1), IDH2 (2) 
5'CpCpT3' / 5'ApGpG3' 1 NRAS (1) 
5'GpCpA3' / 5'TpGpC3' 0 - 
5'GpCpC3' / 5'GpGpC3' 2 KRAS (2) 
5'GpCpG3' / 5'CpGpC3' 8 ZBTB7A (2), ASXL1 (1), TET2 (1), DNMT3A (2), FAT1 (1), WT1 (1) 
5'GpCpT3' / 5'ApGpC3' 0 - 
5'TpCpA3' / 5'TpGpA3' 3 JAK2 (1), FAT1 (1), PTPN11 (1) 
5'TpCpC3' / 5'GpGpA3' 1 JAK3 (1) 
5'TpCpG3' / 5'CpGpA3' 4 ZBTB7A (1), ASXL1 (1), RAD21 (1), TET2 (1) 
5'TpCpT3' / 5'ApGpA3' 1 TET2 (1) 
Total no. of event 38 
 
 
Table 4.2. Trinucleotide sequences in leukaemia relevant genes affected by C > T / G > A transitions. 
Figure shown in parenthesis represents number of C > T / G > A events at specific trinucelotide sequence for each gene. Genes that were 
affected by mutation at C base of 5’CpG3’ dinucleotide sequences are higlighted in grey.
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4.3. Discussion 
 
 Single base substitutions constitute the most frequent type of human gene 
mutation and are a leading cause of genetic disease including cancer. The analysis of 
base substitution has previously been identified as a useful approach to demonstrate 
how the mutation spectra can be specific to tumour type and the underlying mutational 
processes (Helleday et al., 2014). Other types of mutation, such as insertions and 
deletions (indels) also contribute to disease pathogenesis, but these are technically 
difficult to assay due to size local sequence, which is often repetitive. The base 
substitutions included in the analysis presented in this chapter were independently 
derived from unique HPRT mutant clones with just one mutation derived from each 
CHAT-treated cell population. As such, the base substitution analysis includes only 
independent mutations after correction for duplicate mutations which likely represent 
clonal expansions. 
 Single base substitutions identified in the HPRT gene sequence were classified 
into six classes of mutation based on the affected basepair and whether a transition or 
transversion mutation. Furthermore, because it is not possible to discern in which 
strand a mutation was initiated, mutations are grouped by complementary sequence. 
On the basis of type of mutation, there was more transversions than transitions in 
RUNX1/ETO-positive cells. In the human genome, transitions are generated at higher 
spontaneous frequency than transversions somatically, with the latter generally having 
more deleterious effects on the amino acid sequence (Rubin and Green, 2009). The 
data generated in this project suggest that an increase in T > G / A > C mutations is 
largely responsible for the elevated mutation rate in RUNX1/ETO-positive cells. The 
increased of T > G / A > C mutations suggests that DNA repair pathways especially 
those repairing damaged or mismatched DNA bases such as BER and MMR might be 
compromised. A previous study has shown that OGG1 DNA glycosylase, a key 
component in BER pathway, was downregulated in cells expressing RUNX1/ETO 
(Forster et al., 2015). However, impaired activity of OGG1 is associated with G:C > T:A 
transversions, which was not evident at the HPRT locus in this study. Downregulation 
of other key DNA glycosylase in BER pathway such as NEIL1 was also shown to result 
in base substitution mutations, as characterised by a higher rate of spontaneous A:T 
> T:A transversions at the HPRT locus in Chinese hamster lung fibroblast V79 cells 
(Maiti et al., 2008); but, this was also not evident at the HPRT locus in this study. 
Although no strong evidence of OGG1 and NEIL1 downregulation in RUNX1/ETO-
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expressing cells from this study, investigation on association between RUNX1/ETO 
and other DNA repair gene expression especially those involved in BER and MMR 
pathways is warranted, given the potential of these pathways in causing base 
substitution mutations when disrupted. 
 In terms of sequence context, the central T:A base pair in 5′ApTpA3′/5′TpApT3′ 
sequences were most affected by T > G / A > C transversions. However, there is no 
previous evidence of 5′ApTpA3′/5′TpApT3′ susceptibility to mutations in the literature, 
indicating unknown aetiology. Moreover, the mutational pattern observed in 
RUNX1/ETO-positive cells did not resemble any of the recognised mutational 
signatures previously identified in human cancer 
(https://cancer.sanger.ac.uk/cosmic/signatures). Mutational signature 9 which is 
predominantly composed of T > G mutation at the central base of 5’TpTpT3’, 5’CpTpT3’, 
5’TpTpA3’ and 5’ApTpA3’ trinucleotides sequences is the closest resemblance (Figure 
4.10), but caution must be exercised given the limited dataset generated in this study. 
Mutational signature 9 has been observed in CLL and malignant B-cell lymphoma and 
is associated with the activity of activation induced deaminase (AID) during somatic 
hypermutation (https://cancer.sanger.ac.uk/cosmic/signatures); however, no evidence 
of this mutational signature was previously reported in AML. 
 Interrogation of available targeted amplicon sequencing data from 56 diagnostic 
AML t(8;21) samples (Hartmann et al., 2016) revealed that mutation in primary t(8;21) 
AML was dominated by C > T / G > A transitions, which occurred at a substantially 
higher frequency than the other five classes of base substitution. Interestingly, it was 
found that mutation at C bases of 5′CpG3′ dinucleotide sequences dominated the 
primary t(8;21) AML mutational pattern. CpG dinucleotides are susceptible to 
spontaneous mutation via spontaneous deamination of 5-methylcytosine to thymine, 
giving rise to a T:G mispair (Holliday and Grigg, 1993; Wiebauer et al., 1993). T:G 
mismatches are normally corrected by specific DNA glycosylase during base excision 
repair (BER) pathway; however, misrepair often occurred as this DNA lesion is difficult 
to be recognised which can result in the generation of C:G > T:A transition mutations 
at the next round of DNA replication (Kow, 2002). The CpG dinucleotides are 
recognised as a mutation hotspot for some cancer types, especially colorectal cancer 
where there is a predominance of C > T transitions (Sjöblom et al., 2006). The 
observation of most C > T transition mutation at CpG sequences in a number of genes, 
including ZBTB7A, DNMT3A, SMC1A, PTPN11, IDH2, ASXL1, TET2, FAT1, WT1 and  
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Figure 4.10. Comparison of the HPRT mutational signature derived from 
RUNX1/ETO-positive cells in vitro and Signature 9. 
Mutation at central base position is defined by the substitution class and sequence 
context immediately 5’ and 3’ to the mutated base. 
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RAD21, in t(8;21) primary AML, suggesting deamination of 5-methylcytosine as a likely 
source of mutagenesis in this AML sybtype. 
 Collectively, the mutational pattern observed in t(8;21) primary AML was largely 
resembles mutational signature 1 (Figure 4.11) 
(https://cancer.sanger.ac.uk/cosmic/signatures). This mutational signature has been 
found in all cancer types and is associated with endogenous mutational process 
initiated by spontaneous deamination of 5-methylcytosine. Increase deamination of 
cytosine was observed in cells after exposure to DNA damaging agents such as UV, 
ionizing radiation, sodium bisulfite and intercalating agents such as echinomycin (Chen 
and Shaw, 1993; Moyer et al., 1993; Pfeifer et al., 2005; d’Ischia et al., 2011). 
Therefore, it is suggested the mechanisms that increase mutations at CpG sequence 
in primary t(8;21) AML are caused by the hypermutability of methylated CpG which is 
vulnerable to mutagenic effect of various endogenous and exogenous mutagens. 
 In general, the mutational pattern observed in t(8;21) primary AML was different 
to the mutational pattern observed in vitro in RUNX1/ETO-positive cells and there are  
three possible reasons that could be responsible for this observation. Firstly, it is 
important to note that the analysis of base substitutions from in vitro study were limited 
to mutations detected solely in HPRT cDNA sequence. The HPRT coding sequence 
contains only about 2.3% of CpG dinucleotide sequences, which may not be sufficient 
to identify a susceptibility to mutations driven by 5-methylcytosine deamination. 
Secondly, the cell model used for in vitro studies is lymphoblastic in origin and could 
be susceptible to the acquisition of mutations via RAG expression and other B-cell 
specific mutational processes. This could explain why the in vitro HPRT base 
substitution mutational pattern is consistent with mutational signature 9, more 
commonly found in lymphoid cancers, instead of other mutational signatures found in 
myeloid leukaemia. Thirdly, there is a clear selection bias on two levels driving 
mutagenesis in t(8;21) primary AML: firstly, analysis was limited to selected leukaemia 
relevant genes which may not be representative of the entire genome; secondly, the 
mutation spectrum in any human disease, including AML, is driven by functionality 
rather than local base sequence. For example, KIT, FLT3 and NRAS represent the 
most frequently mutated genes in t(8;21) AML (Goemans et al., 2005; Kohl et al., 2005; 
Wang et al., 2005; Krauth et al., 2014), and mutations in these genes have been shown 
to cooperate with RUNX1/ETO to induce AML in murine models (Schessl et al., 2005; 
Chou et al., 2011; Wang et al., 2011). As such, the mutations observed in t(8;21) 
primary AML are positively selected because they affect protein function or expression. 
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Figure 4.11. Comparison of mutational pattern between t(8;21) primary AML and 
Signature 1. 
The mutation at central base position is displayed by the substitution class and 
sequence context immediately 5’ and 3’ to the mutated base. 
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 Despite a lack of supporting evidence from t(8;21) primary AML, 
5’ApTpA3’/5’TpApT3’ sequences appeared to be a putative hotspot for RUNX1/ETO-
induced mutation in vitro. However, given the low number of characterised HPRT 
mutants, no definite conclusion can be made. Therefore, more HPRT mutants need to 
be generated to expand the current dataset and improve statistical power to discern a 
RUNX1/ETO-induced mutational signature. 
 
4.3.1. Summary of chapter 
 
 In summary, these investigations have demonstrated that: 
• RUNX1/ETO potentially increases T:A > G:C transversion at HPRT 
locus in vitro. 
• RUNX1/ETO preferentially induced mutations at central base position of 
5’ApTpA3’ / 5’TpApT3’ sequences at HPRT locus in vitro. 
• The base substitution in t(8;21) primary AML is dominated by C:G > T:A 
transition. 
• 5′CpG3′ dinucleotides sequence were susceptible to C > T transition 
possibly caused by spontaneous deamination of 5-methylcytosine. 
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Chapter 5. Development of Novel Flow Cytometric Method to detect 
Mutated Proteins in TK6 RUNX1/ETO 
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5.1. Introduction 
 
 Evidence suggests that the RUNX1/ETO fusion gene resulting from the t(8;21) 
translocation is a leukaemia initiating lesion, but which is insufficient to cause AML as 
a sole lesion and requires additional co-operating mutation to drive disease 
progression. For example, c-KIT mutations are reported in nearly half of AML patients 
with t(8;21) (Goemans et al., 2005; Kohl et al., 2005; Wang et al., 2005) identifying 
these as a key trigger for leukaemogenesis in combination with RUNX1/ETO (Wang et 
al., 2011). However, the mechanisms driving the acquisition of cooperating mutations 
remain unclear, although there is evidence that RUNX1/ETO promotes mutagenesis 
(Krejci et al., 2008; Araten et al., 2013; Forster et al., 2015). In addition, ectopic 
expression of RUNX1/ETO downregulates several DNA repair proteins (BRCA2, 
OGG1 and ATM) and induces elevated DNA damage (Alcalay et al., 2003), suggesting 
that RUNX1/ETO induces a pro-mutagenic phenotype predisposing cells to the 
acquisition of somatic mutations. Much of these data have been acquired using 
reporter gene assays, such as HPRT and TK (Forster et al., 2015). As such, it would 
be useful to investigate the effect of RUNX1/ETO on mutation frequency in genes with 
an established role in AML pathogenesis, such as FLT3 and NPM1. For the purposes 
of this experiment, the effect of RUNX1/ETO on mutagenesis was investigated at the 
NPM1 locus, based exclusively on the availability of a high quality antibody specific for 
mutated NPM1 and will not reported affinity against wild-type NPM1 protein. However, 
it is noted that NPM1 mutation is reported at very low frequency in t(8;21) AML (Thiede 
et al., 2006) and no oncogenic cooperativity have been demonstrated between these 
lesions in AML leukaemogenesis. 
 The NPM1 gene encodes for a protein involved in several cellular processes, 
including centrosome duplication, protein chaperoning, cell growth and cell 
proliferation (Box et al., 2016). Mutations in this gene are very important diagnostic and 
prognostic markers in AML, and in combination with mutations in other genes such as 
FLT3, CEBPA and DNMT3A, are prognostic in AML. In 2016, a revised World Health 
Organisation (WHO) classification of myeloid neoplasms and acute leukaemia 
changed NPM1 mutations status from a provisional entity to a distinct entity (Arber et 
al., 2016) confirming the importance of dysregulated nucleophosmin in AML 
pathogenesis. 
 Insertion/deletion in exon 12 of NPM1 is the most common mutation in AML, 
reported in approximately 35% of primary AML cases (Falini et al., 2005) and is thought 
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to be an early event in AML leukaemogenesis (Thiede et al., 2006; Cheng et al., 2010; 
Vassiliou et al., 2011). This mutation causes a frameshift in translation and alters the 
amino acid sequence at the C-terminus, resulting in a lengthening of the protein. NPM1 
is a nucleocytoplasmic shuttling protein, but which primarily resides in the nucleolus. 
Mutation causes disruption of normal nucleocytoplasmic shuttling by changing the 
nuclear localisation signal and shifting the balance towards nuclear export. 
Accumulation of NPM1 in the cytoplasm promotes tumour growth by inactivation of 
p53/ARF tumour suppressor function (Falini et al., 2009). 
 There are different types of NPM1 exon 12 insertion mutations. Type A mutation 
are characterised by a duplication and insertion of 4 DNA bases (c.860_863insTCTG), 
and are the most frequent NPM1 mutation in AML, representing 69% of NPM1 
mutations. Type B (c.862_863insCATG) and Type D (c.863_864insCCTG) mutations 
are also relatively common, representing 11% and 8% of NPM1 mutations 
respectively, while other mutations are rare, accounting for  <1% of NPM1 mutations 
(Alpermann et al., 2016; Kumar et al., 2018). NPM1 mutations are significantly more 
common in adult patients, occurring up to 60% of patients with a normal karyotype, 
and are less frequent in children, reported in approximately 25% of patients with normal 
karyotype (Rau and Brown, 2009; Betz and Hess, 2010). Although predominantly 
found in AML with normal karyotype, NPM1 mutations are also reported in AML with 
recurrent genetic abnormalities and minor chromosomal abnormalities (Haferlach et 
al., 2009). 
 Although NPM1 mutation is associated with a good response to induction 
therapy and a favourable prognosis, the favourable impact of NPM1 mutation is highly 
dependent on FLT3-ITD status (Betz and Hess, 2010). In the absence of FLT3-ITD, 
NPM1 mutations are associated with a favourable or better risk prognosis in patients 
with normal karyotype. In contrast, FLT3-ITD and DNMT3A mutations are associated 
with poor outcome regardless of NPM1 status. As such, FLT3 mutations dominate over 
NPM1 mutation in terms of prognostic impact, highlighting the need to identify co-
occurring somatic mutations in order to discern the prognostic impact of NPM1 
mutations. 
 Somatic mutation screening is currently performed using high throughput 
sequencing, typically targeted or exome sequencing. However, immunophenotyping 
using mutant-specific antibody by flow cytometry could potentially replace routine 
sequencing techniques to detect mutated cells with NPM1 mutation, which also has 
the advantage of yielding accurate quantitative information at the phenotype level in 
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newly diagnosed AML patients. Indeed, flow cytometry is now routine practice in 
clinical laboratories for several markers essential to the diagnosis, prognosis and 
monitoring of disease. For example, flow cytometry is commonly used in the clinical 
setting for the assessment of DNA ploidy, cell cycle analysis and the measurement of 
oxidative burst in granulocytes and reticulocytes (RBCs and platelets). In principle, flow 
cytometry uses fluorescently-labelled antibodies against specific proteins to identify 
and measure the target population of cells in a heterogeneous sample such as blood, 
bone marrow or lymphatic material. One of the major advantages of flow cytometry is 
the ability to detect and quantify small numbers of target cells in a vast excess of non-
target cells. For example, minimal residual disease (MRD) monitoring by flow 
cytometry is an example of immunophenotyping able to detect residual tumour cells at 
low frequency, providing data on treatment effectiveness. However, the quality of flow 
cytometry data is determined by the quality of the primary and secondary antibodies, 
and their specificity for their target. Given the availability of a high quality antibody 
raised against mutant NPM1, we sought to use this to develop a flow cytometric 
method for measuring mutagenesis at the NPM1 locus in RUNX1/ETO positive cells.  
 
5.1.1. Aims of Chapter 5 
 
 The purpose of the work described in this chapter was to design and establish 
a reliable flow cytometric method to evaluate the effect of RUNX1/ETO expression on 
mutation frequency in AML relevant genes. Specifically, the primary aim was to 
determine whether the RUNX1/ETO fusion gene predisposes cells to mutations in 
leukaemia relevant genes. 
 The experimental aims were as follows: 
• Determine specificity of NPM1 mutant-specific antibody via western 
immunoblotting for expression of mutant protein. 
• Validate the assay by flow-sorting putative NPM1 mutated cells via 
Sanger sequencing to confirm the mutation. 
• Optimise flow cytometric assay for the identification of NPM1-positive 
cells. 
• Measure the change in frequency of NPM1 mutated cells in 
RUNX1/ETO-positive cell populations cultured over an extended time 
period. 
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5.2. Results 
 
5.2.1. Assessment of NPM1 mutant antibody specificity by western 
immunoblotting 
 
 The specificity of commercially available NPM1 mutant-specific polyclonal 
antibody (#PA1-46356, Lot No.: SE2380401, ThermoFisher Scientific) raised against 
an epitope (within residues 250 – 294) in the C-terminal region of human mutant 
nucleophosmin was determined via western immunoblotting (Figure 5.1). A panel of 
AML cell lines and B lymphoblastoid cell lines (TK6, TK6 RE1 and TK6 RE8) used as 
models in this study were assessed for both NPM1 wild type (WT) and mutant protein 
status. The OCI-AML3 cell line, which harbours a confirmed Type A exon 12 NPM1 
mutation (c.860_863insTCTG; p.W288fs) (Quentmeier et al., 2005; Alpermann et al., 
2016) was used as a positive control. A band corresponding to the expected size of 
NPM1 wild type protein was observed in all cell lines, although there was heterogeneity 
in expression levels (Figure 5.1). In contrast, putative NPM1 mutant protein was 
observed exclusively in AML-3 cells (Figure 5.1). This western blot profile validates the 
specificity of NPM1 mutant-specific antibody for the detection of cells with NPM1 exon 
12 mutation. 
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Figure 5.1. NPM1 protein expression in AML and TK6 cell lines. 
Western immunoblotting was used to determine the specificity of NPM1 mutant-
specific polyclonal antibody (#PA1-46356, Lot No.: SE2380401, ThermoFisher 
Scientific) relative to an antibody raised against wild type NPM1 (#PA5-12447, Lot No.: 
SH090717BE, ThermoFisher Scientific). The AML-3 cell line was included as a positive 
control for NPM1 mutant protein. GAPDH was used as a loading control for all blots. 
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5.2.2. Optimisation of flow cytometric method for the detection of NPM1-mutated 
cells 
 
 A series of initial antibody staining conditions were tested to identify conditions 
with minimal non-specific binding of the mutant-specific antibody against NPM1-WT 
cells, whilst maximising sensitivity of detection for NPM1-mutant cells. AML-3 cells are 
approximately the same cell size and have a similar granularity as TK6 cells (Figure 
5.2), facilitating optimisation of a flow cytometric assay for the detection of NPM1-
mutant TK6 cells. Individual fluorescent intensity profiles for each antibody staining 
condition were determined for AML-3, TK6 and TK6 RE8 (Figure 5.3). There was a 
substantial increase of approximately 10-fold in fluorescence intensity for AML-3 cells 
stained with mutant-specific antibody (positive control) relative to cells stained with IgG 
isotype (negative control), while cells stained with secondary antibody only display far 
less fluorescent intensity relative to the positive control (Figure 5.3A). No clear 
discrimination was observed between cells stained with mutant-specific antibody and 
isotype control for both TK6 (Figure 5.3B) and TK6 RE8 (Figure 5.3C), in contrast to 
clear discrimination observed for AML-3 cells. This data demonstrate the specificity of 
the primary antibody to detect cells with NPM1 exon 12 mutation using flow cytometry. 
 The assay sensitivity was then assessed by mixing NPM1-mutant cells (AML-
3) with NPM1-WT cells (TK6 RE8) to give a mixed population that was 5% positive for 
NPM1-mutant cells (Figure 5.4). The frequency of positive events was measured at 
3.85% in this mixed sample (Figure 5.4B) and was approximate to the expected 
frequency of 5%. This AML-3/TK6 RE8 cell mixture showed clear discrimination 
between the two peaks, with the positive NPM1 mutant population displays 10-fold 
higher in fluorescent intensity relative to negative NPM1 mutant population. The 
median fluorescence intensity (MFI) of the NPM1 peak for the AML-3/TK6 RE8 cell 
mixture was determined and divided by the MFI of the NPM1 peak for the 
simultaneously stained WT control sample to generate the normalised NPM1 MFI 
value (Figure 5.4C). A normalised NPM1 MFI value of 6.0 and above was determined 
to correspond with NPM1-mutant positivity. This data demonstrate the sensitivity of the 
assay to detect NPM1 mutated event at low frequency. 
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Figure 5.2. Density plot for AML-3, TK6 and TK6 RE8 cells. 
 (A) AML-3, (B) TK6 and (C) TK6 transduced with RUNX1/ETO (TK6 RE8). Coloured area represent the relative cell frequency of each 
population. Cells were gated based on forward scatter (size) and side scatter (granularity) to identify the cell population (Gate 1) and 
exclude debris and cell doublets. All cell populations were captured using the same gate. 1 x 104 events were recorded per sample.
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Figure 5.3. Fluorescence intensity profiles for AML-3, TK6 and TK6 RUNX1/ETO 
cells stained with primary antibody, secondary antibody or IgG isotype. 
 (A) AML-3, (B) TK6, and (C) TK6 transduced with RUNX1/ETO (TK6 RE8). Histogram 
displays the fluorescence intensity profiles for each cell line by comparison of the 
negative unstained control cells stained with primary antibody, secondary antibody or 
IgG isotype negative control. Clear discrimination was observed between AML-3 cells 
stained with primary antibody (NMP1 mutant polyclonal antibody) and AML-3 cells 
stained with IgG isotype (internal negative or isotype control), demonstrating specificity 
of the primary antibody to detect cells with mutated NPM1 using flow cytometry. 1 x 
104 events were recorded per sample. 
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Figure 5.4. Sensitivity of detection for NPM1-mutant cells in a majority 
population of NPM1 WT cells. 
 (A) Density plot showing size and granularity of the gated population, (B) Dot plot 
showing clear separation of positive and negative cell populations, and (C) Histogram 
subtraction of TK6 RE cells (NPM1 WT) population from the TK6 RE/AML-3 (5% 
NPM1-mutant) cell population. The NPM1 mutant positive population was generated 
by mixing AML-3 cells (positive control) with TK6 RE8 cells to give a population that 
was 5% positive for NPM-1 mutant cells. Positive events were defined as those having 
normalised MFI of more than 6.0 relative to the negative population.  
 
 
154 
 
5.2.3. Validation of NPM1 mutations in flow-sorted cells by Sanger sequencing 
 
5.2.3.1. Flow-sorting of positive events for NPM1 exon 12 mutation 
 
 To confirm the NPM1 mutation status of positive events, cells were sorted and 
collected for DNA extraction. A mixed population of 5% AML-3/95% TK6 RE8 cells was 
used to determine gating parameters for selection of positive events (Figure 5.5). A 
population of positive events was gated and sorted, representing 2.83% of the total 
mixed cell population. In contrast, using the same gating parameters, only 0.07% of 
positive events were sorted from the pure TK6 RE8 cell population, broadly consistent 
with the low frequency of NPM1 exon 12 mutations expected in this population. 
 
5.2.3.2. PCR and Sanger sequencing analysis of NPM1 exon 12 mutation status 
  
 PCR of DNA extracted from flow-sorted cells was performed using primers 
targeting NPM1 exon 12 predicted to give an amplicon of 269bp (Figure 5.6). Extracted 
DNA was either amplified directly or following whole genome amplification using the 
REPLI-g Single Cell Kit. PCR products for DNA extracted from REPLI-g Single Cell Kit 
produced stronger bands when compared to those amplified using DNA extracted 
directly from QIAamp DNA micro kit that had not been whole genome amplified. 
 Sequencing of the PCR product (DNA extracted from REPLI-g Single Cell Kit) 
confirm a heterozygous 4 bases insertion (TCTG sequence) in cells flow-sorted from 
the AML-3/TK6 RE8 cells (Figure 5.7). This heterozygous insertion was also present 
in flow-sorted TK6 RE8 cells. These findings validate the assay sensitivity to identify 
NPM1 mutated events at low frequency in a cell population using commercially 
available NPM1 mutant-specific polyclonal antibody. 
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Figure 5.5. Fluorescence-activated cell sorting (FACs) of the positive NPM1 exon 12 mutation events. 
 (A) 5% AML-3/TK6 RE8 mixed sample and (B) TK6 RE8.  5% AML-3/TK6 RE8 mixed sample was used as a control to identify the 
positivity of NPM1 exon 12 mutation. Positive events in TK6 RE8 population were gated and sorted based on the positivity of AML-3 cells 
in mixed sample.
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Figure 5.6. PCR amplification of the NPM1 exon 12. 
The gel shows the PCR profile of the flow-sorted cells representing the targeted C-
terminal region of NPM1 exon 12. ‘No DNA template’ was used as negative control for 
PCR amplification. 
aDNA extracted via QIAamp DNA micro kit (Qiagen). 
bDNA extracted via REPLI-g Single Cell Kit (Qiagen). 
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Figure 5.7. Sequencing of the targeted NPM1 exon 12 region. 
Sequencing of DNA from the flow-sorted cells confirmed a heterozygous 4 bases 
duplication in the positive events from the AML-3 / TK6 RE8 mixed population and TK6 
RE8 population. The duplication of a TCTG sequence is highlighted in a red box. 
Unsorted TK6 cells were included as a negative control for NPM1 mutation. Amplified 
NPM1 exon 12 region was sequenced for each cell population; however, only the 
portion of the positive strand (reverse read) containing the mutation is shown.  
Underlying sequence in a chromatogram trace characterised by two peaks and starting 
from the base adjacent to the site of insertion is also shown.
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5.2.4. Effect of RUNX1/ETO expression on the acquisition of somatic mutations  
 
 To investigate whether RUNX1/ETO expression predisposes cells to the 
acquisition of somatic mutations in the NPM1 gene 10 independent subclones each of 
parental TK6 and RUNX1/ETO-transduced clones (TK6 RE1 and TK6 RE8) were 
generated using limiting dilution (see Chapter 2, Section 2.8.1). These subclones were 
assessed for the acquisition of NPM1 mutant cells over an extended culture to 
determine the effect of RUNX1/ETO expression on mutagenesis in exon 12 of NPM1. 
 
5.2.4.1. Expression levels of RUNX1/ETO in TK6 and TK6 RE subclones determined 
by western immunoblotting 
 
 RUNX1/ETO expression was assessed in TK6, TK6 RE1 and TK6 RE8 
subclones relative to Kasumi-1 cells via western immunoblotting (Figure 5.8). 
RUNX1/ETO protein was expressed in all RUNX1/ETO subclones, derived from TK6 
RE1 and TK6 RE8 clones. Quantification of the protein bands revealed RUNX1/ETO 
subclones with a range of expression relative to that found in Kasumi-1 cells. The 
majority of TK6 RE1 subclones demonstrated lower levels of RUNX1/ETO expression 
compared to Kasumi-1 cells, although some TK6 RE1 subclones (TK6 RE1_8, 9, 10) 
had RUNX1/ETO expression levels similar to Kasumi-1. The majority of TK6 RE8 
subclones had RUNX1/ETO expression at levels similar to Kasumi-1, although there 
were some with lower RUNX1/ETO expression. (TK6 RE8_7, 8, 9). RUNX1/ETO 
expression was not observed in TK6 parental cells, as expected (Figure 5.8). All clones 
were cultured long-term and used to determine the effect of RUNX1/ETO expression 
on the acquisition of exon 12 NPM1 mutations. 
 
5.2.4.2. Effect of RUNX1/ETO on NPM1 exon 12 mutation frequency 
 
 The TK6, TK6 RE1 and TK6 RE8 subclones were grouped into 3 groups based 
on the RUNX1/ETO expression level relative to Kasumi-1 cells: 1) No RE expression 
(0%), 2) Low RE expression (10 – 50%) and 3) High RE expression (51 – 100%) (Table 
5.1). Using a normalised NPM1 MFI value of more than 6.0 relative to the negative 
population to correspond with NPM1-mutant positivity (Section 5.2.2), MF of NPM1 
exon 12 mutation was measured in these subclones via flow cytometry for every 2 
weeks, starting at week 7 to week 22 post-cloning. A significant increase in mutation 
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frequency was observed in all clones over the course of the acquisition period (P < 
0.0001; one-way ANOVA) (Table 5.1) (Figure 5.9), although there was some 
fluctuation in mean mutation frequency in each of the groups over the time course of 
the experiment. The effect of RUNX1/ETO fusion expression on the acquisition of 
NPM1 exon 12 mutation was also evaluated by comparing the NPM1 exon 12 MF 
between subclones with RUNX1/ETO expression and subclones with no RUNX1/ETO 
expression at each timepoint. For subclones with low RUNX1/ETO expression, a 
significant increase in MF was observed only at week 22 relative to subclones with no 
RUNX1/ETO expression (P < 0.05; paired t-test), while for subclones with high 
RUNX1/ETO expression, a significant increase in MF was observed at week 11, 20 
and 22 relative to subclones with no RUNX1/ETO expression (week 11: P < 0.05; week 
20: P < 0.05; week 22: P < 0.0001; paired t-test). In addition, no significant increase in 
MF was observed in subclones with high RUNX1/ETO expression relative to subclones 
with low RUNX1/ETO expression at each timepoint except at week 20 (P < 0.05; paired 
t-test). Despite that, overall MF demonstrated subclones with RUNX1/ETO expression 
had significantly higher NPM1 exon 12 mutation frequency compared to subclones with 
no RUNX1/ETO expression (low RE vs no RE, P = 0.01; high RE vs no RE, P < 0.01; 
paired t-test) (Figure 5.10). Furthermore, subclones with high RUNX1/ETO fusion 
expression had a higher mean NPM1 exon 12 mutation frequency than subclones with 
low RUNX1/ETO fusion expression (P < 0.05; paired t-test), indicating the significant 
effect of RUNX1/ETO expression level. Taken together, these data provide evidence 
that RUNX1/ETO predisposes cells to the acquisition of somatic mutations in the NPM1 
gene, although it was not strongly evident at each timepoint.
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Figure 5.8. RUNX1/ETO protein levels in TK6 and its derivative subclones. 
Western immunoblotting was performed to assess RUNX1/ETO fusion protein expression in parental TK6 subclones and TK6 RE 
subclones. Ten subclones for each cell population were generated by cloning in soft agar and expansion in culture. Kasumi-1 cells were 
included as an RE positive control. A band of approximately 120 kDa equivalent to the expected size of RUNX1/ETO is present in 
RUNX1/ETO-transduced sub clones, with the majority of TK6 RE1 subclones having lower expression of RUNX1/ETO compared to TK6 
RE8 subclones. GAPDH was used as a loading control for all blots. 
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Time 
(Week) 
Mean MF (x10-5) Paired t-testb 
No RE 
expression 
Low RE 
expression 
High RE 
expression 
Low RE vs No RE High RE vs No RE High RE vs Low RE 
7 1.81 2.15 1.86 0.4213 0.8834 0.4111 
9 1.85 2.06 2.43 0.4669 0.2811 0.4623 
11 2.16 3.06 3.62 0.0626 0.0021 0.1939 
13 3.19 3.71 3.98 0.0718 0.0930 0.6360 
15 2.99 3.35 4.00 0.4502 0.0939 0.2482 
18 4.64 5.23 5.34 0.3949 0.1562 0.8235 
20 5.00 5.32 6.91 0.5137 0.0428 0.0149 
22 5.63 7.28 8.12 0.0174 < 0.0001 0.2167 
One-way ANOVAa < 0.0001 < 0.0001 < 0.0001    
 
Table 5.1. Effect of RUNX1/ETO expression on NPM1 mutation frequency over time. 
Data represent the mean MF from ten independent subclones for each original clone (no RE expression, low RE expression and high RE 
expression) measured every 2 weeks, starting at week 7 to week 22 post-cloning (Appendix E). These figures are displayed graphically in 
Figure 5.9. 
a Figures represent the P value determined using a one-way analysis of variance (ANOVA) test for effect of time (week) on MF. 
b Figures represent the P value determined using a paired t-test for effect of RUNX1/ETO expression on MF at each timepoint.
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Figure 5.9. Effect of RUNX1/ETO expression on NPM1 mutation frequency over 
time. 
MF of NPM1 exon 12 mutation was measured in no RE expression subclones (blue 
dots), low RE expression subclones (orange dots) and high RE expression subclones 
(red dots) every 2 weeks, starting at week 7 to week 22 post-cloning. (A) Dot plot 
represents data for each subclone. (B) Mean and standard deviation (error bars) for all 
subclones from each original clone at each timepoint. Data is a representative of 10 
subclones for each original clone. 
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Figure 5.10. Effect of RUNX1/ETO expression on NPM1 mutation frequency. 
Overall mean MF of NPM1 exon 12 mutation was measured in no RE expression 
subclones (blue bar), low RE expression subclones (orange bar) and high RE 
expression subclones (red bar) for a total of 22 weeks. P-value was calculated by 
paired t-test comparing the overall MF between groups. P < 0.01 (**), P < 0.05 (*).
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5.3. Discussion 
 
 The effect of RUNX1/ETO in the acquisition of somatic mutations in AML genes 
is poorly documented although numerous studies have identified the co-occurrence of 
mutations with the RUNX1/ETO fusion gene in patients with t(8;21)-positive AML 
(Hartmann et al., 2016; Patel et al., 2017). c-Kit mutation is the most common recurrent 
mutation found in t(8;21) AML, reported in nearly half of cases (Goemans et al., 2005; 
Kohl et al., 2005; Wang et al., 2005) and has been described to cooperate with 
RUNX1/ETO in models of AML (Wang et al., 2011; Wichmann et al., 2015). has been 
identified as a cooperating mutation in this disease (Wang et al., 2011). Other recurrent 
mutations in t(8;21) AML include NRAS, FLT3, ASXL2 and ZBTB7A (Reikvam et al., 
2011; Hartmann et al., 2016). In addition, other mutations were also found in t(8;21) 
AML such as DNMT3A, JAK2 and CBL at low frequency (Hartmann et al., 2016) of 
which can be classified as secondary “passenger” mutations as a result of continuous 
somatic mutation acquisition. Although many of these secondary mutations seem to 
have no importance in RUNX1/ETO AML leukaemogenesis, a contribution to disease 
progression cannot be excluded. In this study, we have evaluated the effect of 
RUNX1/ETO expression on NPM1 exon 12 mutation frequency in RUNX1/ETO 
negative cells and two RUNX1/ETO positive cell populations with different levels of 
RUNX1/ETO expression. 
 A cell line harbouring a confirmed type A exon 12 NPM1 mutation was used in 
conjunction with a commercially available NPM1 mutant specific polyclonal antibody to 
develop a flow cytometric method for the detection of NPM1 mutation. Detection of 
NPM1 mutant cells in a mixed population of primarily NPM1 WT cells requires a very 
sensitive technique. As such, flow cytometry was selected as the method of choice 
based on the ability to screen large numbers of cells quickly and efficiently at the single 
cell level. In contrast, western immunoblotting, for example, is not sensitive enough to 
detect mutation at the single cell level. However, western immunoblotting was essential 
to conform the suitability of this antibody for detection of NPM1 mutated event in flow 
cytometry. During development of the flow cytometric method it was essential to 
investigate non-specific binding and the frequency of false-positive events. Assay 
development included analysis of unstained cell, cells stained with conjugated 
secondary antibody only, cells stained with isotype control and cells stained with 
mutant antibody; controls which are standard practice in evaluating the specificity of 
antibody for flow cytometry. The positive cell population was observed to have a higher 
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fluorescent intensity than cells stained with the IgG isotype control and cells stained 
with conjugated secondary antibody alone, as demonstrated by clear separation 
between the three peaks from the histogram data of AML-3 cells (Figure 5.3A). In 
contrast, due to the low frequency of NPM1 mutation in TK6 cells, the frequency of 
positive events was very low and there was no clear separation in term of fluorescent 
intensity, with most of the cells staining negative and consistent with the IgG control 
(Figure 5.3B and 5.3C). A mixed population of 5% AML-3/95% TK6 cells was used to 
validate the method. This was aided by the fact that AML-3 and TK6 cells have similar 
characteristics (size and granularities), which allowed for a direct comparison based 
solely on fluorescence intensity. The frequency of positive events in the mixed cell 
population was estimated to be 3.85% with positivity defined as MFI of 6.0 and above 
relative to the putative negative population. Sanger sequencing was subsequently 
used to confirm that the population of cells deemed positive were in fact almost 
exclusively positive for NPM1 exon 12 mutation (a heterozygous TCTG insertion), as 
evidenced by a virtually identical profile of sorted positive cells and AML-3 positive 
control cells. These data confirmed the sensitivity of the flow cytometry assay for the 
detection of NPM1 exon 12 mutated cells in a mixed population. 
 TK6 and RUNX1/ETO transduced subclones with a range of RUNX1/ETO 
expression (TK6 RE1 and TK6 RE8) were used as a model to investigate the effect of 
RUNX1/ETO expression on NPM1 exon 12 mutation frequency. Unlike a reporter gene 
assay which takes advantage of a selective agent to reduce the level of spontaneous 
TK and HPRT mutants, there is no mechanism to purge a population of pre-existing 
cells with NPM1 mutation. Alternatively, single cell cloning can be used to ensure that 
a cell population was WT at a given point in time; specifically, when seeded using 
limiting dilution. Therefore, 10 subclones for each TK6 cell population (parental TK6, 
TK6 RE1 and TK6 RE8) were generated and used to monitor the acquisition of NPM1 
mutation over time. Ten independent replicates for each TK6 population was deemed 
sufficient to support statistical analysis. It is noteworthy that all TK6 subclones, 
irrespective of the population from which they were derived, predominantly stained 
negative by flow cytometry, indicating that the initial cell of each clone must have 
therefore been NPM1 WT. However, the acquisition of spontaneous mutations was 
observed in all TK6 subclones as demonstrated by the significant increase at every 
time point within the acquisition period regardless of RUNX1/ETO expression status 
(Table 5.1), suggesting that cells acquired mutations over the time as a result of 
continuous cell division. Furthermore, overall analysis revealed that the frequency of 
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NPM1 mutation was significantly higher in RUNX1/ETO-positive subclones compared 
to RUNX1/ETO-negative subclones (Figure 5.10). The level of RUNX1/ETO 
expression was also observed to influence the induced mutation frequency. TK6 
subclones displaying high levels of RUNX1/ETO expression had a significant higher 
NPM1 mutation frequency compared to TK6 subclones that have lower RUNX1/ETO 
expression (Figure 5.10), although it was not statistically significant at most of the 
timepoint (Table 5.1). Nevertheless, these data provide evidence that RUNX1/ETO 
predisposes cells to the acquisition of somatic mutations in the NPM1 gene, although 
it was not strongly evident at each timepoint. 
 Despite the significant effect of RUNX1/ETO expression on the acquisition of 
somatic mutation in NPM1 exon 12, NPM1 mutations are commonly found in patients 
with normal karyotype (Rau and Brown, 2009), although a very low frequency of NPM1 
mutation was reported in t(8;21) AML (Thiede et al., 2006). Regardless of rare reports 
of NPM1 and RUNX1/ETO concurrence, these mutations are generally considered to 
be mutually exclusive. Furthermore, RUNX1/ETO and NPM1 mutations are classified 
as distinct entities by the WHO classification of myeloid neoplasms and acute 
leukaemia (Arber et al., 2016). Like RUNX1/ETO, NPM1 mutation alone is insufficient 
for leukaemogenesis and requires cooperating events to drive transformation (Grisendi 
et al., 2005; Sportoletti et al., 2008; Cheng et al., 2010; Sportoletti et al., 2013). It has 
been suggested that mutations in receptor tyrosine kinase genes such as c-Kit, FLT3 
and RAS involved in signal transduction pathways, are required for leukaemia 
development in RUNX1/ETO AML (Jiao et al., 2009). In contrast, NPM1 mutations are 
often reported with mutation in genes involved in the regulation of DNA methylation 
(DNMT3A, TET2, IDH1, IDH2), RNA splicing (SRSF2, SF3B1), the cohesin complex 
(RAD21, SMC1A, SMC3, STAG2) and cell signalling pathways (FLT3, NRAS, and 
PTPN11) (Patel et al., 2017). Both mutations have been well characterised as initiating 
mutation in AML (Cheng et al., 2010; Vassiliou et al., 2011; Wang et al., 2011; 
Wichmann et al., 2015) although there are some reports suggesting that NPM1 
mutation can occur late and might be the final transforming event AML pathogenesis, 
and particularly secondary AML (Schnittger et al., 2014; Patel et al., 2017). 
 The data from this study suggests that RUNX1/ETO promotes mutagenesis by 
predisposing cells to the acquisition of somatic mutations in the NPM1 gene. Although 
NPM1 mutations are rarely found to co-exist with the RUNX1/ETO fusion oncoprotein, 
these data provide proof of principle that RUNX1/ETO drives mutagenesis at loci 
relevant in the pathogenesis of AML. Previous studies have shown that RUNX1/ETO 
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alone is sufficient to increase genomic instability by downregulating DNA-repair 
proteins (Alcalay et al., 2003; Krejci et al., 2008; Forster et al., 2015) (see Chapter 1, 
Section 1.3.3). This will lead to the increase of mutation frequency in gene such as 
NPM1 as a result of mutagenic effect of RUNX1/ETO. 
 
5.3.1. Summary of chapter 
 
 In summary, these investigations have demonstrated that: 
• Flow cytometry is sufficiently sensitive to identify and measure NPM1-
mutated cells at low very frequency in a predominantly wild-type cell 
population. 
• NPM1 exon 12 mutation frequency is significantly increased over time, 
suggesting continuous spontaneous somatic mutation acquisition. 
• Mutation frequency is positively associated with RUNX1/ETO 
expression level. 
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Chapter 6. High Throughput Exome Sequencing to Investigate the 
Clonal Evolution of Relapsed AML 
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6.1. Introduction 
 
 Cytogenetic analysis has been used for more than three decades to define the 
molecular pathogenesis of AML, and remains as the first tier screening for AML 
classification. Recurrent chromosomal structural variations such as t(8;21), inv(16), 
t(15;17), del(5) and del(7) are established diagnostic and prognostic markers 
suggesting that acquired genomic abnormalities play an essential role in 
leukaemogenesis (Betz and Hess, 2010). However, nearly half of AML cases have a 
normal karyotype lacking recurrent structural abnormalities. 
 Somatic point mutations affecting numerous genes have been described in AML 
at presentation, many of which are pathogenic and prognostic, including RUNX1 (Tang 
et al., 2009), NPM1 (Becker et al., 2010), NRAS/KRAS (Janssen et al., 1987) and 
CEBPA (Green et al., 2010). High throughput sequencing technology has intensified 
the search for somatic mutations in AML, leading to the discovery of novel mutations 
in established pathways, such as RAS (Tyner et al., 2009), and identified new 
pathways through whole genome-based approaches (Ley et al., 2008). This approach 
has also been applied to the study of relapsed leukaemia, successfully identifying 
relapse-specific coding sequence mutations affecting ETV6 and MYO18B (Ding et al., 
2012). 
 The accumulation of somatic mutations in cancer cells as a result of continuous 
acquisition of mutations during progression of the disease suggests cancer is an 
evolutionary process. Most mutations at disease presentation in AML are thought to 
be acquired after initiating genetic lesions such as t(8;21) and t(15;17), although a 
small number of pre-existing mutations was already present before cells acquire these 
advantageous initiating mutations. There is some evidences that initiating events 
promote mutagenesis predisposing cells to the acquisition of additional somatic 
mutations (Alcalay et al., 2003; Krejci et al., 2008; Araten et al., 2013; Forster et al., 
2015) which may contribute to genomic instability in a cancer genome. Genomic 
instability can increase the mutation rate in the cancer genome through many different 
mechanisms which play an important role in cancer evolution. 
 Chemotherapy using cytotoxic agents during remission induction treatment may 
eradicate cancer cells with dominant clones, however most of AML patients experience 
disease relapse which is difficult to treat. The mechanisms driving relapse evolution 
remain unclear although there is evidence that relapse is driven by novel mutations 
acquired after the chemotherapy. High throughput sequencing of matched 
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presentation and relapse AML samples have revealed two major patterns of AML 
relapse evolution (Ding et al., 2012; Welch et al., 2012; Garg et al., 2015; Sood et al., 
2015). Firstly, a leukaemic clone at disease presentation acquires additional mutations 
and evolves into the relapse clone after the chemotherapy and secondly, the pre-
leukaemic clone from the founding clone acquires additional mutations and evolves 
into a relapse clone. Importantly, both patterns of relapse are defined by the acquisition 
of additional somatic mutations. 
 Therefore, it is thought that there are two major underlying mechanisms driving 
mutagenesis in relapsing AML. Firstly, the genomic instability of the leukaemic clone 
is a major cause of mutagenesis and contributes to genetic heterogeneity in AML. 
Secondly, chemotherapy agents used in induction chemotherapy contribute to 
relapsed AML since most chemotherapy agents are genotoxic which may lead 
mutation. Collectively, both mechanisms are predicted to be responsible for the 
aetiology of relapse-driver mutations. 
 In this study, whole exome sequencing of matched presentation and relapse 
AML samples was performed to map changes in mutational landscape between 
presentation and relapse AML in order to determine the clonal origins of relapsed AML 
and clonal evolution during treatment of AML in order to better understanding disease 
evolution and heterogeneity in AML. 
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6.1.1. Aims of Chapter 6 
 
 The objective of the work described in this chapter was to compare genetic 
variants at initial AML diagnosis to those present at relapse in a cohort of Malaysian 
AML cases in order to identify novel mutations at relapse (relapse-specific mutations) 
and to identify low-frequency mutations at presentation that are selected for by 
chemotherapy important in the clonal evolution of relapsed AML. 
 Specifically, the experimental aims were as follows: 
• Identify a cohort of matched presentation and relapse AML cases for 
whole exome sequencing. 
• Identify somatic variants at presentation and relapse through several 
analysis filters using Ingenuity Variant Analysis™ software (Qiagen 
Bioinformatics) in order to select variants with putative functional impact 
on disease. 
• Interrogate filtered variants for their frequencies and deleterious effect in 
reported and published AML cases using the Catalogue of Somatic 
Mutations in Cancer (COSMIC) database. 
• Compare somatic variants detected at presentation and relapse using 
variant allele fraction (VAF) score to map the clonal evolution of relapsed 
AML in each patient. 
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6.2. Results 
 
6.2.1. Patients and clinical data 
 
 A cohort of 11 matched presentation and relapsed AML cases with different 
cytogenetics and molecular profiles were selected from diagnostic samples referred to 
National Referral Centre for Bone Marrow Cytogenetics and Molecular Genetics, 
Institute for Medical Research, Kuala Lumpur, Malaysia (Table 6.1). All samples have 
insufficient metaphase spread for conclusive karyotyping (fewer than 20 cells and 
some samples were not sent for cytogenetics) except 1 relapse sample (patient 10). 
Multiplex RT-PCR using HemaVision®-28N kit (DNA Diagnostic, Risskov, Denmark) 
was performed for all samples to screen for 28 leukaemia causing translocations 
including common translocations in AML such as t(8;21)(q22;q22), t(15;17)(q24;q21) 
and inv(16)(p13;q22). This qualitative test uses reverse transcription of RNA to cDNA 
followed by multiplex nested polymerase chain reaction and agarose gel 
electrophoresis to identify chromosomes, genes and exons at the breakpoint in fusion 
genes. In addition, some samples were further screened for AML prognostic markers 
including gene mutations in NPM1, KIT and FLT3 via targeted PCR using specific 
primers targeted to regions of interest. 
 
6.2.2. Identification of somatic variants 
 
 Paired-end whole exome sequencing was performed for each sample to identify 
somatic variants. By enriching for exonic sequence, high quality whole exome 
sequencing reads with average coverage of 93.8% of exome (range: 77.3 – 96.5%) 
and average sequencing depth/read depth of 151X (range: 15 – 434X) was achieved. 
 Somatic variants including nonsynonymous single nucleotide variant (SNV, 
both missense and nonsense) and small insertion/deletion (indel, both in-frame and 
frameshift), as well as splice site variants were identified (Table 6.2) following several 
layers of filters using Ingenuity Variant Analysis software (Chapter 2.9.4) and after 
exclusion of variants with benign and uncertain significance. Two mutations at 
presentation, NPM1 p.W288fs (Patient 1), FLT3-ITD (Patient 1) and one mutation at 
relapse, NPM1 p.W288fs (Patient 9) detected from initial RT-PCR screening were not 
detected by exome sequencing. In total, 40 and 48 variants were identified in
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Patient Status Date at Referral 
Age at Referral 
(Years) 
Blast % Cytogenetics 
Molecular Diagnostic 
(28 translocations) 
AML Prognostic Marker 
1 
P 15/05/2014 26 55 46, XX [4] Negative FLT3-ITD positive, NPM1 (MutA) 
R 28/10/2014  30 ND Negative FLT3-ITD negative, NPM1 (MutA) 
2 
P 25/01/2014 10 > 80 ND t(9;11)(p22;q23) ND 
R 05/03/2014  > 80 ND t(9;11)(p22;q23) ND 
3 
P 30/05/2012 10 ND ND t(15;17)(q24;q21) ND 
R 23/04/2013  > 90 ND t(15;17)(q24;q21) ND 
4 
P 18/04/2013 17 > 80 46, XX [11] Negative ND 
R 21/12/2015  60 ND Negative FLT3-ITD negative, NPM1 negative 
5 
P 02/10/2015 43 91 ND Negative FLT3-ITD negative, NPM1 negative 
R 13/06/2016  94 ND Negative FLT3-ITD negative, NPM1 negative 
6 
P 20/01/2015 35 78 ND t(8;21)(q22;q22) FLT3-ITD negative, cKIT negative 
R 20/05/2016  54 ND t(8;21)(q22;q22) FLT3-ITD negative, cKIT negative 
7 
P 15/05/2014 36 > 70 ND t(8;21)(q22;q22) FLT3-ITD negative, cKIT negative 
R 01/12/2015  18 46, XY [4] t(8;21)(q22;q22) FLT3-ITD negative, cKIT negative 
8 
P 16/06/2014 40 11 ND Negative FLT3-ITD negative, NPM1 negative 
R 04/08/2015  70 ND inv(16)(p13;q22) FLT3-ITD negative, NPM1 negative 
9 
P 20/06/2014 51 54 ND Negative FLT3-ITD negative, NPM1 (MutA) 
R 18/12/2015  20 ND Negative FLT3-ITD negative, NPM1 (MutA) 
10 
P 22/01/2016 27 21 46, XY [5] inv(16)(p13;q22) ND 
R 07/02/2017  60 46, XY, inv(16)(p13;q22) [22] inv(16)(p13;q22) FLT3-ITD negative, cKIT negative 
11 
P 21/01/2016 33 61 46, XX [2] Negative FLT3-ITD negative, NPM1 negative 
R 17/03/2017  91 46, XX [2] Negative ND 
 
Table 6.1. Selected features of matched presentation and relapsed AML patients included in this study. 
P – Initial disease presentation, R – relapse disease 
ND – not determined 
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Patient Gene Reference Allele 
Variant 
Allele 
Variation Type 
Gene 
Region 
AA Change 
 
Presentation 
 
Relapse 
Frequency in 
AML as 
reported in 
COSMIC (%) 
Read 
Depth 
VAF 
(%) 
Read 
Depth 
VAF 
(%) 
1 PTPRQ GGGT  deletion exonic c.6452_6453+2delGGGT - - 103 17.5 0.0 (0/0) 
1 SELE C T SNV 
splice 
site 
c.902-1G>A 113 55.8 111 55.9 0.0 (0/0) 
3 LIFR C A SNV 
splice 
site 
c.992-1G>T - - 68 16.2 0.0 (0/0) 
3 PTPRQ GGGT  deletion exonic c.6452_6453+2delGGGT; 111 19.8 - - 0.0 (0/0) 
3 VPS13B C  
frameshift 
deletion 
exonic 
c.5334delC; 
p.R1779fs*2 
252 48.0 222 57.2 0.0 (0/5) 
4 ADAM9  TTTT 
frameshift 
insertion 
exonic 
c.1883_1884insTTTT; 
p.C629fs*3 
43 18.6 - - 0.0 (0/0) 
4 APOB G A 
nonsynonymous 
SNV 
exonic 
c.10579C>T; 
p.R3527W 
278 45.0 247 40.9 0.0 (0/11) 
4 DNAH5 T  deletion 
splice 
site 
c.2578-2delA - - 17 17.7 0.0 (0/8) 
4 NRAS C T 
nonsynonymous 
SNV 
exonic 
c.35G>A; 
p.G12D 
390 14.4 434 33.4 
29.13 
(328/1126) 
5 CEBPA  CTG 
in-frame 
insertion 
exonic 
c.934_936dupCAG; 
p.Q312dup 
283 87.6 268 47.0 
2.08 
(28/1346) 
5 CFTR G A 
nonsynonymous 
SNV 
exonic 
c.1865G>A; 
p.G622D 
103 50.5 94 56.4 0.0 (0/2) 
5 MUTYH C A stop gain SNV exonic 
c.1435G>T; 
p.E479* 
152 47.4 126 48.4 0.0 (0/0) 
 
Table 6.2. Somatic variants identified from whole exome sequencing (continued on next page). 
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Patient Gene Reference Allele 
Variant 
Allele 
Variation Type 
Gene 
Region 
AA Change 
 
Presentation 
 
Relapse 
Frequency in 
AML as 
reported in 
COSMIC (%) 
Read 
Depth 
VAF 
(%) 
Read 
Depth 
VAF 
(%) 
6 ASXL1  G 
frameshift 
insertion 
exonic 
c.1934dupG; 
p.G646fs*12 
- - 126 40.5 
25.56 
(171/669) 
6 CACNA2D4 G T stop gain SNV exonic 
c.2637C>A; 
p.C879* 
86 37.2 54 63.0 0.0 (0/1) 
6 IL12RB1 G A stop gain SNV exonic 
c.1681C>T; 
p.R561* 
111 47.8 71 94.4 0.0 (0/0) 
6 NFIX  T 
frameshift 
insertion 
exonic 
c.1168_1169insT; 
p.P390fs*41 
139 20.1 - - 0.0 (0/11) 
6 RASA2 TG  
frameshift 
deletion 
exonic 
c.2202_2203delTG; 
p.G735* 
170 38.2 128 40.6 0.0 (0/0) 
6 TET2  AGAGG 
frameshift 
insertion 
exonic 
c.1016_1017insGAGGA; 
p.N339fs*10 
246 65.5 184 88.6 0.0 (0/921) 
6 TP53 ACCACTACTC  deletion exonic 
c.783-
6_786delGAGTAGTGGT 
- - 35 80.0 0.0 (0/379) 
6 VPS13B  
TTTTTT
T 
insertion exonic 
c.9406-
1_9406insTTTTTTTTTT 
15 33.3 - - 0.0 (0/5) 
7 CCDC8 CTCT  
frameshift 
deletion 
exonic 
c.1283_1286delAGAG 
p.Q428fs*50 
122 43.4 129 36.4 0.0 (0/0) 
7 CFTR G A 
nonsynonymous 
SNV 
exonic 
c.1865G>A; 
p.G622D 
86 45.4 64 48.4 0.0 (0/2) 
7 FKTN G A SNV 
splice 
site 
c.910+1G>A 132 54.6 114 47.4 0.0 (0/3) 
7 PKP2 C A SNV 
splice 
site 
c.2300-1G>T - - 39 15.4 0.0 (0/0) 
7 USH1C A T start loss SNV exonic 
c.25T>A; 
p.M1K 
92 55.4 95 47.4 0.0 (0/1) 
 
Table 6.2. Somatic variants identified from whole exome sequencing (continued from previous page). 
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Patient Gene Reference Allele 
Variant 
Allele 
Variation Type 
Gene 
Region 
AA Change 
 
Presentation 
 
Relapse 
Frequency in 
AML as 
reported in 
COSMIC (%) 
Read 
Depth 
VAF 
(%) 
Read 
Depth 
VAF 
(%) 
8 ESRRB C T 
nonsynonymous 
SNV 
exonic 
c.1144C>T; 
p.R382C 
202 49.5 236 48.7 0.0 (0/0) 
8 FLT3 G A 
nonsynonymous 
SNV 
exonic 
c.1577C>T; 
p.T526M 
419 48.5 385 48.8 0.0 (0/16119) 
8 HBB AAAG  
frameshift 
deletion 
exonic 
c.126_129delCTTT; 
p.F42fs*19 
241 50.2 263 39.5 0.0 (0/0) 
8 LFNG  GATG 
frameshift 
insertion 
exonic 
c.163_166dupGATG; 
p.E56fs*2 
104 50.0 116 35.3 0.0 (0/1) 
8 MAP3K20 A T SNV 
splice 
site 
c.416-2A>T - - 66 15.2 0.0 (0/0) 
8 MAP3K20 G T SNV 
splice 
site 
c.416-1G>T - - 66 15.2 0.0 (0/0) 
9 ESRRB C T 
nonsynonymous 
SNV 
exonic 
c.1144C>T; 
p.R382C 
218 48.6 216 50.5 0.0 (0/0) 
9 EYS C A stop gain SNV exonic 
c.8170G>T; 
p.E2724* 
155 57.4 153 54.3 0.0 (0/0) 
9 GUCY2D C T 
nonsynonymous 
SNV 
exonic 
c.164C>T; 
p.T55M 
75 66.7 64 53.1 0.0 (0/0) 
9 IDH2 C T 
nonsynonymous 
SNV 
exonic 
c.419G>A; 
p.R140Q 
124 38.7 115 26.1 
42.89 
(636/1483) 
9 NPM1  TCTG 
frameshift 
insertion 
exonic 
c.860_863dupTCTG; 
p.W288fs 
- - 17 41.2 
36.28 
(2252/6207) 
9 SLC12A1 C A stop gain SNV exonic 
c.1584C>A; 
p.Y528* 
204 55.4 146 38.4 0.0 (0/2) 
9 WRN AGGG  deletion 
splice 
site 
c.840-2_841delAGGG; - - 31 19.4 0.0 (0/0) 
9 WRN  TTTT 
frameshift 
insertion 
exonic 
c.844_845insTTTT; 
p.S282fs*24 
- - 31 19.4 0.0 (0/0) 
 
Table 6.2. Somatic variants identified from whole exome sequencing (continued from previous page). 
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Patient Gene Reference Allele 
Variant 
Allele 
Variation Type 
Gene 
Region 
AA Change 
 
Presentation 
 
Relapse 
Frequency in 
AML as 
reported in 
COSMIC (%) 
Read 
Depth 
VAF 
(%) 
Read 
Depth 
VAF 
(%) 
10 AIMP1 C T stop gain SNV exonic 
c.115C>T; 
p.Q63* 
58 60.3 42 47.6 0.0 (0/0) 
10 KIT ACG  
in-frame 
deletion 
exonic 
c.1255_1257delGAC; 
p.D419del 
- - 113 37.2 4.58 (35/764) 
10 TTN C A SNV 
splice 
site 
c.32554+1G>T 127 40.9 120 50.8 0.0 (0/0) 
11 ATM G T 
nonsynonymous 
SNV 
splice 
site 
c.497-1G>T - - 18 33.3 0.0 (0/102) 
11 ATRX G A stop gain SNV exonic 
c.7219C>T 
p.R2407* 
- - 120 44.2 14.29 (2/14) 
11 CEBPA  
TTGGC
CTT 
frameshift 
insertion 
exonic 
c.929_930insAAGGCCAA 
p.Q346fs*10 
303 42.9 349 49.6 0.0 (0/1346) 
11 CEBPA CTCCA  
frameshift 
deletion 
exonic 
c.923_927delTGGAG; 
p.V343fs*11 
329 43.5 350 47.4 0.0 (0/1346) 
11 MPST C A stop gain SNV exonic 
c.52G>T; 
p.E18* 
184 51.1 193 49.7 0.0 (0/0) 
11 RYR2 C T 
nonsynonymous 
SNV 
exonic 
c.13739C>T; 
p.T4580M 
- - 29 51.7 0.0 (0/5) 
11 TBXAS1 C T stop gain SNV exonic 
c.997C>T; 
p.R333* 
148 41.2 150 52.0 0.0 (0/2) 
11 VWF G A 
nonsynonymous 
SNV 
exonic 
c.4195C>T; 
p.R1399C 
161 40.4 154 37.7 0.0 (0/1) 
 
Table 6.2. Somatic variants identified from whole exome sequencing (continued from previous page). 
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presentation and relapse samples respectively (Table 6.3) with an average of 3.6 
variants per patient at presentation (range 0 – 9) and 4.4 variants per patient at relapse 
(range 0 – 8). In terms of type of variant, SNVs were more common than indels at both 
presentation and relapse with 18 indels and 22 SNVs identified at presentation and 19 
indels and 29 SNVs identified at relapse. 
 A total of 34 shared variants occurred at both presentation and relapse (Figure 
6.1). Moreover, 4 variants were presentation-specific, and 14 variants were relapse-
specific. Additional somatic variants were acquired in six relapse samples (Patient 1, 
7, 8, 9, 10 and 11) which gained between 1 and 3 new variants when compared to their 
corresponding presentation samples. Four patients had the same number of variants 
at both presentation and relapse samples (Patient 3, 4, 5 and 6), of which 3 patients 
(Patient 3, 4 and 6) acquired and lost equivalent numbers of variants. 
 
6.2.3. Evaluation of somatic variants at presentation and relapse 
 
 The filtered somatic variants were further evaluated to define the oncogenic 
effect of the variants in determining their potential importance as AML driver mutations 
via interrogation of the COSMIC database. The mutated genes were ranked according 
to frequency of genes implicated in AML as reported in the COSMIC database (Figure 
6.2) regardless of type and position of the variants in genes, as either classical types 
of variants, or previously reported and/or recurrent hotspots variants, or novel variants. 
 Somatic variants in recurrently mutated genes in AML (NPM1, FLT3, NRAS, 
TET2, ATM, CEBPA, IDH2, TP53, ASXL1 and KIT) were identified in 8 patients 
(Patient 1, 4, 5, 6, 8, 9, 10 and 11) with four of these variants newly acquired at relapse. 
Six of these variants are classic AML driver and recurrent hotspot mutations whereas 
variants such as TET2 p.N339fs*10 (Patient 6), TP53 c.783-6_786del (Patient 6), FLT3 
p.T526M (Patient 8), ATM c.497-1G>T (Patient 11), CEBPA p.Q346fs*10 (Patient 11) 
and CEBPA p.V343fs*11 (Patient 11) were not previously reported in AML (Table 6.2). 
In addition to somatic variants in recurrently mutated genes, there were 14 mutated 
genes that have been previously reported in a small number of AML cases in COSMIC 
(less than 2%) and an additional 18 mutations in genes not previously reported in AML 
(Figure 6.2). 
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Patient 
Presentation Relapse 
Indel SNV 
Total no. of 
variants 
Indel SNV 
Total no. of 
variants 
1 2 1 3 3 1 4 
2 0 0 0 0 0 0 
3 2 0 2 1 1 2 
4 1 2 3 1 2 3 
5 1 2 3 1 2 3 
6 4 2 6 4 2 6 
7 1 3 4 1 4 5 
8 2 2 4 2 4 6 
9 3 5 8 3 5 8 
10 0 2 2 1 2 3 
11 2 3 5 2 6 8 
Total no. of variants 18 22 40 19 29 48 
 
Table 6.3. Number of somatic variants at presentation and relapse. 
 
 
 
 
Figure 6.1. Total number of somatic variants specific to presentation or relapse 
and somatic variants shared at both disease stages. 
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Figure 6.2. Mutational spectrum of somatic variants at presentation and relapse 
characterised according to frequency in AML as reported in COSMIC. 
The mutated genes identified in each patient were ranked according to frequency of 
genes implicated in AML as reported in the COSMIC database. 
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 To further analyse identified mutations, the mutated genes were clustered into 
four groups based on their putative effect that may relevant for leukaemic 
transformation according to existing model of leukaemogenesis (Kelly and Gilliland, 
2002; Conway O'Brien et al., 2014): (1) mutations affecting genes that contribute to 
cell proliferation (class I mutations); (2) mutations affecting genes involved in myeloid 
differentiation (class II mutations); (3) mutations affecting genes involved in epigenetic 
modification and (4) mutations affecting genes that have as yet unknown function in 
leukaemogenesis (Figure 6.3). All patients have mutations in at least one gene that 
either affect cell proliferation, are involved in myeloid differentiation or involved in 
epigenetic modification at presentation, with 4 patients (Patient 1, 5, 6 and 9) having 
both class I and II mutations at presentation. At relapse, acquisition of both classes of 
mutations was observed in 3 patients (3, 10 and 11) that lack complementary class of 
mutation at presentation. In contrast, the remaining 28 mutated genes identified in this 
cohort have yet unknown functions in leukaemogenesis. 
 
6.2.4. Correlation of presentation VAF and relapse 
 
 VAF was used to track each somatic variant from presentation to relapse to map 
clones that persisted, those that resolved from presentation to relapse as well as novel 
mutations that emerged at relapse in order to delineate the clonal architecture of 
leukaemic cells and to identify driver mutations that promote clonal expansion in 
relapse AML (Figure 6.4). However, caution must be exercised given that the VAF will 
vary according to the blast count, therefore minor differences in VAF between 
diagnosis and relapse samples cannot be considered as significant. 
 NRAS p.G12D (Patient 4), CEBPA p.Q312dup (Patient 5), TET2 p.N339fs*10 
(Patient 6), FLT3 p.T526M (Patient 8), IDH2 p.R140Q (Patient 9), CEBPA p.Q346fs*10 
(Patient 11) and CEBPA p.V343fs*11 (Patient 11) were among mutations in known 
AML driver genes that were retained after chemotherapy with VAF of 14.4%, 87.6%, 
65.5%, 48.5%, 38.7%, 42.9% and 43.5%, respectively, in the presentation samples 
and 33.4%, 47.0%, 88.6%, 48.8%, 26.1%, 49.6% and 47.4% in the relapse samples. 
On the other hand, ASXL1 p.G646fs*12 (Patient 6), TP53 (Patient 6), KIT p.D419del 
(Patient 10) and ATM c.497-1G>T (Patient 11) were mutations in known AML driver 
genes acquired at relapse with VAF of 40.5%, 80.0%, 37.2% and 33.3% respectively. 
VAF score for two mutations at both presentation and relapse in Patient 1 (NPM1 
p.W288fs and FLT3-ITD) and one mutation at presentation in Patient 9 (NPM1  
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Figure 6.3. Relationship between somatic variants at presentation and relapse 
samples based on their known or predicted role in leukaemogenesis (Kelly and 
Gilliland, 2002; Conway O'Brien et al., 2014). 
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Figure 6.4. Variant allele fraction (VAF) score for each somatic variants identified 
from disease presentation to relapse in individual patient (continued on next 
page). 
 
 
 
 
 
 
 
184 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4. Variant allele fraction (VAF) score for somatic variants in each 
individual AML patient (continued from previous page). 
VAF score for two mutations at both presentation and relapse in Patient 1 (NPM1 
p.W288fs and FLT3-ITD) and one mutation at presentation in Patient 9 (NPM1 
p.W288fs) were not available (not detected by exome sequencing). Each line represent 
one variant. 
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p.W288fs) detected by molecular diagnostic screening, were not available as they 
were not detectable by exome sequencing. In addition, mutations in other genes 
acquired at relapse include PTPRQ c.6452-6453+2del (Patient 1), LIFR c.992-1G>T 
(Patient 3), DNAH5 c.2578-2delA (Patient 4), PKP2 c.2300-1G>T (Patient 7), 
MAP3K20 c.416-2A>T (Patient 8), MAP3K20 c.416-1G>T (Patient 8), WRN c.840-
2_841delAGGG (Patient 9), WRN p.S282fs*24 (Patient 9), ATRX p.R2407* (Patient 
11) and RYR2 p.T4580M (Patient 11) with a range of 15.2% – 80.0% VAF score. 
 Variants were further clustered into four groups to define the effect of 
chemotherapy on the prevalence of somatic variants at relapse specifically in known 
AML driver genes based on comparison between VAF score at presentation and 
relapse (Figure 6.5). Except for NPM1 p.W288fs and FLT3-ITD mutations in which no 
VAF scores were available (not detected by exome sequencing), FLT3 p.T526M, 
CEBPA p.Q346fs*10 and CEBPA p.V343fs*10 mutations were found to be persist after 
treatment by having similar values at presentation and relapse (less than 10% 
difference). NRAS p.G12D and TET2 p.N339fs*10 mutations were predicted to confer 
relative resistance to standard combination chemotherapy treatment based on their 
increased VAF (greater than 10% difference) at relapse, whereas CEBPA p.Q312dup 
mutation was predicted to confer sensitivity to chemotherapy based on a reduced VAF 
score (greater than 10% difference) at relapse. Four mutations including ASXL1 
p.G646fs*12, TP53 c.783-6_786del, KIT p.D419del and ATM c.497-1G>T are 
predicted to be induced by or selected by chemotherapy since these were not detected 
at presentation. 
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Figure 6.5. Effect of chemotherapy on the prevalence of somatic variants in 
known AML driver genes based on comparison of VAF score at presentation and 
relapse. 
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6.3. Discussion 
 
 Genetic heterogeneity is a major concern in cancer especially AML as it drives 
phenotypic adaptability which may contribute to clonal selection during treatment. One 
of the important causes of genetic heterogeneity is genomic instability. This instability 
leads to an increased mutation rate which can shape the evolution of the cancer 
genome through many mechanisms. Moreover, the diversity of genetic events in a 
cancer genome poses a significant challenge to identifying the oncogenic effect of 
specific genetic abnormalities. The advent of next generation sequencing (NGS) 
technology has allowed for more comprehensive analysis of somatic variants which 
has facilitated understanding of AML initiation and progression (Ding et al., 2012; 
Welch et al., 2012; Cancer Genome Atlas Research, 2013; Garg et al., 2015; Sood et 
al., 2015; Farrar et al., 2016; Patel et al., 2017). 
 In this study, high-throughput paired-end exome sequencing of 11 matched 
presentation and relapse AML samples was performed which enabled comparison of 
mutational landscape to better understand cancer evolution from presentation to 
relapse. The advantage of paired-end sequencing allowed both ends of a DNA 
fragment to be sequenced thus generating high-quality and alignable sequence data 
to facilitate detection of genomic variants with high confidence. However, one caveat 
with this approach is that the genome coverage was very low (the human exome 
represents ~1.2% of the total genome) and mutations in non-coding sequence were 
not identified. Despite that, with high read depth achieved in this study as a result of 
exonic sequence enrichment, identification of somatic variants present in minor 
leukaemic cell clones both at presentation and relapse was achieved. 
 Despite the sensitivity of NGS to identify low frequency mutations, this approach 
depends on good quality DNA with a high proportion of the leukaemic DNA (purity) in 
the sample to be sequenced. As such, poor quality sequencing or low purity can lead 
to false negative results, as evidenced by the failure to detect known FLT3-ITD and 
NPM1 pW288fs (TCTG insertion) by exome sequencing in patients 1 and 9 that had 
previously been confirmed using targeted PCR. These mutations might have been 
present at very low frequency at presentation and were not detected via NGS due to 
low read depth. Unfortunately, further investigation of these mutations could not be 
performed due to the unavailability of raw sequencing data (.bam files) for these 
samples. 
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6.3.1. Somatic variants at presentation and relapse 
 
 SNVs and indels are the most abundant type of genetic variation in the human 
genome with ratios of indels to SNVs were 0.19 – 0.22 in WGS and 0.14 in WES (Mills 
et al., 2011; Shigemizu et al., 2013). Higher ratio of indels to SNVs were identified in 
this study with 0.82 at presentation and 0.66 at relapse. However, these data is 
incomparable since the former data was generated solely based on the prevalence of 
all genetic variation in the human genome whereas SNVs and indels identified in this 
study were strictly limited to somatic variants that may have biological implications in 
AML pathogenesis. Nevertheless, accurate identification of pathogenic SNVs and 
indels is one of the most important challenges in cancer genome analysis and requires 
detailed information of their impact on disease development. Ingenuity Variant Analysis 
software is equipped with linked databases that provides comprehensive information 
of each variant which can be used to discern functionality and a role in 
leukaemogenesis. 
 The average number of somatic variants (SNVs and indels) identified in this 
study were fewer compared to average number of mutation found in previous somatic 
mutation studies (Cancer Genome Atlas Research, 2013; Garg et al., 2015; Sood et 
al., 2015; Farrar et al., 2016; Hartmann et al., 2016). However, some previous studies 
had greater coverage of the genome (whole genome sequencing) and larger sample 
sizes. Despite this, the number of somatic mutations in AML is relatively low with an 
average of 13 mutations per genome as opposed to other cancers occurring in adults 
which often have hundreds of somatic mutations, especially solid tumours such as 
breast, lung or pancreas (Cancer Genome Atlas Research, 2013). 
 
6.3.2. Coexisting variants within individual patients 
 
 The two-hit model of leukaemogenesis has served as a basis to understand 
how mutations in certain genes drive AML (Kelly and Gilliland, 2002). Based on this 
model, mutations were divided according to two fundamental characteristics of cancer 
cells, including mutations that confer cellular proliferation (class I mutations) and 
mutations that impair myeloid differentiation (class II mutations). The model predicts 
that both classes of mutation are required for AML transformation. However, genomic 
studies have revealed the presence of mutations in genes associated with epigenetic 
modification (ASXL1, DNMT3A, IDH1/2, TET2, EZH2 and MLL) in a significant 
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proportion of AML patients (Shih et al., 2012). Disruption of epigenetic processes 
including DNA methylation and histone modification can lead to altered function in 
genes involve in key cellular pathways such as DNA repair, RAS signalling, cell cycle 
and apoptosis which may cause malignant cellular transformation in cancer (Kanwal 
and Gupta, 2012). In addition, a genome-wide DNA methylation profiling study has 
demonstrated that specific methylation profiles are associated with specific AML 
subtypes (Figueroa et al., 2010b), which identified oncogenic cooperativity between 
somatic alterations in epigenetic regulators and known AML driver mutations. 
 However, determining oncogenic cooperativity between mutations is difficult as 
it requires prior knowledge of the function of the genes as well as the impact of the 
mutated genes on the translated protein. Therefore, given the abundant number of 
mutated genes with uncertain significance identified in this cohort, analysis was limited 
to genes most recurrently mutated in AML as reported in COSMIC and genes not 
previously implicated in AML pathogenesis that have important functions potentially 
relevant for leukaemogenesis. 
 The mutational spectrum exhibited by each patient was totally different which 
demonstrates the heterogeneous nature and complexity of the genomic landscape in 
AML. However, despite this variation, more than half of patients (7 out of 11 patients) 
had mutations in at least one known AML driver genes that is reported as recurrently 
mutated in AML in COSMIC. NPM1, FLT3, NRAS, CEBPA, TET2 and IDH2 were the 
mutated genes identified in these patients at presentation which are well reported for 
their importance and contribution to AML pathogenesis. Co-occurrence of class I and 
II mutations was observed in three patients with normal karyotype at presentation 
(Patient 1, 5 and 9). FLT3-ITD and NPM1 p.W288fs (TCTG insertion) mutations 
harboured by Patient 1 are inarguably defined as AML driver mutations since 
numerous studies has showed the co-occurrence of these mutations in AML patients 
(Krönke et al., 2013; Garg et al., 2015; Alpermann et al., 2016; Patel et al., 2017). In 
patient 5, CEBPA mutation appeared to be a driver mutation as it is recurrently mutated 
in AML patients (Pabst et al., 2001; Fasan et al., 2013) and plays a key role in AML 
initiation as demonstrated in murine models (Kirstetter et al., 2008; Bereshchenko et 
al., 2009). Although no additional mutations in known AML driver genes were detected 
in this patient, mutation in MUTYH gene appeared as a candidate mutation to 
cooperate with CEBPA mutation at presentation since its involvement in oxidative DNA 
damage repair (Banda et al., 2017; Dumanski et al., 2017) compared to another 
accompanying mutation in CFTR gene which was commonly reported in patients with 
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cystic fibrosis (Ortiz et al., 2017; Furgeri et al., 2018). WRN gene was recognised as 
tumour-suppressor gene and evidence suggests a role in promoting oncogenic 
proliferation (Agrelo et al., 2006; Opresko et al., 2007) which may likely contribute to 
AML transformation in patient 9 in addition to NPM1 and IDH2 mutations. 
 The mutational landscape observed in two patients with t(8;21) AML (Patient 6 
and 7) provides further evidence for the complexity of AML, despite these leukaemias 
sharing a common driver lesion. It is well described that RUNX1/ETO fusion gene (a 
product of t(8;21)) alone is insufficient for leukaemogenesis, as it requires additional 
co-operating mutations for progression to AML. KIT and FLT3 mutations are commonly 
found in t(8;21) patients (Boissel et al., 2006; Santos et al., 2011) and their oncogenic 
cooperativity for leukaemogenesis have been well established in murine models 
(Schessl et al., 2005; Wichmann et al., 2015). However, both patients lack these 
mutations which suggests that other mutations may also cooperate with t(8;21) to drive 
leukaemogenesis. TET2 mutation is commonly associated with cytogenetically normal 
AML and concurrently observed with mutations in NPM1, FLT3, JAK2, RUNX1, 
CEBPA, CBL and KRAS (Weissmann et al., 2011). Targeted amplicon sequencing of 
46 leukaemia relevant genes in 56 t(8;21) patients has revealed TET2 mutation in 12% 
of AML (Hartmann et al., 2016). Furthermore, TET2 is predicted to act as a tumour-
suppressor (Delhommeau et al., 2008; Mohamedali et al., 2009; Smith et al., 2010; 
Mercher et al., 2012) which might cooperates with the RUNX1/ETO fusion gene to 
cause AML phenotype in patient 6. Moreover, an interesting candidate gene, RASA2 
was identified in this patient as mutation in this gene is thought to have oncogenic 
effects due to its important role in suppressing RAS function (RAS signalling pathway) 
which control cell proliferation and differentiation (Arafeh et al., 2015). 
 Collectively, these findings emphasise the necessity of further investigation of 
mutation cooperativity, especially for mutations in genes that does not belong to either 
class I or class II mutations. Indeed, it is particularly important to identify mutation 
cooperativity in patients that lack known recurrent combinations of mutations (Patient 
3, 4, 8 and 11) as this might identify novel mechanisms of AML leukaemogenesis. 
 
6.3.3. Clonal evolution from presentation to relapse 
 
 One major advantage of NGS approaches is that it can be used to quantitate 
the proportion of variant reads for any given mutation, also known as the variant allele 
fraction (VAF), which indicates the percentage of tumour cells that harbour a specific 
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mutation assuming a relatively pure leukaemic sample. Using this VAF score, each 
mutation at presentation can be tracked to map clones that persisted, those that 
resolved from presentation to relapse as well as novel mutations that emerged at 
relapse in order to delineate clonal evolution from presentation to relapse. 
 A relationship between the presentation and relapse samples was clearly 
observed in all patients studied. In most cases, mutations detected at presentation 
were also present at relapse with additional mutations (epitomised by patient 11; 
Figure 6.6A), except for one case (Patient 5) which had no additional mutation acquired 
at relapse. Despite no evidence of additional mutations at relapse in patient 5, the VAF 
score for CEBPA p.Q312dup was 40% higher than VAF scores of other two 
accompanying mutations which had rather similar VAF score at presentation, 
suggesting two major clones at presentation as illustrated in Figure 6.6B. The clone 
with CEBPA p.Q312dup, CFTR p.G622D, MUTYH p.E479* mutations persisted at 
relapse, suggesting relative resistance to chemotherapy, whereas the second clone 
with a CEBPA p.Q312dup mutation failed to survived chemotherapy. 
 The characterisation and study of acquired cytogenetic abnormalities, 
especially common translocations, has facilitated a better understanding of AML 
leukaemogenesis. The prevailing evidence identifies chromosomal translocations such 
as t(8;21), inv(16) and t(15;17) as early driver mutations in AML based on the fact that 
they are recurrently found in 6 to 15% of AML patients  (Schoch and Haferlach, 2002) 
and promote mutagenesis that give rise to secondary mutations (Alcalay et al., 2003; 
Krejci et al., 2008; Araten et al., 2013; Forster et al., 2015). These chromosomal 
translocations are assumed to play an essential role in the early stages of 
leukaemogenesis as demonstrated in murine models which showed their cooperativity 
with other mutations to cause clonal expansion or block differentiation (Schessl et al., 
2005; Wichmann et al., 2015). In addition, other studies have identified these AML- 
associated chromosomal translocations in non-leukaemic cells in a small number of 
healthy individuals which further supports their occurrence as early genetic events 
(Quina Ana et al., 2000; Mori et al., 2002). Given this evidence, characterising these 
genetic lesions in terms of order of acquisition would facilitate in understanding their 
role in leukaemogenesis. In this regard, there is evidence to suggest that the order of 
mutation acquisition can affect disease progression in AML (Ortmann et al., 2013; 
Ortmann et al., 2015; Sun et al., 2016). In patients with chromosomal translocations, 
there are two possible patterns of clonal evolution suggested. Firstly, the leukaemic 
clone at presentation acquired additional somatic mutations and evolve into relapse 
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Figure 6.6. Clonal evolution of AML (continued on next page). 
 
 
 
 
 
 
 
193 
 
clone. Secondly, rather than evolving directly from the major presentation clone, the 
relapse clone is derived from an ancestral, pre-leukaemic clone. This is illustrated in 
the case of patient 6 (Figure 6.6C) where two major clones at relapse have been 
identified in which one additional mutation was acquired by the presentation clone and 
pre-leukaemic clone respectively after chemotherapy. 
 Collectively, the findings from this study suggests two possible mechanisms of 
relapse: (1) a subclone at disease presentation survived chemotherapy and re-
emerged after acquired additional mutations; (2) a pre-leukaemic clone survived 
chemotherapy and acquired additional mutations during remission and gave rise to 
relapse. Both mechanisms showed that relapse is driven by the acquisition of 
additional somatic mutations. These findings are consistent with other previous studies 
investigating clonal evolution of AML (Ding et al., 2012; Welch et al., 2012; Garg et al., 
2015; Sood et al., 2015; Greif et al., 2018). However, in some cases, relapse might be 
driven by the same set of mutations acquired at presentation, suggesting these 
mutations confer selective advantage during AML treatment, resulting in clonal 
expansion and eventually leading to relapse. Sequence analysis of a remission sample 
is therefore essential to determine the VAF of these mutations at remission in order to 
confidently identify the pattern of clonal evolution. 
 Data from this study suggest that further investigations of the clonal origins of 
relapse in AML using high-throughput sequencing approaches are warranted in order 
to further understand the relationship between presentation and relapse AML. 
Critically, such studies should focus on the use of more samples sequenced using 
whole genome approaches to a greater depth. Ultimately, this approach will allow for 
the identification of relapse-driver mutations that could be exploited for the 
development of synthetic lethal interactions and novel therapies to improve outcomes 
and reduce death from disease. 
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Figure 6.6. Clonal evolution of AML (continued from previous page).  
A. Evolution from the major clone detected at disease presentation (patient 11). 
B. Evolution from a pre-leukaemic clone detectable at disease presentation but 
resolved at disease relapse (patient 5). 
C. Evolution from a pre-leukaemic clone detectable at disease presentation (patient 6). 
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6.3.4. Summary of chapter 
 
 In summary, these investigations have demonstrated that: 
• High-throughput sequencing is a powerful approach that can provide in-
depth analysis of the genome to identify somatic mutations in AML. 
• In many cases, at least two driver mutations are required for AML 
transformation at presentation. 
• Clonal evolution of relapsed AML is frequently characterised by the 
acquisition of additional somatic mutations after chemotherapy. 
• Larger studies are required to fully delineate the heterogeneity of AML 
and disease evolution from presentation to relapse. 
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Chapter 7. Concluding Discussion 
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7.1. The Mutagenicity of Chemotherapeutic Agents used in AML Treatment 
 
 Despite significant progress in AML treatment, which includes alternative 
nucleoside analogues and targeted therapies, the current treatment of AML remains 
primarily dependent of ara-C and anthracycline containing chemotherapy, which 
function by inducing DNA damage and inhibiting DNA replication. Although these DNA 
damaging agents are efficacious in the treatment of AML, the majority of the patients 
experience relapse, leading to morbidity and mortality. The primary mechanism that 
contributes to disease recurrence or relapse is the acquired resistance of cancer cells 
to chemotherapy (Cheung-Ong et al., 2013). Resistance to chemotherapy can arise in 
various ways, including mutations in genes involved in pathways that promote drug 
metabolism and degradation (Housman et al., 2014). Emerging evidence 
demonstrates that the majority of genotoxic chemotherapeutic agents are mutagenic 
(Silva et al., 2005; Pendleton et al., 2014; Fordham et al., 2015; Szikriszt et al., 2016), 
demonstrating their ability to induce pro-mutagenic DNA damage which may give rise 
to mutations after chemotherapy. 
 The data from this study adds to a growing body of literature demonstrating that 
both ara-C and daunorubicin are mutagenic, as evidenced by increasing mutation 
frequency at doses that induce significant cytotoxicity (Chapter 3). In addition, the type 
of mutation induced by these chemotherapeutic agents is determined by their specific 
mechanism of action. Although the ara-C-induced mutational spectrum was not 
investigated in this project, a previous study has demonstrated that ara-C is a base 
substitution mutagen which preferentially induces mutation at G:C basepairs of 
5′TpGpA3′/5′TpCpA3′ sequences, consistent with its function as a cytosine analogue 
(Fordham et al., 2015). This finding was supported by the interrogation of somatic base 
substitutions in presentation and relapsed AML samples, which demonstrated 
significant increase of mutations at the central base position of 5′TpGpA3′/5′TpCpA3′ in 
relapse disease after treatment with ara-C-containing regimes (Fordham et al., 2015). 
In contrast to ara-C, daunorubicin induces almost exclusively large deletions, 
consistent with its primary function as topo II enzyme inhibitor which resulted in DNA 
strand breaks (Chapter 3). Indeed, daunorubicin and related anthracyclines have been 
identified as direct inducers of DNA strand breaks (Blasiak et al., 2002; Yang et al., 
2015) which can results in LOH or genetic rearrangements such as deletion and 
chromosomal translocation (Lehmann et al., 2004). In addition, balanced 
translocations involving chromosome bands 11q23 (MLL) or 21q22 (RUNX1) observed 
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in t-AML have been associated with prior exposure to anthracyclines/topo II inhibitor-
containing therapy (Pedersen-Bjergaard and Philip, 1991; Godley and Larson, 2008; 
Bhatia, 2013), demonstrating their ability to induce mutational events that drive 
leukaemogenesis. Taken together, these observations suggest that the use of pro-
mutagenic agents during AML treatment contributes to genomic instability and causes 
mutations in key genes that drive relapsed AML. 
 
7.2. Expression of the RUNX1/ETO Fusion Gene Promotes a Mutator Phenotype 
 
 Fusion genes are one of the most frequent types of somatic DNA alteration in 
cancer and have been recognised as important drivers in various human cancers, 
particularly haematological malignancies (Mertens et al., 2015; Gao et al., 2018). Gene 
fusion can be generated through structural chromosomal rearrangements such as 
translocations, deletions and inversions, which involves the co-localisation of coding 
or regulatory DNA sequences between previously separated genes. The identification 
of recurrent chromosomal translocations and their corresponding fusion genes in 
leukaemia has provided important insight into the underlying mechanisms involved in 
leukaemogenesis. The first fusion gene identified, BCR/ABL1 (encoded by the 
Philadelphia (Ph) chromosome), results from a balanced translocation between 
chromosome 9 and 22 (t(9;22)(q34;q11) and was identified in CML (Nowell, 1960; 
Rowley, 1973; Klein et al., 1982). The BCR/ABL fusion gene occurs in more than 95% 
of CML cases (Harrison, 2001; Frazer et al., 2007; Bennour et al., 2016). The 
BCR/ABL1 fusion gene exerts its oncogenic influence by encoding a constitutively 
active tyrosine kinase that disrupt downstream signalling pathways, causing increased 
cell proliferation, blocked differentiation and evasion of apoptosis (Cilloni and Saglio, 
2012; Hantschel, 2012; Sinclair et al., 2013). The identification of the BCR/ABL fusion 
led to the first approved fusion-targeted drug (Imatinib) for newly diagnosed CML 
patients, which inhibits constitutive tyrosine kinase activity resulting in blocked 
transmission of proliferative signals to the nucleus and induced cell apoptosis 
(Schindler et al., 2000; Cohen et al., 2002). A considerable number of fusion genes 
now had been identified in leukaemia and many have served as important diagnostic 
and prognostic markers as they show specificity for distinct types of leukaemia. Many 
leukaemia-specific fusion genes represent therapeutic target for promising new 
treatments that could significantly improve patient outcomes. 
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 In AML, t(15;17)(q22;q12), inv(16)(p13;q22) or t(16;16)(p13;q22), 
t(8;21)(q22;q22) and t(9;11)(p22;q23) are the most common chromosomal 
abnormalities that resulted in the formation of fusion genes in AML (Wang et al., 2017). 
Of these, the RUNX1/ETO fusion gene is the most extensively studied fusion gene in 
AML, with a large body of literature investigating the molecular and cellular basis of 
this type of t(8;21) AML (Ferrara and Del Vecchio, 2002; Reikvam et al., 2011; Solh et 
al., 2014). Although patients with t(8;21) have relatively favourable prognosis 
compared to other types of AML, the presence of additional genetic abnormalities can 
impact on outcome. In addition, substantial numbers of t(8;21) AML patients eventually 
relapse, which is thought to be associated with the genetic heterogeneity of the 
leukaemic cells. It is well described that RUNX1/ETO expression alone is insufficient 
for leukaemogenesis and additional cooperating mutations are required (Yuan et al., 
2001; Higuchi et al., 2002; Schessl et al., 2005; Chou et al., 2011; Wang et al., 2011). 
However, the mechanism by which RUNX1/ETO driving the acquisition of additional 
cooperating mutations remains unclear, although evidence suggests that RUNX1/ETO 
promotes a mutator phenotype through downregulation of genes involved in several 
DNA repair pathways (Alcalay et al., 2003; Krejci et al., 2008; Forster et al., 2015). 
 The proposed mutator phenotype theory in cancer suggests that the 
spontaneous mutation rate in normal cells is insufficient to cause large number of 
mutations observed in cancer cells, and other events are required to increase the 
spontaneous mutation rate and drive genomic instability (Loeb, 1991). The first direct 
evidence supporting this theory was demonstrated in cells from patients with HNPCC, 
which exhibit genomic instability in due to mutations in DNA MMR genes (Eshleman 
and Markowitz, 1996). In leukaemia, the BCR/ABL1 fusion gene induces a mutator 
phenotype through inhibition of the MMR pathway, driving genomic instability and point 
mutations in tumour suppressor genes including p53 and Rb, eventually leading to 
malignant progression of the disease (Stoklosa et al., 2008). In addition, a recent study 
has demonstrated that expression of the RUNX1/ETO fusion protein predisposes cells 
to the acquisition of somatic mutations, both spontaneously and after exposure to 
genotoxic chemotherapy, with downregulation of OGG1 expression hypothesised as 
one possible mechanism (Forster et al., 2015), providing evidence that RUNX1/ETO 
induces a mutator phenotype. Collectively, these studies showed that a mutator 
phenotype is associated with mutations in key genes and pathways such as DNA 
repair, which may promote an elevated mutation rate and increase the chances of 
acquiring subsequent genetic alterations. 
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 As an extension from the Forster study (Forster et al., 2015), the present study 
was undertaken to evaluate the influence of the RUNX1/ETO fusion gene on the 
mutagenesis, both spontaneously and after exposure to genotoxic agents. It was 
demonstrated that RUNX1/ETO significantly increases spontaneous mutation 
frequency at two independent loci (TK and HPRT) in vitro, despite no strong evidence 
that RUNX1/ETO expression renders cells more susceptible to mutagenesis after 
exposure to chemotherapeutic agents (Chapter 3). RUNX1/ETO fusion protein has 
been recognised as a leukaemia-initiating transcription factor that interferes with 
normal RUNX1 function, which includes deregulation of genes involved in 
haematopoiesis (Lam and Zhang, 2012) and repression of genes involved in several 
DNA repair pathways (Alcalay et al., 2003; Wildonger and Mann, 2005; Krejci et al., 
2008; Forster et al., 2015). One gene of particular interest is OGG1, which encodes a 
key DNA glycosylase involved in the excision of 8-oxoG lesions during base excision 
repair (Ba and Boldogh, 2018). Although the association of RUNX1/ETO and OGG1 
was not investigated in this project, previous studies have provided strong evidence 
that OGG1 is downregulated in cells expressing RUNX1/ETO (Krejci et al., 2008; 
Forster et al., 2015). Moreover, OGG1 gene is a direct transcriptional target of 
RUNX1/ETO fusion protein, which is negatively regulated by RUNX1/ETO (Ptasinska 
et al., 2012; Forster et al., 2015), providing a plausible mechanism by which 
RUNX1/ETO downregulates OGG1 expression and drives mutagenesis in t(8;21) 
AML. Impaired OGG1 DNA glycosylase activity can lead to the accumulation 8-oxoG 
lesion, giving rise to G:C > T:A transversion mutations (Suzuki et al., 2010). 
Interrogation of the spontaneous base substitution mutational spectrum at the HPRT 
locus in vitro however showed no significant increase of G:C > T:A transversion in cells 
expressing RUNX1/ETO (Chapter 4). Instead, an increase of T:A > G:C transversions 
was observed, particularly at the central base position of 5’ApTpA3’ / 5’TpApT3’ 
trinucleotide sequences, although it was not statistically significant. However, the 
aetiology of T:A > G:C transversions is currently unknown and no mutational signature 
that exhibit the dominance of T:A > G:C transversions, particularly at 5’ApTpA3’ / 
5’TpApT3’ sequences was previously reported in human cancer 
(https://cancer.sanger.ac.uk/cosmic/signatures). Moreover, there is lack of evidence 
for both G:C > T:A and T:A > G:C transversions in t(8;21) primary AML, which is 
dominated by C:G > T:A transitions. Interestingly, most of C:G > T:A transitions in 
primary t(8;21) AML occurred at the C base of 5′CpG3′ dinucleotides sequences, which 
is associated with spontaneous deamination of 5-methylcytosine (Holliday and Grigg, 
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1993; Wiebauer et al., 1993). The apparently contradictory findings between data from 
cell based reporter assays and and primary t(8;21) AML is likely influenced by the 
potential at specific DNA bases to affect protein function. Specifically, HPRT is 
considered a good reporter gene because mutation at over 60% of bases in the coding 
sequence affect protein function and can be detected using the reporter assay. In 
contrast, mutation in primary AML in genes such as NPM1 and FLT3 is observed at a 
relatively small number of bases, which affect protein function when mutated. As such, 
it is likely that mutation at the majority of bases in these and other leukaemia-specific 
genes is not observed because it is not functional. In this regard, many leukaemia-
associated genes, such as FLT3, do not represent appropriate reporter genes with 
which to identify mutational signatures. 
 The data from this project has demonstrated that RUNX1/ETO expression 
predisposes to acquisition of the type A exon 12 NPM1 mutation (c.863_864insTCTG), 
providing direct evidence that this fusion protein predisposes cells to the acquisition of 
somatic mutation at loci relevant to leukaemogenesis (Chapter 5). Although NPM1 
mutation is commonly associated with normal karyotype, it is reported at very low 
frequency in t(8;21) AML (Thiede et al., 2006). Specifically, two NPM1 base 
substitutions have been reported  in a patient with t(8;21), which were a T > G (W290G) 
transversion and a T > C (S293P) transition (Braoudaki et al., 2010), with none of these 
mutations were previously reported in other AML subtype. Taken together, these data 
suggest that RUNX1/ETO drives genomic instability and mutagenesis at other loci in 
the genome, including leukaemia-relevant genes such as NPM1. It is well described 
that mutations in certain categories of genes, such as type III RTK family, co-operate 
with RUNX1/ETO to drive t(8;21) AML (Yuan et al., 2001; Higuchi et al., 2002). For 
example, mutations in KIT gene are found in up to 50% of t(8;21) AML cases, but are 
comparatively rare in other AML subtypes (Goemans et al., 2005; Kohl et al., 2005; 
Wang et al., 2005). KIT mutation co-operates with RUNX1/ETO to drive AML in mice 
(Wang et al., 2011). The most common KIT mutations reported in AML are N822K, 
D816H, D816V and D816Y, which are caused by T > G, G > C, A > T and G > T base 
substitutions, respectively (Care Rory et al., 2003; Beghini et al., 2004; Wang et al., 
2005; Roumier et al., 2006). Of these, only KIT D816Y mutation is possibly caused by 
direct downregulation of OGG1 by RUNX1/ETO. It is hypothesised that downregulation 
of other genes involved in the BER pathway might responsible for other base 
substitution mutations in KIT. A study has shown that downregulation of the NEIL1 
DNA glycosylase in Chinese hamster lung fibroblast V79 cells results in a higher rate 
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of spontaneous A > T base substitutions, causing amino acid change from aspartic 
asid (D) to valine (V) at the HPRT locus (Maiti et al., 2008), which might explain the 
acquisition of D816V in KIT gene. Moreover, majority of the mutations occurred at A:T 
basepairs, indicating that NEIL1 has a preference for repair of oxidatively damaged 
A:T basepairs (Maiti et al., 2008). However, there is no data on NEIL1 expression in 
t(8;21) AML. Hence, further studies are needed to confirm the downregulation of NEIL1 
in RUNX1/ETO-expressing cells in order to fully understand the mechanisms by which 
RUNX1/ETO predisposes the acquisition of base substitutions in KIT as well as in other 
common cooperating mutation hotspot of RUNX1/ETO such as NRAS G12D (G > A). 
 
7.3. Clonal Evolution and Clonal Heterogeneity in AML 
 
 Genomic diversity within single cancers has long be recognised. Some of the 
first evidence of genetic heterogeneity in leukaemia was reported by Anderson et al., 
(2010), who demonstrated low frequency of genetically distinct cell populations in 
propagating cells at leukaemia diagnosis. This clonal heterogeneity represents a key 
factor contributing to chemotherapy resistance by providing a reservoir of cells with the 
potential for clonal expansion leading to relapse. The advent of NGS technology has 
allowed for a more comprehensive analysis of cancer evolution and provided a better 
understanding of cancer initiation and progression. The exome sequencing data of 
matched presentation and relapsed AML samples in  this project (Chapter 6) has 
provided insight on clonal evolution in AML, along with data from other studies (Ding 
et al., 2012; Welch et al., 2012; Garg et al., 2015; Sood et al., 2015; Greif et al., 2018). 
Consistent with these studies, two major patterns of relapsed AML were identified from 
this project, with relapse evolving either from the major leukaemic clone at 
presentation, or from an ancestral, pre-leukaemic clone. Critically, both patterns of 
relapse are defined by the acquisition of additional somatic mutations. The fact that 
relapse is driven by additional acquired mutations acquired suggests that 
chemotherapeutic agents used in AML remission induction treatment either induces 
pro-mutagenic DNA damage or selects for pre-existing cells with mutations. However, 
in some cases, the dominant clone at disease presentation persists at relapse without 
the addition of novel somatic mutations, suggesting the presence of non-genetic 
alterations, such as epigenetic alterations, that might confer chemotherapy resistance. 
Taken together, the findings from this study suggest that the relapse-initiating clones 
may pre-exist before therapy, which harbour or acquire mutations that confer selective 
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advantage during chemotherapy, resulting in clonal expansion and eventually leading 
to relapse. 
 
7.4. Summary of Findings 
 
 In summary, this project has demonstrated that chemotherapeutic agents used 
in AML remission induction treatment are mutagenic to DNA in vitro. Additionally, the 
influence of RUNX1/ETO fusion gene expression on mutagenesis has been 
demonstrated, with data suggesting that RUNX1/ETO confers a mutator phenotype by 
predisposing cells to the acquisition of additional mutations through downregulation of 
genes involved in DNA repair. Comparison of the mutational landscape between 
presentation and relapse AML samples has provided important insight into the clonal 
origins of relapsed AML, although additional studies are required to fully delineate the 
clonal evolution of this complex disease. Nevertheless, these data could prove 
valuable in the development of novel targeted therapies specifically tailored to 
individual patients with certain AML subgroups, thus limiting the use of genotoxic pro-
mutagenic chemotherapy. 
 
7.5. Limitations of the Study 
 
Despite several major findings obtained from this study, there are few limitations 
that need to be addressed: 
 
- The use of lymphoblastoid cells is perhaps not the best model to study myeloid 
specific mutations (Chapter 3 and 4). Specifically, consideration needs to be 
given to the expression of recombination-activating genes (RAGs) and other 
mechanisms intrinsic to B cells that have evolved to drive mutation at 
immunoglobulin loci, and how these might affect mutation at other sites in the 
genome, as described in Section 2.2. 
 
- Ideally, antibodies raised against specific mutant proteins such as KIT D816V 
and RAS G12D should be used to study the effect of RUNX1/ETO fusion gene 
expression on the acquisition of mutations because these genes are relevant to 
t(8;21) AML pathogenesis (Chapter 5). In contrast, NPM1 mutation is a very 
rare occurrence in t(8;21) AML and is therefore less relevant as mutational 
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target in RUNX1/ETO expressing cells. The selection of genes for study in this 
model was primarily determined by the availability of high specificity antibodies 
for mutant proteins. In addition, there is a concern that the increasing level of 
NPM1 mutation over time which might represent a false-positive result as the 
intrinsic NPM1 mutation is assumed to be very rare in normal cells especially in 
B cell lines. However, the data from the study demonstrated a reasonable 
increase in spontaneous NPM1 mutation frequency over time as a result of 
continuous cell division in long term culture. 
 
- The ability to quantify VAF is one of the major advantages of NGS technology 
that can provide information of the percentage of tumour cells that harbour a 
specific mutation (Chapter 6). However, VAF will vary according to the blast cell 
count and a high proportion of leukaemic DNA in the sample to be sequenced 
is essential to give accurate results. Therefore, a reasonable cut-off for major 
difference in VAF between diagnosis and relapse samples need to be 
determined for the changes to be considered significant, as applied in this study. 
In addition, strict selection criteria for the sample to be sequenced can be 
implemented for future studies to exclude samples with low blast cell count and 
samples contaminated with normal cells. 
 
7.6. Future Directions 
 
 A number of further investigations are anticipated following the findings of the 
present study. 
 
7.6.1. In vitro mutagenicity of other chemotherapeutic agents used in AML 
treatment 
 
 Exposure to daunorubicin and ara-C results in a significant dose-dependent 
increase in mutation frequency at both the TK and HPRT loci in TK6 cells, providing 
evidence on the in vitro mutagenicity of both chemotherapeutic agents (Chapter 3). In 
addition, mutation screening at the HPRT coding region in TK6 cells revealed that 
daunorubicin can induce a spectrum of mutations which are unique compared to 
spontaneous background mutation spectrum. Thus, the data from this study may form 
the basis for future studies to investigate the mutagenic potential of other 
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chemotherapeutic agents used in AML in order to discern their likely contribution to the 
aetiology of relapse driver mutations. 
 
7.6.2. RUNX1/ETO-induced spontaneous mutation spectrum 
 
 Interrogation of the spontaneous HPRT base substitution spectrum revealed 
that RUNX1/ETO can induces unique mutation at the central base position of 5’ApTpA3’ 
/ 5’TpApT3’ trinucleotide sequences, but this mutation was not evident in primary t(8;21) 
AML (Chapter 4). Therefore, a much larger number of independent spontaneous 
RUNX1/ETO-induced HPRT mutants need to be generated to expand the current 
dataset and improve statistical power to discern a RUNX1/ETO-induced mutation 
signature. Alternatively, whole genome sequencing of RUNX/ETO-positive cells can 
be carried out to identify all mutations in genes other than the leukaemia-relevant 
genes. 
 
7.6.3. Effect of RUNX1/ETO gene expression on mutation frequency at specific 
loci relevant to AML pathogenesis 
 
 A reliable flow cytometric method was established to evaluate the effect of 
RUNX1/ETO fusion gene expression on mutation frequency at specific base residue 
in NPM1 (Chapter 5). It is now planned to perform similar mutation screening at other 
loci relevant to t(8;21) AML pathogenesis using commercially available antibodies 
raised against specific mutant proteins such as Kit D816V and RAS G12D. 
 
7.6.4. Relationship between RUNX1/ETO and DNA repair gene expression 
 
 As most RUNX1/ETO cooperating mutations are base substitutions, an 
investigation on the association between RUNX1/ETO and DNA repair gene 
expression is warranted, with a particular focus on pathways that protect against base 
substitution mutation, such as BER and MMR. Such studies can be performed via 
quantification of transcript level of the candidate genes by real-time PCR (qPCR) or 
RNA-sequencing to also identify alternative transcripts that could affect repair function. 
Furthermore, ChIP sequencing can be used to identify DNA repair genes that are 
transcriptional targets of the RUNX1/ETO oncoprotein. 
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7.6.5. High-throughput sequencing of matched presentation and relapsed AML 
 
 Data from high-throughput exome sequencing of a small cohort of matched 
presentation and relapse AML samples has provided evidence of clonal evolution 
during disease progression (Chapter 6). Future studies should focus on the analysis 
of additional cytogenetically defined cases, including t(8;21), using whole genome 
approaches to a greater depth in order to fully delineate the heterogeneity of AML and 
disease evolution from presentation to relapse and fully elucidate the origins of 
relapse-initiating clones. 
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Appendix A: Cytotoxicity in response to daunorubicin in TK6 and TK6 
RUNX1/ETO cells. 
The survival fraction at each dose was determined by calculating the mean CE of the 
dosed cells as a percentage of the mean CE of the vehicle-treated cells and each 
experiment was repeated three times. 
 
Daunorubicin dose 
(nM) 
TK6 TK6 RE8 
Survival fraction (%) Mean 
(%) 
Survival fraction (%) Mean 
(%) Exp 1 Exp 2 Exp 3 Exp 1 Exp 2 Exp 3 
0 (vehicle-treated) 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 
2 60.12 59.90 79.60 66.54 61.40 94.22 86.09 80.57 
4 22.88 18.91 12.96 18.25 30.81 56.64 38.84 41.98 
6 0.30 0.55 0.46 0.44 2.25 5.15 4.86 4.09 
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Appendix B: Effect of daunorubicin exposure on mutation frequency at TK and HPRT loci in TK6 and TK6 RUNX1/ETO. 
MF at the TK and HPRT loci was assessed in parental TK6 cells and TK6 RUNX1/ETO cells following a 16 hour exposure to daunorubicin. 
Each experiment was repeated three times. 
 
Daunorubicin 
(nM) 
TK 
TK6 TK6 RUNX1/ETO 
Exp 1 Exp 2 Exp 3 Mean MF (x10-6) Exp 1 Exp 2 Exp 3 Mean MF (x10-6) 
0 8.12 6.9 9.66 8.2 11.9 12.4 14.8 13.0 
15 61.9 58.5 52.9 57.8 54.2 61.9 50.5 55.5 
25 64.8 62.9 50.0 59.2 63.4 72.2 69.3 68.3 
30 66.9 56.9 60.0 60.9 79.5 76.0 67.4 74.3 
 
Daunorubicin 
(nM) 
HPRT 
TK6 TK6 RUNX1/ETO 
Exp 1 Exp 2 Exp 3 Mean MF (x10-6) Exp 1 Exp 2 Exp 3 Mean MF (x10-6) 
0 1.9 2.3 4.4 2.9 5.2 3.4 3.4 4.0 
15 30.6 29.1 19.3 26.3 15.6 25.1 15.4 18.7 
25 41.6 39.9 34.1 38.5 27.8 36.9 35.0 33.2 
30 43.9 39.6 35.5 39.6 33.7 44.7 43.8 40.7 
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Appendix C: Effect of ara-C exposure on mutation frequency at TK and HPRT loci in TK6 and TK6 RUNX1/ETO 
MF at the TK and HPRT loci was assessed in parental TK6 cells and TK6 RUNX1/ETO cells following a 16 hour exposure to ara-C. Each 
experiment was repeated two times. ‘x’ denotes experimental replicate not done. 
 
Ara-C 
(µM) 
TK 
TK6 TK6 RUNX1/ETO 
Exp 1 Exp 2 Exp 3 Mean MF (x10-6) Exp 1 Exp 2 Exp 3 Mean MF (x10-6) 
0 8.4 10.6 x 9.5 14.4 14.6 x 14.5 
1 42.9 33.8 x 38.4 38.3 35.1 x 36.7 
3 48.3 44.8 x 46.6 48.6 38.7 x 43.7 
5 56.0 49.8 x 52.9 58.9 48.1 x 53.5 
 
Ara-C 
(µM) 
HPRT 
TK6 TK6 RUNX1/ETO 
Exp 1 Exp 2 Exp 3 Mean MF (x10-6) Exp 1 Exp 2 Exp 3 Mean MF (x10-6) 
0 3.7 1.5 x 2.6 3.9 3.7 x 3.8 
1 8.2 14.8 x 11.5 7.1 4.5 x 5.8 
3 13.6 16.6 x 15.1 10.6 16.7 x 13.7 
5 16.7 27.3 x 22.0 15.9 21.2 x 18.6 
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Appendix D: Sequence of HPRT cDNA (NCBI Reference Sequence: NM_000194). 
 
GGCGGGGCCTGCTTCTCCTCAGCTTCAGGCGGCTGCGACGAGCCCTCAGGCGAACCTCTCGGCTTTCCCGCGC
GGCGCCGCCTCTTGCTGCGCCTCCGCCTCCTCCTCTGCTCCGCCACCGGCTTCCTCCTCCTGAGCAGCAGCCCGC
GCGCCGGCCGGCTCCGTTATGGCGACCCGCAGCCCTGGCGTCGTGATTAGTGATGATGAACCAGGTTATGACC
TTGATTTATTTTGCATACCTAATCATTATGCTGAGGATTTGGAAAGGGTGTTTATTCCTCATGGACTAATTATGG
ACAGGACTGAACGTCTTGCTCGAGATGTGATGAAGGAGATGGGAGGCCATCACATTGTAGCCCTCTGTGTGCT
CAAGGGGGGCTATAAATTCTTTGCTGACCTGCTGGATTACATCAAAGCACTGAATAGAAATAGTGATAGATCC
ATTCCTATGACTGTAGATTTTATCAGACTGAAGAGCTATTGTAATGACCAGTCAACAGGGGACATAAAAGTAAT
TGGTGGAGATGATCTCTCAACTTTAACTGGAAAGAATGTCTTGATTGTGGAAGATATAATTGACACTGGCAAA
ACAATGCAGACTTTGCTTTCCTTGGTCAGGCAGTATAATCCAAAGATGGTCAAGGTCGCAAGCTTGCTGGTGA
AAAGGACCCCACGAAGTGTTGGATATAAGCCAGACTTTGTTGGATTTGAAATTCCAGACAAGTTTGTTGTAGG
ATATGCCCTTGACTATAATGAATACTTCAGGGATTTGAATCATGTTTGTGTCATTAGTGAAACTGGAAAAGCAA
AATACAAAGCCTAAGATGAGAGTTCAAGTTGAGTTTGGAAACATCTGGAGTCCTATTGACATCGCCAGTAAAA
TTATCAATGTTCTAGTTCTGTGGCCATCTGCTTAGTAGAGCTTTTTGCATGTATCTTCTAAGAATTTTATCTGTTT
TGTACTTTAGAAATGTCAGTTGCTGCATTCCTAAACTGTTTATTTGCACTATGAGCCTATAGACTATCAGTTCCCT
TTGGGCGGATTGTTGTTTAACTTGTAAATGAAAAAATTCTCTTAAACCACAGCACTATTGAGTGAAACATTGAA
CTCATATCTGTAAGAAATAAAGAGAAGATATATTAGTTTTTTAATTGGTATTTTAATTTTTATATATGCAGGAAA
GAATAGAAGTGATTGAATATTGTTAATTATACCACCGTGTGTTAGAAAAGTAAGAAGCAGTCAATTTTCACATC
AAAGACAGCATCTAAGAAGTTTTGTTCTGTCCTGGAATTATTTTAGTAGTGTTTCAGTAATGTTGACTGTATTTT
CCAACTTGTTCAAATTATTACCAGTGAATCTTTGTCAGCAGTTCCCTTTTAAATGCAAATCAATAAATTCCCAAA
AATTTAAAAAAAAAAAAAAAAAAAAAA 
 
Different coloured letters represent different exon of HPRT (exon 1 – 9). 
Start codon is highlighted in light blue. 
Forward primers are highlighted in green. 
Reverse primers are highlighted in yellow. 
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Appendix E: Effect of RUNX1/ETO expression on NPM1 mutation frequency over time (continued of next page). 
 
Week 
No RE expression Low RE expression High RE expression 
Clone 
Positive 
event 
Gated 
event 
MF (x10-5) Clone 
Positive 
event 
Gated 
event 
MF (x10-5) Clone 
Positive 
event 
Gated 
event 
MF (x10-5) 
7 1 6 350204 1.71 1 3 364383 0.82 1 4 330681 1.21 
 2 2 304717 0.66 2 15 362736 4.14 2 8 338807 2.36 
 3 5 230834 2.17 3 6 344971 1.74 3 11 353997 3.11 
 4 6 344495 1.74 4 4 348021 1.15 4 7 338075 2.07 
 5 6 310541 1.93 5 6 350092 1.71 5 5 328952 1.52 
 6 8 348034 2.30 6 7 336006 2.08 6 5 398978 1.25 
 7 11 445475 2.47 7 8 358257 2.23 7 9 338075 2.66 
 8 3 333974 8.98 8 8 334301 2.39 8 7 341107 2.05 
 9 7 294954 2.37 9 10 366220 2.73 9 3 339519 0.88 
 10 6 330538 1.82 10 9 352337 2.55 10 5 346527 1.44 
9 1 7 298812 2.34 1 4 333888 1.20 1 10 309892 3.23 
 2 7 303499 2.31 2 6 398370 1.51 2 8 299325 2.67 
 3 4 310888 1.29 3 6 300554 2.00 3 4 296842 1.35 
 4 2 292176 6.85 4 7 326267 2.15 4 12 304630 3.94 
 5 7 285463 2.45 5 6 311426 1.93 5 5 298305 1.68 
 6 5 287081 1.74 6 5 337695 1.48 6 9 289189 3.11 
 7 6 284843 2.11 7 7 322538 2.17 7 2 348788 5.73 
 8 6 292781 2.05 8 9 288761 3.12 8 6 316825 1.89 
 9 7 307843 2.27 9 9 313934 2.87 9 5 327654 1.53 
 10 4 311012 1.29 10 7 318292 2.20 10 13 297746 4.37 
11 1 8 341066 2.35 1 11 335360 3.28 1 17 298610 5.69 
 2 6 347807 1.73 2 15 299735 5.00 2 15 317815 4.72 
 3 6 344732 1.74 3 8 289410 2.76 3 12 363393 3.30 
 4 8 320327 2.50 4 8 311793 2.57 4 9 316623 2.84 
 5 8 310843 2.57 5 7 344427 2.03 5 13 329718 3.94 
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Appendix E: Effect of RUNX1/ETO expression on NPM1 mutation frequency over time (continued of next page). 
 
Week 
No RE expression Low RE expression High RE expression 
Clone 
Positive 
event 
Gated 
event 
MF (x10-5) Clone 
Positive 
event 
Gated 
event 
MF (x10-5) Clone 
Positive 
event 
Gated 
event 
MF (x10-5) 
11 6 6 324241 1.85 6 9 303318 2.97 6 9 325869 2.76 
 7 8 328703 2.43 7 7 293969 2.38 7 14 312942 4.47 
 8 8 312070 2.56 8 5 323979 1.54 8 9 363760 2.47  
9 8 387374 2.07 9 12 313108 3.83 9 10 297726 3.36  
10 6 331766 1.81 10 13 308105 4.22 10 8 298210 2.68 
13 1 11 407178 2.70 1 11 386466 2.85 1 16 413232 3.87  
2 10 337389 2.96 2 8 370393 2.16 2 22 371260 5.93  
3 6 305792 1.96 3 13 366749 3.54 3 10 395011 2.53  
4 8 349667 2.29 4 20 379940 5.26 4 22 360374 6.10  
5 9 372216 2.42 5 14 358878 3.90 5 11 363153 3.03  
6 6 358848 1.67 6 11 378992 2.90 6 14 363426 3.85  
7 15 351643 4.27 7 16 374996 4.27 7 17 422907 4.02  
8 15 327744 4.58 8 16 358565 4.46 8 12 430448 2.79  
9 9 322686 2.79 9 9 361026 2.49 9 17 401458 4.23  
10 13 318828 4.08 10 19 360878 5.26 10 13 378705 3.43 
15 1 9 287685 3.13 1 12 332790 3.61 1 20 348763 5.73  
2 10 338996 2.95 2 7 339426 2.06 2 13 355045 3.66  
3 4 337841 1.18 3 10 325511 3.07 3 14 380378 3.68  
4 13 340043 3.82 4 11 349011 3.15 4 17 353870 4.80  
5 9 336717 2.67 5 8 316022 2.53 5 20 337855 5.92  
6 12 318583 3.77 6 8 330095 2.42 6 6 333631 1.80  
7 12 311133 3.86 7 12 327508 3.66 7 8 312825 2.56  
8 7 324698 2.16 8 19 345937 5.49 8 13 314827 4.13  
9 10 312154 3.20 9 18 398135 4.52 9 10 315013 3.17  
10 11 344704 3.19 10 11 367228 3.00 10 15 326951 4.59 
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Appendix E: Effect of RUNX1/ETO expression on NPM1 mutation frequency over time (continued of next page). 
 
Week 
No RE expression Low RE expression High RE expression 
Clone 
Positive 
event 
Gated 
event 
MF (x10-5) Clone 
Positive 
event 
Gated 
event 
MF (x10-5) Clone 
Positive 
event 
Gated 
event 
MF (x10-5) 
18 1 21 319573 6.57 1 18 308130 5.84 1 18 324954 5.54  
2 18 318644 5.65 2 23 333136 6.90 2 18 328741 5.48  
3 8 315535 2.54 3 23 307127 7.49 3 15 318388 4.71  
4 9 309959 2.90 4 22 338473 6.50 4 18 290089 6.20  
5 16 346933 4.61 5 11 317899 3.46 5 19 325623 5.83  
6 13 309164 4.20 6 7 250469 2.79 6 12 326856 3.67  
7 16 336416 4.76 7 14 307903 4.55 7 12 249676 4.81  
8 21 317874 6.61 8 16 250172 6.40 8 18 312548 5.76  
9 15 324607 4.62E 9 7 160056 4.37 9 15 263229 5.70  
10 12 304760 3.94 10 10 248454 4.02 10 18 313451 5.74 
20 1 12 318933 3.76 1 18 338183 5.32 1 27 285419 9.46  
2 16 321044 4.98 2 21 340392 6.17 2 24 307006 7.82  
3 15 306725 4.89 3 20 316990 6.31 3 30 328896 9.12  
4 13 332907 3.90 4 19 330064 5.76 4 19 298312 6.37  
5 16 309415 5.17 5 17 323468 5.26 5 29 353932 8.19  
6 19 312786 6.07 6 15 339759 4.41 6 21 327920 6.40  
7 18 312615 5.76 7 18 327902 5.49 7 13 301587 4.31  
8 23 309054 7.44 8 18 323864 5.56 8 15 315106 4.76  
9 10 297810 3.36 9 18 334025 5.39 9 21 316569 6.63  
10 14 300481 4.66 10 12 340186 3.53 10 21 347717 6.04 
22 1 27 329623 8.19 1 24 289968 8.28 1 35 299240 1.17  
2 12 300051 4.00 2 27 324988 8.31 2 21 337030 6.23  
3 18 315816 5.70 3 21 310745 6.76 3 10 146062 6.85  
4 18 310723 5.79 4 29 329132 8.81 4 23 239753 9.59  
5 17 322712 5.27 5 14 319618 4.38 5 25 337503 7.41 
215 
 
Appendix E: Effect of RUNX1/ETO expression on NPM1 mutation frequency over time (continued from previous page). 
 
Week 
No RE expression Low RE expression High RE expression 
Clone 
Positive 
event 
Gated 
event 
MF (x10-5) Clone 
Positive 
event 
Gated 
event 
MF (x10-5) Clone 
Positive 
event 
Gated 
event 
MF (x10-5) 
22 6 21 320773 6.55 6 26 330786 7.86 6 35 319203 1.10  
7 15 322585 4.65 7 20 313897 6.37 7 25 331562 7.54  
8 18 336046 5.36 8 21 315378 6.66 8 20 313312 6.38  
9 23 330868 6.95 9 23 327640 7.02 9 26 312200 8.33  
10 12 310718 3.86 10 28 336254 8.33 10 19 306382 6.20 
 
Detection of NPM1-mutant positive event was performed every 2 weeks, starting at week 7 to week 22 post-cloning using flow cytometry. 
The frequency (MF) of NPM1 exon 12 mutation in no RE expression subclones, low RE expression subclones and high RE expression 
subclones was calculated by dividing the no. of positive event with the no. of gated event. 
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